

Approved



Uganda
Country Operational Plan
FY 2016



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
State		310,061		310,061	140,000	450,061
USAID		166,771,987	0	166,771,987	3,677,217	170,449,204
DOD		11,317,099		11,317,099	1,231,339	12,548,438
PC		883,101		883,101	1,401,600	2,284,701
HHS/CDC	3,212,500	187,471,645		190,684,145	5,780,000	196,464,145
HHS/HRSA		450,000		450,000	0	450,000
State/PRM		741,823		741,823	0	741,823
Total	3,212,500	367,945,716	0	371,158,216	12,230,156	383,388,372

Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency							On Hold Amount	Total
	State	DOD	HHS/CDC	HHS/HRSA	PC	State/PRM	USAID		
CIRC		1,031,983	13,867,103			65,477	10,764,629	0	25,729,192
HBHC	21,119	1,816,335	24,840,615		0	99,865	15,670,914	0	42,448,848
HKID	38,014	797,593	5,602,647		48,619	169,720	19,129,619	0	25,786,212
HLAB		65,042	4,642,118	450,000			1,730,919	0	6,888,079
HMBL			3,579					0	3,579
HMIN		0	1,788					0	1,788
HTXD		2,945	31,869,797				28,121,116	0	59,993,858
HTXS	16,895	3,008,430	47,621,709			195,226	35,425,591	0	86,267,851
HVAB		0	0			0	15,226	0	15,226
HVCT		632,474	9,613,734			92,350	8,266,526	0	18,605,084

Approved



HVMS	234,033	519,721	10,934,795		747,637		7,214,262	0	19,650,448
HVOP		507,449	5,019,059		86,845	0	5,819,082	0	11,432,435
HVSI		417,362	7,082,472				7,245,023	0	14,744,857
HVTB		1,260,925	3,833,547			25,047	3,915,285	0	9,034,804
IDUP			0					0	0
MTCT		429,018	9,133,300			30,281	4,869,361	0	14,461,960
OHSS			6,005,514				11,123,827	0	17,129,341
PDCS		642,239	7,502,192			48,807	5,288,489	0	13,481,727
PDTX		185,583	3,110,174			15,050	2,172,118	0	5,482,925
	310,061	11,317,099	190,684,143	450,000	883,101	741,823	166,771,987	0	371,158,214



Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	42,023,290	0
HKID	24,682,270	0
HVTB	8,774,966	0
PDCS	13,235,373	0
Total Technical Area Planned Funding:	88,715,899	0

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	6,454,044	0
HVSI	12,660,014	0
OHSS	15,396,088	0
Total Technical Area Planned Funding:	34,510,146	0

Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
CIRC	25,464,008	0
HMBL	0	
HMIN	0	
HVAB	0	0
HVCT	18,304,162	0
HVOP	11,130,300	0
IDUP	0	0
MTCT	13,938,000	0

Approved



Total Technical Area Planned Funding:	68,836,470	0
--	-------------------	----------

Technical Area: Treatment

Budget Code	Budget Code Planned Amount	On Hold Amount
HTXD	59,623,237	0
HTXS	85,687,966	0
PDTX	5,181,284	0
Total Technical Area Planned Funding:	150,492,487	0



Technical Area Summary Indicators and Targets

Indicator Number	Label	2017
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	n/a
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	994,680
	Number of new ANC and L&D clients	1,020,378
	By: Known positives at entry	37,113
	By: Number of new positives identified	27,120
	Sum of Positives Status disaggregates	64,233
	Required only for DREAMS Countries - By Number of new positives: <15	
	Required only for DREAMS Countries - By Number of new positives: 15-19	
	Required only for DREAMS Countries - By Number of new positives: 20-24	
	Required only for DREAMS Countries - By Number of known positives: <15	
	Required only for DREAMS Countries - By Number of known	



	positives: 15-19	
	Required only for DREAMS Countries - By Number of known positives: 20-24	
	Required only for DREAMS Countries - Denominator: <15	
	Required only for DREAMS Countries - Denominator: <15-19	
	Required only for DREAMS Countries - Denominator: 20-24	
	Required only for DREAMS Countries - Denominator: 25-49	
	Required only for DREAMS Countries - Denominator: 50+	
	Required only for DREAMS Countries - By Number of known positives: 25-49	
	Required only for DREAMS Countries - By Number of known positives: 50+	
	Required only for DREAMS Countries - By Number of new positives: 25-49	
	Required only for DREAMS Countries - By Number of new positives: 50+	
	By Age (DREAMS SNU's ONLY): <15	
	By Age (DREAMS SNU's ONLY): 15-19	
	By Age (DREAMS SNU's ONLY): 20-24	
	By Age (DREAMS SNU's ONLY): 25-49	



	By Age (DREAMS SNU's ONLY): 50+	
PMTCT_STAT_TA	PMTCT_STAT_TA Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (TA)	n/a
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	582,975
	Number of new ANC and L&D clients	597,880
	By: Known positives at entry	17,234
	By: Number of new positives identified	13,753
	Sum of Positives Status disaggregates	30,987
	Required only for DREAMS countries - By known positives: <15	
	Required only for DREAMS countries - By known positives: 15-19	
	Required only for DREAMS countries - By known positives: 20-24	
	Required only for DREAMS countries - By new positives: <15	
	Required only for DREAMS countries - By new positives: 15-19	
	Required only for DREAMS countries - By new positives: 20-24	
	Required only for DREAMS countries - Denominator: <15	



	Required only for DREAMS countries - Denominator: 15-19	
	Required only for DREAMS countries - Denominator: 20-24	
	Required only for DREAMS countries - Denominator: 25-49	
	Required only for DREAMS countries - Denominator: 50+	
	Required only for DREAMS countries - By known positives: 25-49	
	Required only for DREAMS countries - By known positives: 50+	
	Required only for DREAMS countries - By new positives: 25-49	
	Required only for DREAMS countries - By new positives: 50+	
	By Age (DREAMS SNUs ONLY): <15	
	By Age (DREAMS SNUs ONLY): 15-19	
	By Age (DREAMS SNUs ONLY): 20-24	
	By Age (DREAMS SNUs ONLY): 25-49	
	By Age (DREAMS SNUs ONLY): 50+	
PMTCT_ART_DSD	PMTCT_ART_DSD Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	n/a
	Number of HIV-positive pregnant women who	



	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	994,680
	New on ART	25,822
	Already on ART at beginning of current pregnancy	35,252
PMTCT_ART_TA	PMTCT_ART_TA Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	n/a
	Number of HIV-positive pregnant women who	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	582,975
	New on ART	12,351
	Already on ART at beginning of current pregnancy	17,203
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	1,011,964
	By Age: 0-60 days	
	By Age: 2 months - 9 years	
	By Age: 10-14	394,665
	By Age: 15-19	293,474
	By Age: 20-24	141,693
	By Age: 25-29	80,948
	By Age: 30-49	80,948
By Age: 50+	20,236	



	Sum of age disaggregates (Prior to FY15)	850,068
	Sum of age disaggregates (FY15-Current)	1,011,964
	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	
	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	
	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	
	By circumcision technique: Surgical VMMC	999,901
	By circumcision technique: Device-based VMMC	12,063
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	
	By follow-up status: Number of device based circumcision clients who returned at least once for follow-up care within 14 days of device placement	
PrEP_NEW_DSD	PrEP_NEW_DSD Number of individuals who have received antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV infection in the reporting period.	n/a
	Number of individuals who have received antiretroviral preexposure	6,831



	Male 10-14	
	Male 15-19	1,693
	Male 20-24	450
	Male 25-49	619
	Male 50+	53
	Female 10-14	
	Female 15-19	2,289
	Female 20-24	1,048
	Female 25-49	619
	Female 50+	60
PrEP_NEW_TA	PrEP_NEW_TA Number of adult women and adolescent girls newly enrolled on oral or topical PrEP	n/a
	Number of adult women and adolescent girls newly enrolled on oral or topical PrEP	600
	Male 10-14	
	Male 15-19	150
	Male 20-24	42
	Male 25-49	54
	Male 50+	6
	Female 10-14	
	Female 15-19	198
	Female 20-24	90
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a
	Number of the target population	589,809



	who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	
	Total number of people in the target population	2,539,716
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Denominator: Age/sex: 10-14 Male	
	Denominator: Age/sex: 15-19 Male	
	Denominator: Age/sex: 20-24 Male	
	Denominator: Age/sex: 25-49 Male	
	Denominator: Age/sex: 50+ Male	
	Denominator: Age/sex: 10-14 Female	
	Denominator: Age/sex: 15-19 Female	
	Denominator: Age/sex: 20-24 Female	
	Denominator: Age/sex: 25-49 Female	
	Denominator: Age/sex: 50+ Female	
	Service: PP known positive	
	Service: PP tested or referred for testing as part of program	



	New Client: New beneficiary	
	New Client: Returning Beneficiary	
	Aggregated Age/sex: <15 Male	105,811
	Aggregated Age/sex: 15+ Male	135,096
	Aggregated Age/sex: <15 Female	128,026
	Aggregated Age/sex: 15+ Female	220,876
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	51,805
	Total estimated number of key population in the catchment area	90,617
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	50,976
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet	825



	the minimum standards required)	
	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key	



	populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	6,380
	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	2,735
	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key	81,502



	population in the catchment area)	
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	
	By Service: KP known status	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: REturniong beneficiary within the current report period	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	5,600,890
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	132,586
	Age/sex: 15-19 Male	542,451
	Age/sex: 20-24 Male	813,734
	Age/sex: 25-49 Male	1,247,665



	Age/sex: 50+ Male	108,434
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	132,749
	Age/sex: 15-19 Female	484,580
	Age/sex: 20-24 Female	726,904
	Age/sex: 25-49 Female	1,114,507
	Age/sex: 50+ Female	96,813
	Test Result by Age and Sex: Positive: 10-14 Male	5,270
	Test Result by Age and Sex: Positive: 15-19 Male	13,173
	Test Result by Age and Sex: Positive: 20-24 Male	19,807
	Test Result by Age and Sex: Positive: 25-49 Male	30,291
	Test Result by Age and Sex: Positive: 50+ Male	2,577
	Test Result by Age and Sex: Positive: 10-14 Female	5,343
	Test Result by Age and Sex: Positive: 15-19 Female	18,450
	Test Result by Age and Sex: Positive: 20-24 Female	27,733
	Test Result by Age and Sex: Positive: 25-49 Female	42,447
	Test Result by Age and Sex: Positive: 50+ Female	3,642
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex:	



	Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	232,761
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,712,284
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	233,041
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	2,422,804
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age and Sex: Positive <15 Male	9,114
	Test Result by Aggregated Age	65,848



	and Sex: Positive 15+ Male	
	Test Result by Aggregated Age and Sex: Positive <15 Female	9,273
	Test Result by Aggregated Age and Sex: Positive 15+ Female	92,272
	Test Result by Age: Positive: <1	1,708
	Test Result by Age: Positive: 1-9	6,066
	Age/sex: <1	46,708
	Age/sex: 1-9	153,759
	Service Delivery Point (Community): Index testing	
	Service Delivery Point (Community): Homebased testing	
	Service Delivery Point (Community): Mobile testing	
	Service Delivery Point (Community): Other	
	Service Delivery Point (Community) by Age: <15 index testing	
	Service Delivery Point (Community) by Age: 15+ index testing	
	Service Delivery Point (Community) by Age: <15 homebased testing	
	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Facility):	950,949



	Inpatient	
	Service Delivery Point (Facility): Outpatient	1,683,217
	Service Delivery Point (Facility): Pediatric	417,224
	Service Delivery Point (Facility): Malnutrition facilities	
	Service Delivery Point (Facility): Other PITC	314,962
	Service Delivery Point (Facility): VCT	
	Service Delivery Point (Facility): VMMC	907,011
	Service Delivery Point (Facility): PMTCT	973,016
	Service Delivery Point (Facility): TB Clinics	39,916
	Service Delivery Point (Facility): Index testing	314,595
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatric	
	Service Delivery Point (Facility) by Age: >15 Pediatric	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by	



	Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	2,247,487
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	61,382
	Age/sex: 15-19 Male	171,297
	Age/sex: 20-24 Male	257,005
	Age/sex: 25-49 Male	394,010



	Age/sex: 50+ Male	34,176
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	61,405
	Age/sex: 15-19 Female	235,070
	Age/sex: 20-24 Female	352,669
	Age/sex: 25-49 Female	540,676
	Age/sex: 50+ Female	46,921
	Test Result by Age and Sex: Positive: 10-14 Male	2,251
	Test Result by Age and Sex: Positive: 15-19 Male	4,111
	Test Result by Age and Sex: Positive: 20-24 Male	6,234
	Test Result by Age and Sex: Positive: 25-49 Male	9,458
	Test Result by Age and Sex: Positive: 50+ Male	801
	Test Result by Age and Sex: Positive: 10-14 Female	2,330
	Test Result by Age and Sex: Positive: 15-19 Female	7,809
	Test Result by Age and Sex: Positive: 20-24 Female	11,800
	Test Result by Age and Sex: Positive: 25-49 Female	17,987
	Test Result by Age and Sex: Positive: 50+ Female	1,502
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex:	



	Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: <1 Female	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	107,820
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	856,488
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	107,870
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,175,336
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age	3,770



	and Sex: Positive <15 Male	
	Test Result by Aggregated Age and Sex: Positive 15+ Male	20,604
	Test Result by Aggregated Age and Sex: Positive <15 Female	3,878
	Test Result by Aggregated Age and Sex: Positive 15+ Female	39,098
	Test Result by Age: Positive: <1	594
	Test Result by Age: Positive: 1-9	2,473
	Age/sex: <1	21,694
	Age/sex: 1-9	71,209
	Service Delivery Point (Community): Index testing	
	Service Delivery Point (Community): Homebased testing	
	Service Delivery Point (Community): Mobile testing	
	Service Delivery Point (Community): Other	
	Service Delivery Point (Community) by Age: <15 index testing	
	Service Delivery Point (Community) by Age: 15+ index testing	
	Service Delivery Point (Community) by Age: <15 homebased testing	
	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Community)	



	by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	394,896
	Service Delivery Point (Facility): Outpatient	721,318
	Service Delivery Point (Facility): Pediatric	191,296
	Service Delivery Point (Facility): Malnutrition facilities	
	Service Delivery Point (Facility): Other PITC	134,674
	Service Delivery Point (Facility): VCT	
	Service Delivery Point (Facility): VMMC	104,953
	Service Delivery Point (Facility): PMTCT	576,425
	Service Delivery Point (Facility): TB Clinics	17,350
	Service Delivery Point (Facility): Index testing	106,575
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatroc	
	Service Delivery Point (Facility) by Age: >15 Pediatroc	
	Service Delivery Point (Facility) by	



	Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	n/a
	Number of registered new and relapsed TB cases with	36,004



	documented HIV status, during the reporting period.	
	Total number of registered new and relapsed TB cases, during the reporting period.	36,004
	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 50+ (Numerator: Number of registered new and	



	relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,121
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	21,936



	documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	842
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	12,091
	Result: Known HIV positive at service entry	
	Result: New HIV positive	
	Result: HIV Negative	
	Age/Sex: <1 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB	



	cases, during the reporting period.)	
	Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of	



	registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
TB_STAT_TA	TB_STAT_TA Percentage of registered new and relapsed TB cases with documented HIV status.	n/a
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	11,221
	Total number of registered new and relapsed TB cases, during the reporting period.	11,222
	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	



	Age/Sex: Male 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 25-49	



	(Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	319
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	6,914
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	223
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,748
	Result: Known HIV positive at service entry	
	Result: New HIV positive	
	Result: HIV negative	
	Age/Sex: <1 (Denominator: Total number of registered new and	



	relapsed TB cases, during the reporting period)	
	Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 20-24	



	(Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
GEND_GBVDSD	Number of people receiving post-GBV care	57,783
	Age/Sex: <10 Male	1,712
	Age/Sex: 10-14 Male	1,712
	Age/Sex: 15-17 Male	
	Age/Sex: 18-19 Male	
	Age/Sex: 20-24 Male	2,893
	Age/Sex: 25-49 Male	2,893
	Age/Sex: 50+ Male	
	Age/Sex: <10 Female	2,893
	Age/Sex: 10-14 Female	8,098
	Age/Sex: 15-17 Female	
	Age/Sex: 18-19 Female	
	Age/Sex: 20-24 Female	14,433
	Age/Sex: 25-49 Female	5,838
	Age/Sex: 50+ Female	
	Sum of Age/Sex Disaggregates	14,415
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	12,716
	By type of service: Sexual Violence (Post-Rape Care)	45,067
By PEP service provision (related to sexual violence services provided)	5,212	
Age/Sex: 15-19 Female	14,447	



	Age/Sex: 15-19 male	2,864
GEND_GBV_TA	Number of people receiving post-GBV care	33,152
	Age/Sex: <10 Male	989
	Age/Sex: 10-14 Male	989
	Age/Sex: 20-24 Male	1,688
	Age/Sex: 25-49 Male	1,688
	Age/Sex: 50+ Male	
	Age/Sex: <10 Female	1,688
	Age/Sex: 10-14 Female	4,660
	Age/Sex: 20-24 Female	8,231
	Age/Sex: 25-49 Female	3,352
	Age/Sex: 50+ Female	
	Sum of Age/Sex Disaggregates	8,326
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	7,319
	By type of service: Sexual Violence (Post-Rape Care)	25,833
	By PEP service provision (related to sexual violence services provided)	2,983
Age/Sex: 15-19 Female	8,277	
Age/Sex: 15-19 Male	1,590	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	424,531
	Age/Sex: 10-14 Male	
	Age/Sex: 15-17 Male	
	By: Age/sex: Male 18-24	
	By: Age/sex: Male 25+	
	Age/Sex: 18+ Male	39,348



	Age/Sex: 10-14 Female	
	Age/Sex: 15-17 Female	
	By: Age/sex: 18-24 Female	
	By: Age/sex: 25+ Female	
	Age/Sex: 18+ Female	47,885
	Sum of Age/Sex disaggregates	87,233
	Required only for DREAMS countries - By service, age and sex: Education Support Female <1	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	
	Required only for DREAMS countries - By service, age and sex: Education Support Male <1	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	



	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	
	Required only for DREAMS	



	countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	



	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1	
	Required only for DREAMS countries - By service, age and	



	sex: Economic Strengthening Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	
	Required only for DREAMS countries - By service, age and sex: Other Services Female <1	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	22,017
	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	14,234
	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	34,731
	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	
	Required only for DREAMS countries - By service, age and sex: Other Services Male <1	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	



	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	
	Age/Sex: <1	
	Age/Sex: 1-9	
	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Male	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 1-9	
	Program Completion: Active	
	Program Completion: Graduation	
	Program Completion: Transferred	
	Program Completion: Exited without graduation	



	By Aggregated Age/Sex: <18 Male	126,460
	By Aggregated Age/Sex: 18+ Male	
	By Aggregated Age/Sex: <18 Female	135,364
	By Aggregated Age/Sex: 18+ Female	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 1-9	
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	13,202
	The number of registered new and relapse TB cases with documented	13,202



	HIV-positive status during TB treatment during the reporting period	
	Age/Sex: >1 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented	



	HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during	



	the reporting period)	
	Age/Sex: Female 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	197
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	8,417
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	130
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4,447
	On ART: Already on ART	



	On ART: New on ART	
	Age/Sex: >1 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: The number of	



	registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: The number of registered new and relapse TB cases with documented	



	HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB	



	treatment during the reporting period)	
TB_ART_TA	TB_ART_TA Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	4,093
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	4,093
	Age/Sex: <1 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: The number of registered new and	



	relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	



	<p>Age/Sex: Female 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	
	<p>Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	<p>50</p>
	<p>Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)</p>	<p>2,690</p>
	<p>Aggregated Age/Sex: Female <15 (Numerator: The number of</p>	<p>33</p>



	registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,312
	On ART: Already on ART	
	On ART: New on ART	
	Age/Sex: <1 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB	



	cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB	



	treatment during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	



	period)	
	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	977,210
	Screened for TB by Age/Sex:<15 Male	34,001
	Screened for TB by Age/Sex: 15+ Male	307,286
	Screened for TB by Age/Sex:<15 Female	38,718
	Screened for TB by Age/Sex: 15+ Female	597,239
	Screen Result: Screened Positive for TB	19,549
	TB Positive by Age/Sex: <15 Male	
	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	



	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	78,177
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	23,499
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	46,917
	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	7,765
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	238,965
	Screened for TB by Age/Sex: <15 Male	7,918
	Screened for TB by Age/Sex: 15+ Male	75,445
	Screened for TB by Age/Sex: <15 Female	9,015
	Screened for TB by Age/Sex: 15+ Female	146,587
	Screen Results: Screened Positive for TB	4,796
	TB Positive by Age/Sex: <15 Male	
	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	
	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	19,121
	[Sub-disagg of Specimen Sent]	5,775



	Diagnostic Test: Smear Only	
	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	11,475
	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	1,878
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	
	By infants who received a virologic test within 2 months of birth	39,828
	By infants who received their first virologic HIV test between 2 and 12 months of age	11,016
	Sum of Infant Age disaggregates	50,844
	By infants with a positive virologic test result within 12 months of birth	
	Number of infants with a positive virological test result within 2 months of birth	1,998
	Number of infants with a negative virological test result within 2 months of birth	
	Number of infants with a positive virological test result between 2 and 12 months of birth	



	Number of infants with a negative virological test result between 2 and 12 months of birth	
	Number of infants with a positive virological test result within 12 months of birth	447
	PMTCT_EID_TA Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (TA)	n/a
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	
	By infants who received a virologic test within 2 months of birth	19,479
	By infants who received their first virologic HIV test between 2 and 12 months of age	5,312
	Sum of Infant Age disaggregates	24,791
	By infants with a positive virologic test result within 12 months of birth	
	Number of infants with a positive virological test result within 2 months of birth	986
	Number of infants with a negative virological test result within 2 months of birth	
	Number of infants with a positive virological test result between 2 and 12 months of birth	



	Number of infants with a negative virological test result between 2 and 12 months of birth	
	Number of infants with a positive virological test result within 12 months of birth	161
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	977,076
	Age/Sex: 15-19 Male	9,200
	Age/Sex: 15-19 Female	29,878
	Age/Sex: 20+ Female	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	34,001
	Aggregated Age/Sex: 15+ Male	307,286
	Aggregated Age/Sex: <15 Female	38,718
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	597,239
	Sum of Aggregated Age/Sex <15	72,719
	Sum of Aggregated Age/Sex 15+	904,525
	Sum of Aggregated Age/Sex disaggregates	977,244
	Age/Sex: <1	2,809
	Age/Sex: <1-9	17,493
	Age/Sex: 10-14 Male	24,156
	Age/Sex: 10-14 Female	28,508
	Aggregated Age/Sex: 1-14 Male	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	61,677
	Age/Sex: 25-49 Male	221,241
	Age/Sex: 50+ Male	15,364



	Age/Sex: 20-24 Female	137,357
	Age/Sex: 25-49 Female	400,126
	Age/Sex: 50+ Female	29,878
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	238,965
	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-14 Male	
	Age/Sex: 15-19 Male	2,257
	Age/Sex: 20+ Male	
	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
	Age/Sex: 5-14 Female	
	Age/Sex: 15-19 Female	7,345
	Age/Sex: 20+ Female	
	Sum of Age/Sex disaggregations	9,602
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	7,918
	Aggregated Age/Sex: 1-14 Male	
	Aggregated Age/Sex: 15+ Male	75,445
	Aggregated Age/Sex: <15 Female	9,015
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	146,587
	Sum of Aggregated Age/Sex <15	16,933
	Sum of Aggregated Age/Sex 15+	222,032
	Sum of Aggregated Age/Sex disaggregates	238,965
	Age/Sex: <1	565
	Age/Sex: 1-9	4,190
	Age/Sex: 10-14 Male	5,628



	Age/Sex: 10-14 Female	6,550
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	15,096
	Age/Sex: 25-49 Male	54,302
	Age/Sex: 50+ Male	3,790
	Age/Sex: 20-24 Female	33,714
	Age/Sex: 25-49 Female	98,183
	Age/Sex: 50+ Female	7,345
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	235,567
	By Age/Sex: <1	528
	By Age/Sex: 1-9	4,034
	By Age/Sex: 10-14 Male	5,603
	By Age/Sex: 15-19 Male	2,202
	By Age/Sex: 20-24 Male	14,854
	By Age/Sex: 25-49 Male	53,488
	By Age/Sex: 50+ Male	3,742
	By Age/Sex: 10-14 Female	6,712
	By Age/Sex: 15-19 Female	7,215
	By Age/Sex: 20-24 Female	33,232
	By Age/Sex: 25-49 Female	96,748
	By Age/Sex: 50+ Female	7,207
	Sum of Age/Sex disaggregates	231,003
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	7,891
	Aggregated Grouping by Age/Sex: 1-14 Male	
Aggregated Grouping by Age/Sex:	74,286	



	15+ Male	
	Aggregated Grouping by Age/Sex: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	8,986
	Aggregated Grouping by Age/Sex: 15+ Female	144,402
	Sum of Aggregated Age/Sex disaggregates	235,565
	Pregnancy status	
	Breastfeeding status	
	Aggregated Grouping by Age/Sex: 1-14 Female	
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	74,724
	By Age/Sex: <1	
	By Age/Sex: 1-9	1,119
	By Age/Sex: <1 Male	
	By Age/Sex: 1-4 Male	
	By Age/Sex: 5-9 Male	
	By Age/Sex: 10-14 Male	1,614
	By Age/Sex: 15-19 Male	636
	By Age/Sex: 20-24 Male	4,750
	By Age/Sex: 25-49 Male	17,076
	By Age/Sex: 50+ Male	1,166
	By Age/Sex: <1 Female	
	By Age/Sex: 1-4 Female	
	By Age/Sex: 5-9 Female	
	By Age/Sex: 10-14 Female	2,150
	By Age/Sex: 15-19 Female	2,294
	By Age/Sex: 20-24 Female	10,609
By Age/Sex: 25-49 Female	29,652	



	By Age/Sex: 50+ Female	2,272
	Sum of Age/Sex disaggregates	72,219
	Aggregated Grouping by Age: <1	98
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	2,268
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	23,695
	Aggregated Grouping by Age: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	2,718
	Aggregated Grouping by Age/Sex: 1-14 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	46,042
	Sum of Aggregated Age/Sex disaggregates	74,723
	Pregnancy status	
	Breastfeeding status	
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records	703,212



	and /or supporting laboratory results within the past 12 months.	
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	781,314
	Numerator: Indication: Routine	703,212
	Numerator: Indication: Targeted	
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication:	



	15-19 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by	



	Indication: 15+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Indication: Routine	781,314
	Denominator: Indication: Targeted	
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by	



	Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by	



	Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator Aggregated Age/Sex: <15 Male	24,467
	Numerator Aggregated Age/Sex: 15+ Male	221,288
	Numerator Aggregated Age/Sex: <15 Female	27,850
	Numerator Aggregated Age/Sex: 15+ Female	429,607
	Denominator Aggregated Age/Sex: <15 Male	27,204
	Denominator Aggregated Age/Sex: 15+ Male	245,748
	Denominator Aggregated Age/Sex: <15 Female	30,974
	Denominator Aggregated Age/Sex:	477,388



	15+ Female	
TX_PVLS_TA	TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	159,242
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	176,912
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	



	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	



	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Indication: Routine	159,242
	Numerator: Indication: Targeted	
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Indication: Routine	176,912
	Denominator: Indication: Targeted	
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 1-9 Targeted	



	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Routine	



	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Numerator Aggregated Age/Sex: <15 Male	5,208
	Numerator Aggregated Age/Sex: 15+ Male	50,388



	Numerator Aggregated Age/Sex: <15 Female	5,933
	Numerator Aggregated Age/Sex: 15+ Female	97,713
	Denominator Aggregated Age/Sex: <15 Male	5,813
	Denominator Aggregated Age/Sex: 15+ Male	55,885
	Denominator Aggregated Age/Sex: <15 Female	6,631
	Denominator Aggregated Age/Sex: 15+ Female	108,583
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	173,033
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	194,410
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	175
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,757
	Age/Sex: 10-14 Male (Numerator:	2,887



	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,339
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	623
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	80,432
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	27,308
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,640
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,689
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	12,410
	Age/Sex: 25-49 Female	36,083



	(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,690
	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	215
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,948
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,196
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,	3,748



	those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	25,080
	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	90,369
	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,302
	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,927
	Age/Sex: 15-19 Female (Denominator: Total number of	3,040



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	13,948
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	40,605
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,032
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who	



	are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,022
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	111,702
	Aggregated Age/Sex: <15 Female	3,437



	(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	53,872
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,469
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	125,499
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,817
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated	60,625



	ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	53,553
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	60,169
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	21
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	477
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	901
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,031



	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	153
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	25,225
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8,635
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	856
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	798
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,747
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10,878
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	831



	Age/Sex: <1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	32
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	518
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	957
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,161
	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,	7,871



	those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	28,351
	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,997
	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	910
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	905
	Age/Sex: 20-24 Female (Denominator: Total number of	4,219



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	12,291
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	957
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,	



	those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,218
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	35,044
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,037
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after	16,254



	initiating ART)	
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,310
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	39,380
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,107
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	18,372
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate	



	and successfully pass in an analyte-specific proficiency testing (PT) program	
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	1,342
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	1,342
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1,342
	CD4: Number of laboratories that perform this testing	144
	CD4: Number of laboratories that participate in this PT program	180
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	144
	Early infant diagnostics: Number of laboratories that perform this testing	1
	Early infant diagnostics: Number of laboratories that participate in this PT program	1
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
	HIV viral load: Number of laboratories that perform this testing	437
	HIV viral load: Number of laboratories that participate in this	2



	PT program	
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	2
	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	1,131
	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	1,414
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	1,131
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	105
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	105
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	105
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	1
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	1
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	1



HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	542
	By Graduates: Doctors	
	By Graduates: Nurses	25
	By Graduates: Midwives	60
	By Graduates: Social service workers	
	By Graduates: Laboratory professionals	
	By Graduates: Other	457
	Sum of Graduates disaggreagtes	542



Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
9043	Henry Jackson Foundation	Private Contractor	U.S. Department of Defense	GHP-State	8,193,639
9167	Kalangala District Health Office	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,230,044
9183	The AIDS Support Organization	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	8,703,140
9303	U.S. Department of Defense (Defense)	Other USG Agency	U.S. Department of Defense	GHP-State	0
9483	Infectious Disease Institute	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GAP	0
9879	Management Sciences for	NGO	U.S. Agency for International	GHP-State	894,778



	Health		Development		
10326	University Research Corporation, LLC	Private Contractor	U.S. Agency for International Development	GHP-State	16,332,296
11479	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	0
11480	U.S. Peace Corps	Other USG Agency	U.S. Peace Corps	GHP-State	120,161
12477	Baylor College of Medicine Children's Foundation	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12486	Associazione Volontari Per Il Servizio Internazionale, Uganda	FBO	U.S. Agency for International Development	GHP-State	2,154,750
12496	Social and Scientific Systems	Private Contractor	U.S. Agency for International Development	GHP-State	1,018,794
12801	Cardno Emerging Markets	NGO	U.S. Agency for International Development	GHP-State	1,674,458
12981	Uganda Virus Research Institute	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,285,000
13002	United Nations	Multi-lateral	U.S. Department	GHP-State	741,823



	High Commissioner for Refugees	Agency	of State/Bureau of Population, Refugees, and Migration		
13029	Regional Procurement Support Office/Frankfurt	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	0
13047	Makerere University School of Medicine	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13104	Baylor College of Medicine Children's Foundation	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13136	Infectious Disease Institute	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13161	Uganda Virus Research Institute	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0



13170	Makerere University School of Public Health	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	250,000
13226	Medical Access Uganda Limited (MAUL)	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13317	Joint Clinical Research Center, Uganda	NGO	U.S. Agency for International Development	GHP-State	1,857,988
13325	Reach Out Mbuya	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13383	African Medical and Research Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13416	Mildmay International	FBO	U.S. Department of Health and Human Services/Centers for Disease	GHP-State	0



			Control and Prevention		
13466	Uganda Protestant Medical Board	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,920,238
13486	Protecting Families from AIDS, Uganda	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13717	Registered Trustees for the Uganda Episcopal Conference	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	7,180,310
13833	Management Sciences for Health	NGO	U.S. Agency for International Development	GHP-State	1,200,000
13835	Baylor College of Medicine Children's Foundation	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	14,231,103
13837	QED Group, LLC	Private Contractor	U.S. Agency for International Development	GHP-State	1,821,639



13841	World Health Organization	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	320,000
13864	Ministry of Health, Uganda	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,030,000
13874	Program for Appropriate Technology in Health	NGO	U.S. Agency for International Development	GHP-State	430,357
13877	Children's AIDS Fund	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,022,837
13880	Makerere University School of Public Health	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,697,229
13892	Research Triangle International	Private Contractor	U.S. Agency for International Development	GHP-State	1,000
13897	African Field	NGO	U.S. Department	GHP-State	0



	Epidemiology Network		of Health and Human Services/Centers for Disease Control and Prevention		
13901	FHI 360	NGO	U.S. Agency for International Development	GHP-State	2,002,161
13924	RECO Industries	Implementing Agency	U.S. Agency for International Development	GHP-State	203,260
16594	University of North Carolina at Chapel Hill, Carolina Population Center	University	U.S. Agency for International Development	GHP-State	960,000
16626	Cardno Emerging Markets	NGO	U.S. Agency for International Development	GHP-State	6,635,668
17063	Uganda Health Marketing Group	NGO	U.S. Agency for International Development	GHP-State	1,500,000
17065	Catholic Relief Services	FBO	U.S. Agency for International Development	GHP-State	6,281,620
17066	World Vision	NGO	U.S. Agency for International Development	GHP-State	1,066,311
17078	University Research Council	NGO	U.S. Agency for International Development	GHP-State	10,872,533
17090	Measure Evaluation	NGO	U.S. Agency for International Development	GHP-State	0



17094	Management Sciences for Health	NGO	U.S. Agency for International Development	GHP-State	6,650,000
17649	University Research Council	NGO	U.S. Agency for International Development	GHP-State	11,408,310
17651	TBD	TBD	Redacted	Redacted	Redacted
17654	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Agency for International Development	GHP-State	15,293,346
17688	TBD	TBD	Redacted	Redacted	Redacted
17690	IntraHealth International, Inc	NGO	U.S. Agency for International Development	GHP-State	2,848,876
17696	TBD	TBD	Redacted	Redacted	Redacted
17698	Uganda Prisons Services	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	150,000
17703	Makerere University School of Public Health	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	7,012,253
17704	African Society for Laboratory Medicine	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and	GHP-State	0



			Prevention		
17705	TBD	TBD	Redacted	Redacted	Redacted
17706	Infectious Disease Institute	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	12,735,606
17855	Research Triangle International	Private Contractor	U.S. Department of Defense	GHP-State	2,359,499
17874	National Medical Research Unit	NGO	U.S. Department of Defense	GHP-State	150,000
17976	Association of Public Health Laboratories	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	200,000
17977	American International Health Alliance Twinning Center	NGO	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	450,000
17978	TBD	TBD	Redacted	Redacted	Redacted
17979	TBD	TBD	Redacted	Redacted	Redacted
18003	Global Healthcare Public Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and	GHP-State	500,000



			Prevention		
18017	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	400,000
18029	TBD	TBD	Redacted	Redacted	Redacted
18030	TBD	TBD	Redacted	Redacted	Redacted
18031	TBD	TBD	Redacted	Redacted	Redacted
18032	TBD	TBD	Redacted	Redacted	Redacted
18033	TBD	TBD	Redacted	Redacted	Redacted
18034	TBD	TBD	Redacted	Redacted	Redacted
18041	TBD	TBD	Redacted	Redacted	Redacted
18042	TBD	TBD	Redacted	Redacted	Redacted
18273	TBD	TBD	Redacted	Redacted	Redacted
18274	TBD	TBD	Redacted	Redacted	Redacted
18276	DevTech Systems Inc	Private Contractor	U.S. Agency for International Development	GHP-State	400,000
18361	TBD	TBD	Redacted	Redacted	Redacted
18369	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State	49,757,913
18502	Population Services International	NGO	U.S. Department of Defense		



Implementing Mechanism(s)

Implementing Mechanism Details

Mechanism ID: 9043	Mechanism Name: Makerere University Walter Reed Project (MUWRP)
Funding Agency: DOD	Procurement Type: Cooperative Agreement
Prime Partner Name: Henry Jackson Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 8,193,639	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 8,193,639	
Funding Source	Funding Amount
GHP-State	8,193,639

Cross-Cutting Budget Attribution(s)

Human Resources for Health	100,000
Food and Nutrition: Policy, Tools, and Service Delivery	2,000
Food and Nutrition: Commodities	10,000
Economic Strengthening	8,000
Construction	2,000,000
Motor Vehicles: Purchased	210,000
Key Populations: MSM and TG	12,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance



Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	30,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Renovation	1,000,000
Gender: GBV	120,000
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

Budget Code Information

Mechanism ID: 9043			
Mechanism Name: Makerere University Walter Reed Project (MUWRP)			
Prime Partner Name: Henry Jackson Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	1,363,410	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	734,675	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HVTB	1,145,716	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	385,564	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	60,624	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	260,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	739,476	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	413,948	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	503,031	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	349,271	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,121,941	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	115,983	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	50,423
PMTCT_ART_DSD	New on ART	1,492
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	2,077
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	9,284
PMTCT_ART_TA	New on ART	279
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	392
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	50,423
PMTCT_STAT_DSD	Number of new ANC and L&D clients	51,712
PMTCT_STAT_DSD	By: Known positives at entry	2,113
PMTCT_STAT_DSD	By: Number of new positives identified	1,647
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	3,760
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	9,284
PMTCT_STAT_TA	Number of new ANC and L&D clients	9,526
PMTCT_STAT_TA	By: Known positives at entry	380
PMTCT_STAT_TA	By: Number of new positives identified	318
PMTCT_STAT_TA	Sum of Positives Status disaggregates	698
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	60,724
VMMC_CIRC_DSD	By Age: 10-14	23,685
VMMC_CIRC_DSD	By Age: 15-19	17,611



VMMC_CIRC_DSD	By Age: 20-24	8,505
VMMC_CIRC_DSD	By Age: 25-29	4,854
VMMC_CIRC_DSD	By Age: 30-49	4,854
VMMC_CIRC_DSD	By Age: 50+	1,215
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	51,016
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	60,724
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	59,864
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	860
PrEP_NEW_DSD	Number of individuals who have received antiretroviral preexposure	1,000
PrEP_NEW_DSD	Male 15-19	248
PrEP_NEW_DSD	Male 20-24	66
PrEP_NEW_DSD	Male 25-49	91
PrEP_NEW_DSD	Male 50+	7
PrEP_NEW_DSD	Female 15-19	335
PrEP_NEW_DSD	Female 20-24	153
PrEP_NEW_DSD	Female 25-49	91
PrEP_NEW_DSD	Female 50+	9
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	34,205
PP_PREV_DSD	Total number of people in the target population	112,986
PP_PREV_DSD	Aggregated Age/sex: <15 Male	5,047
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	6,436
PP_PREV_DSD	Aggregated Age/sex: <15 Female	5,469
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	17,253
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	6,215
KP_PREV_DSD	Total estimated number of key population in the catchment area	9,466
KP_PREV_DSD	By key population type: Men who have sex with men	6,215



	who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	9,466
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	253,855
HTC_TST_DSD	Age/sex: 10-14 Male	3,533
HTC_TST_DSD	Age/sex: 15-19 Male	26,579
HTC_TST_DSD	Age/sex: 20-24 Male	39,869
HTC_TST_DSD	Age/sex: 25-49 Male	61,132
HTC_TST_DSD	Age/sex: 50+ Male	5,313
HTC_TST_DSD	Age/sex: 10-14 Female	3,528
HTC_TST_DSD	Age/sex: 15-19 Female	21,711
HTC_TST_DSD	Age/sex: 20-24 Female	32,566
HTC_TST_DSD	Age/sex: 25-49 Female	49,931
HTC_TST_DSD	Age/sex: 50+ Female	4,337
HTC_TST_DSD	Sum of Age/Sex disaggregates	248,499
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	165
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	584
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	877
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	1,338
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	112
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	164
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	957
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	1,443
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	2,208
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	187
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	6,214



HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	132,893
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	6,203
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	108,545
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	12,417
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	241,438
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	253,855
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	283
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	2,911
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	277
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	4,795
HTC_TST_DSD	Test Result by Age: Positive: <1	47
HTC_TST_DSD	Test Result by Age: Positive: 1-9	184
HTC_TST_DSD	Age/sex: <1	1,253
HTC_TST_DSD	Age/sex: 1-9	4,103
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	26,989
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	79,547
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	9,470
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	14,266
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	59,226
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	50,243
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	1,245
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	12,869
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	29,475
HTC_TST_TA	Age/sex: 10-14 Male	573



HTC_TST_TA	Age/sex: 15-19 Male	2,181
HTC_TST_TA	Age/sex: 20-24 Male	3,278
HTC_TST_TA	Age/sex: 25-49 Male	5,023
HTC_TST_TA	Age/sex: 50+ Male	431
HTC_TST_TA	Age/sex: 10-14 Female	573
HTC_TST_TA	Age/sex: 15-19 Female	3,308
HTC_TST_TA	Age/sex: 20-24 Female	4,963
HTC_TST_TA	Age/sex: 25-49 Female	7,610
HTC_TST_TA	Age/sex: 50+ Female	660
HTC_TST_TA	Sum of Age/Sex disaggregates	28,600
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Male	25
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Male	64
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Male	103
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Male	156
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Male	20
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Female	32
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Female	151
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Female	228
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Female	348
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Female	29
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,006
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	10,913
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,015
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	16,541
HTC_TST_TA	Sum of Aggregated Age/Sex <15	2,021
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	27,454
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	29,475
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15	39



	Male	
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	343
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	45
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	756
HTC_TST_TA	Test Result by Age: Positive: <1	5
HTC_TST_TA	Test Result by Age: Positive: 1-9	22
HTC_TST_TA	Age/sex: <1	205
HTC_TST_TA	Age/sex: 1-9	670
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	3,715
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	9,734
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	1,471
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	1,831
HTC_TST_TA	Service Delivery Point (Facility): VMMC	1,498
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	9,254
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	168
HTC_TST_TA	Service Delivery Point (Facility): Index testing	1,804
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	886
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	886
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	25
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	543
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	21
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number	297



	of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	59
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	59
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	36
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	23
GEND_GBV_DSD	Number of people receiving post-GBV care	3,164
GEND_GBV_DSD	Age/Sex: <10 Male	95
GEND_GBV_DSD	Age/Sex: 10-14 Male	95
GEND_GBV_DSD	Age/Sex: 20-24 Male	160
GEND_GBV_DSD	Age/Sex: 25-49 Male	160
GEND_GBV_DSD	Age/Sex: <10 Female	160
GEND_GBV_DSD	Age/Sex: 10-14 Female	441
GEND_GBV_DSD	Age/Sex: 20-24 Female	780
GEND_GBV_DSD	Age/Sex: 25-49 Female	321
GEND_GBV_DSD	Sum of Age/Sex Disaggregates	791
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	698
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	2,466
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	286
GEND_GBV_DSD	Age/Sex: 15-19 Female	798
GEND_GBV_DSD	Age/Sex: 15-19 male	154
GEND_GBV_TA	Number of people receiving post-GBV care	534
GEND_GBV_TA	Age/Sex: <10 Male	13
GEND_GBV_TA	Age/Sex: 10-14 Male	13
GEND_GBV_TA	Age/Sex: 20-24 Male	26



GEND_GBV_TA	Age/Sex: 25-49 Male	26
GEND_GBV_TA	Age/Sex: <10 Female	26
GEND_GBV_TA	Age/Sex: 10-14 Female	76
GEND_GBV_TA	Age/Sex: 20-24 Female	146
GEND_GBV_TA	Age/Sex: 25-49 Female	54
GEND_GBV_TA	Sum of Age/Sex Disaggregates	128
GEND_GBV_TA	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	118
GEND_GBV_TA	By type of service: Sexual Violence (Post-Rape Care)	416
GEND_GBV_TA	By PEP service provision (related to sexual violence services provided)	46
GEND_GBV_TA	Age/Sex: 15-19 Female	132
GEND_GBV_TA	Age/Sex: 15-19 Male	22
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	14,364
OVC_SERV_DSD	Age/Sex: 18+ Male	1,159
OVC_SERV_DSD	Age/Sex: 18+ Female	1,401
OVC_SERV_DSD	Sum of Age/Sex disaggregates	2,560
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	1,219
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	813
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	2,033
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	3,740
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	3,999
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	372
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	372



TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	249
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	118
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	24
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	24
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	16
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	8
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	36,895
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	1,038
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	11,792



TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	1,172
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	22,893
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	736
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	2,952
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	887
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	1,773
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	292
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	2,564
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	79
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	815
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	91
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	1,579
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	50
TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	206
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	61
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	124
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	21
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	2,358
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	651
PMTCT_EID_DSD	Sum of Infant Age disaggregates	3,009
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	120



PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	25
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	439
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	121
PMTCT_EID_TA	Sum of Infant Age disaggregates	560
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	18
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	1
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	36,895
TX_CURR_DSD	Age/Sex: 15-19 Male	353
TX_CURR_DSD	Age/Sex: 15-19 Female	1,146
TX_CURR_DSD	Sum of age/sex disaggregates	1,499
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,038
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	11,792
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,172
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	22,893
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	2,210
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	34,685
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	36,895
TX_CURR_DSD	Age/Sex: <1	83
TX_CURR_DSD	Age/Sex: <1-9	538
TX_CURR_DSD	Age/Sex: 10-14 Male	737
TX_CURR_DSD	Age/Sex: 10-14 Female	852
TX_CURR_DSD	Age/Sex: 20-24 Male	2,360
TX_CURR_DSD	Age/Sex: 25-49 Male	8,488
TX_CURR_DSD	Age/Sex: 50+ Male	591
TX_CURR_DSD	Age/Sex: 20-24 Female	5,265
TX_CURR_DSD	Age/Sex: 25-49 Female	15,336
TX_CURR_DSD	Age/Sex: 50+ Female	1,146



TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	2,564
TX_CURR_TA	Age/Sex: 15-19 Male	25
TX_CURR_TA	Age/Sex: 15-19 Female	78
TX_CURR_TA	Sum of Age/Sex disaggregations	103
TX_CURR_TA	Aggregated Age/Sex: <15 Male	79
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	815
TX_CURR_TA	Aggregated Age/Sex: <15 Female	91
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	1,579
TX_CURR_TA	Sum of Aggregated Age/Sex <15	170
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	2,394
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	2,564
TX_CURR_TA	Age/Sex: <1	3
TX_CURR_TA	Age/Sex: 1-9	45
TX_CURR_TA	Age/Sex: 10-14 Male	56
TX_CURR_TA	Age/Sex: 10-14 Female	66
TX_CURR_TA	Age/Sex: 20-24 Male	163
TX_CURR_TA	Age/Sex: 25-49 Male	585
TX_CURR_TA	Age/Sex: 50+ Male	42
TX_CURR_TA	Age/Sex: 20-24 Female	363
TX_CURR_TA	Age/Sex: 25-49 Female	1,060
TX_CURR_TA	Age/Sex: 50+ Female	78
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	11,000
TX_NEW_DSD	By Age/Sex: <1	9
TX_NEW_DSD	By Age/Sex: 1-9	105
TX_NEW_DSD	By Age/Sex: 10-14 Male	137
TX_NEW_DSD	By Age/Sex: 15-19 Male	104
TX_NEW_DSD	By Age/Sex: 20-24 Male	721
TX_NEW_DSD	By Age/Sex: 25-49 Male	2,587
TX_NEW_DSD	By Age/Sex: 50+ Male	181
TX_NEW_DSD	By Age/Sex: 10-14 Female	175



TX_NEW_DSD	By Age/Sex: 15-19 Female	349
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,607
TX_NEW_DSD	By Age/Sex: 25-49 Female	4,678
TX_NEW_DSD	By Age/Sex: 50+ Female	347
TX_NEW_DSD	Sum of Age/Sex disaggregates	10,886
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	195
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	3,593
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	231
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	6,981
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	11,000
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	883
TX_NEW_TA	By Age/Sex: 1-9	9
TX_NEW_TA	By Age/Sex: 10-14 Male	12
TX_NEW_TA	By Age/Sex: 15-19 Male	8
TX_NEW_TA	By Age/Sex: 20-24 Male	57
TX_NEW_TA	By Age/Sex: 25-49 Male	208
TX_NEW_TA	By Age/Sex: 50+ Male	15
TX_NEW_TA	By Age/Sex: 10-14 Female	21
TX_NEW_TA	By Age/Sex: 15-19 Female	27
TX_NEW_TA	By Age/Sex: 20-24 Female	127
TX_NEW_TA	By Age/Sex: 25-49 Female	370
TX_NEW_TA	By Age/Sex: 50+ Female	29
TX_NEW_TA	Sum of Age/Sex disaggregates	874
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	18
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	288
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	24
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	553
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	883
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting	26,563



	laboratory results within the past 12 months.	
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	29,514
TX_PVLS_DSD	Numerator: Indication: Routine	26,563
TX_PVLS_DSD	Denominator: Indication: Routine	29,514
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	748
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	8,496
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	843
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	16,476
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	831
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	9,435
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	938
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	18,310
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	1,845
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	2,050
TX_PVLS_TA	Numerator: Indication: Routine	1,845
TX_PVLS_TA	Denominator: Indication: Routine	2,050
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	56
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	589
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	65
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	1,135
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	63
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	651
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	73
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	1,263
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	9,514



TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	10,688
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	11
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	96
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	157
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	188
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	35
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,453
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,511
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	141
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	148
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	672
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults	1,953



	and children who are still alive and on treatment at 12 months after initiating ART	
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	149
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	12
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	103
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	172
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	211
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,389
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,015



TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	339
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	155
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	170
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	757
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,203
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	162
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	220
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,187



TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	185
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,922
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	240
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,954
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	202
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,292
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	607
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	680
TX_RET_TA	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3



TX_RET_TA	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	12
TX_RET_TA	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	12
TX_RET_TA	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1
TX_RET_TA	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	282
TX_RET_TA	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	98
TX_RET_TA	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	11
TX_RET_TA	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	11
TX_RET_TA	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	41
TX_RET_TA	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	126
TX_RET_TA	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10
TX_RET_TA	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3



TX_RET_TA	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	13
TX_RET_TA	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	13
TX_RET_TA	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	89
TX_RET_TA	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	318
TX_RET_TA	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	22
TX_RET_TA	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	11
TX_RET_TA	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	12
TX_RET_TA	Age/Sex: 20-24 Female (Denominator: Total number of	48



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	142
TX_RET_TA	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	14
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	393
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	12
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	188
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	15
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	442



	stopped ART, and those lost to follow-up)	
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	12
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	211
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	105
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	105
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	105

Implementing Mechanism Details

Mechanism ID: 9167	Mechanism Name: Provision of Comprehensive Public Health services for the fishing communities in Kalangala District in the Republic of Uganda under the President's Emergency Plan for AIDS Relief
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Kalangala District Health Office	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 2,230,044	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,230,044	
Funding Source	Funding Amount



GHP-State	2,230,044
-----------	-----------

Cross-Cutting Budget Attribution(s)

Key Populations: FSW	100,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Gender: GBV	150,000
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	50,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation



Budget Code Information

Mechanism ID:		9167	
Mechanism Name:		Provision of Comprehensive Public Health services for the fishing communities in Kalangala District in the Republic of Uganda under the	
Prime Partner Name:		President's Emergency Plan for AIDS Relief Kalangala District Health Office	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	664,617	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	7,235	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	105,014	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	47,556	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	25,450	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	52,443	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	62,551	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	HTXS	1,250,061	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	15,117	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	284
PMTCT_ART_DSD	New on ART	30
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	42
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	2,165
PMTCT_ART_TA	New on ART	227
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	321
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	284
PMTCT_STAT_DSD	Number of new ANC and L&D clients	291
PMTCT_STAT_DSD	By: Known positives at entry	45
PMTCT_STAT_DSD	By: Number of new positives identified	28
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	73
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	2,165
PMTCT_STAT_TA	Number of new ANC and L&D clients	2,219
PMTCT_STAT_TA	By: Known positives at entry	359
PMTCT_STAT_TA	By: Number of new positives identified	215



PMTCT_STAT_TA	Sum of Positives Status disaggregates	574
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	1,964
VMMC_CIRC_DSD	By Age: 10-14	766
VMMC_CIRC_DSD	By Age: 15-19	569
VMMC_CIRC_DSD	By Age: 20-24	275
VMMC_CIRC_DSD	By Age: 25-29	158
VMMC_CIRC_DSD	By Age: 30-49	158
VMMC_CIRC_DSD	By Age: 50+	38
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	1,648
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	1,964
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	1,964
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	3,229
PP_PREV_DSD	Total number of people in the target population	14,428
PP_PREV_DSD	Aggregated Age/sex: <15 Male	698
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	888
PP_PREV_DSD	Aggregated Age/sex: <15 Female	756
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	887
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	85
KP_PREV_DSD	Total estimated number of key population in the catchment area	162
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	85
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key	162



	population in the catchment area)	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	2,155
HTC_TST_DSD	Age/sex: 10-14 Male	33
HTC_TST_DSD	Age/sex: 15-19 Male	198
HTC_TST_DSD	Age/sex: 20-24 Male	297
HTC_TST_DSD	Age/sex: 25-49 Male	455
HTC_TST_DSD	Age/sex: 50+ Male	40
HTC_TST_DSD	Age/sex: 10-14 Female	31
HTC_TST_DSD	Age/sex: 15-19 Female	210
HTC_TST_DSD	Age/sex: 20-24 Female	315
HTC_TST_DSD	Age/sex: 25-49 Female	483
HTC_TST_DSD	Age/sex: 50+ Female	42
HTC_TST_DSD	Sum of Age/Sex disaggregates	2,104
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	4
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	7
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	10
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	16
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	1
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	2
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	13
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	20
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	31
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	3
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	60
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	990
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	55
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,050



HTC_TST_DSD	Sum of Aggregated Age/Sex <15	115
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	2,040
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	2,155
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	5
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	34
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	3
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	67
HTC_TST_DSD	Test Result by Age: Positive: 1-9	2
HTC_TST_DSD	Age/sex: <1	12
HTC_TST_DSD	Age/sex: 1-9	39
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	696
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	168
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	56
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	687
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	290
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	171
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	87
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	12,063
HTC_TST_TA	Age/sex: 10-14 Male	192
HTC_TST_TA	Age/sex: 15-19 Male	1,228
HTC_TST_TA	Age/sex: 20-24 Male	1,842
HTC_TST_TA	Age/sex: 25-49 Male	2,824
HTC_TST_TA	Age/sex: 50+ Male	244
HTC_TST_TA	Age/sex: 10-14 Female	198
HTC_TST_TA	Age/sex: 15-19 Female	1,049
HTC_TST_TA	Age/sex: 20-24 Female	1,572
HTC_TST_TA	Age/sex: 25-49 Female	2,410



HTC_TST_TA	Age/sex: 50+ Female	207
HTC_TST_TA	Sum of Age/Sex disaggregates	11,766
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Male	15
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Male	29
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Male	44
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Male	65
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Male	3
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Female	16
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Female	79
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Female	115
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Female	176
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Female	16
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	339
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	6,138
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	348
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	5,238
HTC_TST_TA	Sum of Aggregated Age/Sex <15	687
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	11,376
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	12,063
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	22
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	141
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	26
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	386
HTC_TST_TA	Test Result by Age: Positive: <1	3
HTC_TST_TA	Test Result by Age: Positive: 1-9	14



HTC_TST_TA	Age/sex: <1	69
HTC_TST_TA	Age/sex: 1-9	228
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	2,930
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	708
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	238
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	2,914
HTC_TST_TA	Service Delivery Point (Facility): VMMC	1,964
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	2,211
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	729
HTC_TST_TA	Service Delivery Point (Facility): Index testing	369
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	200
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	200
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	6
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	121
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	5
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	68
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,598
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	1,598
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	50
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of	973



	registered new and relapsed TB cases with documented HIV status, during the reporting period)	
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	38
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	537
GEND_GBV_DSD	Number of people receiving post-GBV care	16
GEND_GBV_DSD	Age/Sex: 10-14 Female	3
GEND_GBV_DSD	Age/Sex: 20-24 Female	8
GEND_GBV_DSD	Age/Sex: 25-49 Female	1
GEND_GBV_DSD	Sum of Age/Sex Disaggregates	3
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	4
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	12
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	1
GEND_GBV_DSD	Age/Sex: 15-19 Female	4
GEND_GBV_TA	Number of people receiving post-GBV care	122
GEND_GBV_TA	Age/Sex: <10 Male	1
GEND_GBV_TA	Age/Sex: 10-14 Male	1
GEND_GBV_TA	Age/Sex: 20-24 Male	6
GEND_GBV_TA	Age/Sex: 25-49 Male	6
GEND_GBV_TA	Age/Sex: <10 Female	6
GEND_GBV_TA	Age/Sex: 10-14 Female	17
GEND_GBV_TA	Age/Sex: 20-24 Female	37
GEND_GBV_TA	Age/Sex: 25-49 Female	13
GEND_GBV_TA	Sum of Age/Sex Disaggregates	25
GEND_GBV_TA	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	28
GEND_GBV_TA	By type of service: Sexual Violence (Post-Rape Care)	94
GEND_GBV_TA	By PEP service provision (related to sexual violence	11



	services provided)	
GEND_GBV_TA	Age/Sex: 15-19 Female	33
GEND_GBV_TA	Age/Sex: 15-19 Male	2
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	113
OVC_SERV_DSD	Age/Sex: 18+ Male	13
OVC_SERV_DSD	Age/Sex: 18+ Female	15
OVC_SERV_DSD	Sum of Age/Sex disaggregates	28
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	41
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	44
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	135
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	135
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	85
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	46
TB_ART_TA	The number of registered new and relapse TB cases	1,075



	with documented HIV-positive status who are on ART during TB treatment during the reporting period	
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,075
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	20
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	673
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	15
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	367
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	281
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	1
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	94
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	3
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	183
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	6
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	22
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	7
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert	14



	MTB/RIF assay	
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	1
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	18,713
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	123
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	6,270
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	142
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	12,178
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	377
TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	1,496
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	449
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	898
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	149
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	47
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	11
PMTCT_EID_DSD	Sum of Infant Age disaggregates	58
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	3
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	360
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	101
PMTCT_EID_TA	Sum of Infant Age disaggregates	461
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	18
PMTCT_EID_TA	Number of infants with a positive virological test result	4



	within 12 months of birth	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	281
TX_CURR_DSD	Age/Sex: 15-19 Male	3
TX_CURR_DSD	Age/Sex: 15-19 Female	9
TX_CURR_DSD	Sum of age/sex disaggregates	12
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	94
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	3
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	183
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	4
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	277
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	281
TX_CURR_DSD	Age/Sex: 10-14 Male	1
TX_CURR_DSD	Age/Sex: 10-14 Female	3
TX_CURR_DSD	Age/Sex: 20-24 Male	18
TX_CURR_DSD	Age/Sex: 25-49 Male	69
TX_CURR_DSD	Age/Sex: 50+ Male	4
TX_CURR_DSD	Age/Sex: 20-24 Female	42
TX_CURR_DSD	Age/Sex: 25-49 Female	123
TX_CURR_DSD	Age/Sex: 50+ Female	9
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	18,713
TX_CURR_TA	Age/Sex: 15-19 Male	189
TX_CURR_TA	Age/Sex: 15-19 Female	610
TX_CURR_TA	Sum of Age/Sex disaggregations	799
TX_CURR_TA	Aggregated Age/Sex: <15 Male	123
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	6,270
TX_CURR_TA	Aggregated Age/Sex: <15 Female	142
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	12,178
TX_CURR_TA	Sum of Aggregated Age/Sex <15	265
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	18,448



TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	18,713
TX_CURR_TA	Age/Sex: <1	9
TX_CURR_TA	Age/Sex: 1-9	65
TX_CURR_TA	Age/Sex: 10-14 Male	87
TX_CURR_TA	Age/Sex: 10-14 Female	104
TX_CURR_TA	Age/Sex: 20-24 Male	1,255
TX_CURR_TA	Age/Sex: 25-49 Male	4,513
TX_CURR_TA	Age/Sex: 50+ Male	313
TX_CURR_TA	Age/Sex: 20-24 Female	2,802
TX_CURR_TA	Age/Sex: 25-49 Female	8,156
TX_CURR_TA	Age/Sex: 50+ Female	610
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	34
TX_NEW_DSD	By Age/Sex: 20-24 Male	2
TX_NEW_DSD	By Age/Sex: 25-49 Male	8
TX_NEW_DSD	By Age/Sex: 50+ Male	1
TX_NEW_DSD	By Age/Sex: 15-19 Female	1
TX_NEW_DSD	By Age/Sex: 20-24 Female	5
TX_NEW_DSD	By Age/Sex: 25-49 Female	15
TX_NEW_DSD	By Age/Sex: 50+ Female	2
TX_NEW_DSD	Sum of Age/Sex disaggregates	34
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	11
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	23
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	34
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,656
TX_NEW_TA	By Age/Sex: 1-9	7
TX_NEW_TA	By Age/Sex: 10-14 Male	10
TX_NEW_TA	By Age/Sex: 15-19 Male	27
TX_NEW_TA	By Age/Sex: 20-24 Male	178
TX_NEW_TA	By Age/Sex: 25-49 Male	639
TX_NEW_TA	By Age/Sex: 50+ Male	47



TX_NEW_TA	By Age/Sex: 10-14 Female	14
TX_NEW_TA	By Age/Sex: 15-19 Female	87
TX_NEW_TA	By Age/Sex: 20-24 Female	397
TX_NEW_TA	By Age/Sex: 25-49 Female	1,163
TX_NEW_TA	By Age/Sex: 50+ Female	87
TX_NEW_TA	Sum of Age/Sex disaggregates	2,649
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	14
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	891
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	17
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	1,734
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	2,656
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	203
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	225
TX_PVLS_DSD	Numerator: Indication: Routine	203
TX_PVLS_DSD	Denominator: Indication: Routine	225
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	1
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	68
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	3
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	131
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	1
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	75
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	3
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	146
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	13,473
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral	14,969

	load result documented in the patient medical record and /or laboratory records in the past 12 months.	
TX_PVLS_TA	Numerator: Indication: Routine	13,473
TX_PVLS_TA	Denominator: Indication: Routine	14,969
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	88
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	4,517
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	104
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	8,764
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	99
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	5,015
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	115
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	9,740
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	293
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	330
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	6
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	6
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	137
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and	45



	children who are still alive and on treatment at 12 months after initiating ART	
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	22
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	60
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including	42



	those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	154
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	10
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	23
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	69
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4



	and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	189
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	91
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	213
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	102
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	6,395



TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	7,184
TX_RET_TA	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8
TX_RET_TA	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	65
TX_RET_TA	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	102
TX_RET_TA	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	123
TX_RET_TA	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	23
TX_RET_TA	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,996
TX_RET_TA	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,020
TX_RET_TA	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	91
TX_RET_TA	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	98
TX_RET_TA	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	454
TX_RET_TA	Age/Sex: 25-49 Female (Numerator: Number of adults	1,319



	and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_TA	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	96
TX_RET_TA	Age/Sex: <1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9
TX_RET_TA	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	72
TX_RET_TA	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	113
TX_RET_TA	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	141
TX_RET_TA	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	937
TX_RET_TA	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,366



TX_RET_TA	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	231
TX_RET_TA	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	103
TX_RET_TA	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	111
TX_RET_TA	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	509
TX_RET_TA	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,481
TX_RET_TA	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	111
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	145
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,162



TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	121
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,967
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	161
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,675
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	136
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,212

Implementing Mechanism Details

Mechanism ID: 9183	Mechanism Name: Accelerating Delivery of Comprehensive HIV/AIDS/TB services including Prevention, Care, Support and Treatment of people living with HIV/AIDS in the Republic of Uganda under the President's Emergency Plan for AIDS Relief
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: The AIDS Support Organization	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 8,703,140	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 8,703,140	
Funding Source	Funding Amount
GHP-State	8,703,140

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	9183		
Mechanism Name:	Accelerating Delivery of Comprehensive HIV/AIDS/TB services including Prevention, Care, Support and Treatment of people living with HIV/AIDS		
Prime Partner Name:	in the Republic of Uganda under the President's Emergency Plan for AIDS Relief		
	The AIDS Support Organization		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	1,710,303	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	415,487	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	620,400	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	1,102,675	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	649,620	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	260,808	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	171,161	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	3,555,115	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	217,570	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	21,259
PMTCT_ART_DSD	New on ART	303
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	428



PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	32,762
PMTCT_ART_TA	New on ART	430
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	594
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	21,259
PMTCT_STAT_DSD	Number of new ANC and L&D clients	21,806
PMTCT_STAT_DSD	By: Known positives at entry	428
PMTCT_STAT_DSD	By: Number of new positives identified	330
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	758
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	32,762
PMTCT_STAT_TA	Number of new ANC and L&D clients	33,598
PMTCT_STAT_TA	By: Known positives at entry	594
PMTCT_STAT_TA	By: Number of new positives identified	473
PMTCT_STAT_TA	Sum of Positives Status disaggregates	1,067
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	54,590
VMMC_CIRC_DSD	By Age: 10-14	21,289
VMMC_CIRC_DSD	By Age: 15-19	15,832
VMMC_CIRC_DSD	By Age: 20-24	7,644
VMMC_CIRC_DSD	By Age: 25-29	4,370
VMMC_CIRC_DSD	By Age: 30-49	4,370
VMMC_CIRC_DSD	By Age: 50+	1,085
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	45,850
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	54,590
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	54,590
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the	14,269



	minimum components during the reporting period.	
PP_PREV_DSD	Total number of people in the target population	80,082
PP_PREV_DSD	Aggregated Age/sex: <15 Male	3,082
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	3,932
PP_PREV_DSD	Aggregated Age/sex: <15 Female	3,338
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	3,918
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	10,728
KP_PREV_DSD	Total estimated number of key population in the catchment area	14,897
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	10,618
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	110
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	852
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	366
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	13,679
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	203,009



HTC_TST_DSD	Age/sex: 10-14 Male	5,539
HTC_TST_DSD	Age/sex: 15-19 Male	22,779
HTC_TST_DSD	Age/sex: 20-24 Male	34,173
HTC_TST_DSD	Age/sex: 25-49 Male	52,398
HTC_TST_DSD	Age/sex: 50+ Male	4,554
HTC_TST_DSD	Age/sex: 10-14 Female	5,547
HTC_TST_DSD	Age/sex: 15-19 Female	13,932
HTC_TST_DSD	Age/sex: 20-24 Female	20,898
HTC_TST_DSD	Age/sex: 25-49 Female	32,041
HTC_TST_DSD	Age/sex: 50+ Female	2,781
HTC_TST_DSD	Sum of Age/Sex disaggregates	194,642
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	249
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	583
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	874
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	1,338
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	118
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	257
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	541
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	809
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	1,242
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	108
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	9,722
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	113,904
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	9,731
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	69,652
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	19,453
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	183,556
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	203,009



HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	436
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	2,913
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	444
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	2,700
HTC_TST_DSD	Test Result by Age: Positive: <1	82
HTC_TST_DSD	Test Result by Age: Positive: 1-9	292
HTC_TST_DSD	Age/sex: <1	1,947
HTC_TST_DSD	Age/sex: 1-9	6,420
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	9,114
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	71,553
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	18,853
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	12,218
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	54,590
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	20,970
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	1,828
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	13,883
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	73,472
HTC_TST_TA	Age/sex: 10-14 Male	1,785
HTC_TST_TA	Age/sex: 15-19 Male	3,920
HTC_TST_TA	Age/sex: 20-24 Male	5,882
HTC_TST_TA	Age/sex: 25-49 Male	9,018
HTC_TST_TA	Age/sex: 50+ Male	783
HTC_TST_TA	Age/sex: 10-14 Female	1,785
HTC_TST_TA	Age/sex: 15-19 Female	9,517
HTC_TST_TA	Age/sex: 20-24 Female	14,277
HTC_TST_TA	Age/sex: 25-49 Female	21,891
HTC_TST_TA	Age/sex: 50+ Female	1,896



HTC_TST_TA	Sum of Age/Sex disaggregates	70,754
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Male	51
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Male	63
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Male	93
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Male	145
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Male	12
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Female	54
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Female	185
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Female	283
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Female	427
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Female	38
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3,143
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	19,603
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	3,145
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	47,581
HTC_TST_TA	Sum of Aggregated Age/Sex <15	6,288
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	67,184
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	73,472
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	78
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	313
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	85
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	933
HTC_TST_TA	Test Result by Age: Positive: <1	7
HTC_TST_TA	Test Result by Age: Positive: 1-9	51
HTC_TST_TA	Age/sex: <1	637



HTC_TST_TA	Age/sex: 1-9	2,081
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	13,133
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	11,419
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	5,445
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	7,493
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	32,260
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	1,595
HTC_TST_TA	Service Delivery Point (Facility): Index testing	2,127
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,516
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,516
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	49
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	922
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	37
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	505
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	304
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	304
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	8
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	187



TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	5
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	89
GEND_GBV_DSD	Number of people receiving post-GBV care	1,191
GEND_GBV_DSD	Age/Sex: <10 Male	35
GEND_GBV_DSD	Age/Sex: 10-14 Male	35
GEND_GBV_DSD	Age/Sex: 20-24 Male	58
GEND_GBV_DSD	Age/Sex: 25-49 Male	58
GEND_GBV_DSD	Age/Sex: <10 Female	58
GEND_GBV_DSD	Age/Sex: 10-14 Female	167
GEND_GBV_DSD	Age/Sex: 20-24 Female	310
GEND_GBV_DSD	Age/Sex: 25-49 Female	120
GEND_GBV_DSD	Sum of Age/Sex Disaggregates	295
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	259
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	932
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	106
GEND_GBV_DSD	Age/Sex: 15-19 Female	294
GEND_GBV_DSD	Age/Sex: 15-19 male	56
GEND_GBV_TA	Number of people receiving post-GBV care	1,842
GEND_GBV_TA	Age/Sex: <10 Male	57
GEND_GBV_TA	Age/Sex: 10-14 Male	57
GEND_GBV_TA	Age/Sex: 20-24 Male	94
GEND_GBV_TA	Age/Sex: 25-49 Male	94
GEND_GBV_TA	Age/Sex: <10 Female	94
GEND_GBV_TA	Age/Sex: 10-14 Female	259
GEND_GBV_TA	Age/Sex: 20-24 Female	456
GEND_GBV_TA	Age/Sex: 25-49 Female	185
GEND_GBV_TA	Sum of Age/Sex Disaggregates	467

GEND_GBV_TA	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	403
GEND_GBV_TA	By type of service: Sexual Violence (Post-Rape Care)	1,439
GEND_GBV_TA	By PEP service provision (related to sexual violence services provided)	167
GEND_GBV_TA	Age/Sex: 15-19 Female	458
GEND_GBV_TA	Age/Sex: 15-19 Male	88
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	683
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	683
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	11
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	427
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	8
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	235
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	81
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	81

TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	53
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	19
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	89,973
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	3,294
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	28,197
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	3,715
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	54,767
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	1,802
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	7,196
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	2,159
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	4,318
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	719
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	9,317
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	306
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	2,946
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	348

TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	5,717
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	188
TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	746
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	224
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	447
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	75
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	481
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	128
PMTCT_EID_DSD	Sum of Infant Age disaggregates	609
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	24
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	5
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	675
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	181
PMTCT_EID_TA	Sum of Infant Age disaggregates	856
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	37
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	5
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	89,973
TX_CURR_DSD	Age/Sex: 15-19 Male	841
TX_CURR_DSD	Age/Sex: 15-19 Female	2,739
TX_CURR_DSD	Sum of age/sex disaggregates	3,580
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	3,294



TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	28,197
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	3,715
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	54,767
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	7,009
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	82,964
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	89,973
TX_CURR_DSD	Age/Sex: <1	276
TX_CURR_DSD	Age/Sex: <1-9	1,680
TX_CURR_DSD	Age/Sex: 10-14 Male	2,342
TX_CURR_DSD	Age/Sex: 10-14 Female	2,711
TX_CURR_DSD	Age/Sex: 20-24 Male	5,640
TX_CURR_DSD	Age/Sex: 25-49 Male	20,306
TX_CURR_DSD	Age/Sex: 50+ Male	1,410
TX_CURR_DSD	Age/Sex: 20-24 Female	12,596
TX_CURR_DSD	Age/Sex: 25-49 Female	36,693
TX_CURR_DSD	Age/Sex: 50+ Female	2,739
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	9,317
TX_CURR_TA	Age/Sex: 15-19 Male	88
TX_CURR_TA	Age/Sex: 15-19 Female	289
TX_CURR_TA	Sum of Age/Sex disaggregations	377
TX_CURR_TA	Aggregated Age/Sex: <15 Male	306
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	2,946
TX_CURR_TA	Aggregated Age/Sex: <15 Female	348
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	5,717
TX_CURR_TA	Sum of Aggregated Age/Sex <15	654
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	8,663
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	9,317
TX_CURR_TA	Age/Sex: <1	15
TX_CURR_TA	Age/Sex: 1-9	172
TX_CURR_TA	Age/Sex: 10-14 Male	217
TX_CURR_TA	Age/Sex: 10-14 Female	250



TX_CURR_TA	Age/Sex: 20-24 Male	591
TX_CURR_TA	Age/Sex: 25-49 Male	2,119
TX_CURR_TA	Age/Sex: 50+ Male	148
TX_CURR_TA	Age/Sex: 20-24 Female	1,315
TX_CURR_TA	Age/Sex: 25-49 Female	3,824
TX_CURR_TA	Age/Sex: 50+ Female	289
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	10,928
TX_NEW_DSD	By Age/Sex: <1	47
TX_NEW_DSD	By Age/Sex: 1-9	282
TX_NEW_DSD	By Age/Sex: 10-14 Male	392
TX_NEW_DSD	By Age/Sex: 15-19 Male	97
TX_NEW_DSD	By Age/Sex: 20-24 Male	663
TX_NEW_DSD	By Age/Sex: 25-49 Male	2,385
TX_NEW_DSD	By Age/Sex: 50+ Male	168
TX_NEW_DSD	By Age/Sex: 10-14 Female	459
TX_NEW_DSD	By Age/Sex: 15-19 Female	323
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,478
TX_NEW_DSD	By Age/Sex: 25-49 Female	4,311
TX_NEW_DSD	By Age/Sex: 50+ Female	323
TX_NEW_DSD	Sum of Age/Sex disaggregates	10,599
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	554
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	3,313
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	626
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	6,435
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	10,928
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,165
TX_NEW_TA	By Age/Sex: 1-9	14
TX_NEW_TA	By Age/Sex: 10-14 Male	34
TX_NEW_TA	By Age/Sex: 15-19 Male	15
TX_NEW_TA	By Age/Sex: 20-24 Male	141



TX_NEW_TA	By Age/Sex: 25-49 Male	509
TX_NEW_TA	By Age/Sex: 50+ Male	43
TX_NEW_TA	By Age/Sex: 10-14 Female	55
TX_NEW_TA	By Age/Sex: 15-19 Female	69
TX_NEW_TA	By Age/Sex: 20-24 Female	312
TX_NEW_TA	By Age/Sex: 25-49 Female	909
TX_NEW_TA	By Age/Sex: 50+ Female	64
TX_NEW_TA	Sum of Age/Sex disaggregates	2,151
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	41
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	708
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	62
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	1,354
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	2,165
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	50,920
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	56,576
TX_PVLS_DSD	Numerator: Indication: Routine	50,920
TX_PVLS_DSD	Denominator: Indication: Routine	56,576
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	1,933
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	15,920
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	2,182
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	30,885
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	2,148
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	17,680
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	2,426
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	34,322
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting	4,264



	laboratory results within the past 12 months.	
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	4,738
TX_PVLS_TA	Numerator: Indication: Routine	4,264
TX_PVLS_TA	Denominator: Indication: Routine	4,738
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	153
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	1,344
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	175
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	2,592
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	170
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	1,491
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	195
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	2,882
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	8,821
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	9,911
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	13
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	87
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	138
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	172
TX_RET_DSD	Age/Sed: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12	35



	months after initiating ART	
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,128
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,398
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	127
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	134
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	625
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,825
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	139
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	17
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	97
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including	156



	those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	192
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,287
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,634
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	326
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	143
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	152
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART,	704



	and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,050
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	153
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	195
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,733
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	170
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,723
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	221
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,439
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the	192



	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,059
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,102
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,239
TX_RET_TA	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6
TX_RET_TA	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	23
TX_RET_TA	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	22
TX_RET_TA	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2
TX_RET_TA	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	516
TX_RET_TA	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	178
TX_RET_TA	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	19



TX_RET_TA	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	16
TX_RET_TA	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	80
TX_RET_TA	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	222
TX_RET_TA	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	18
TX_RET_TA	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6
TX_RET_TA	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	24
TX_RET_TA	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	24
TX_RET_TA	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	161
TX_RET_TA	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including	584



	those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	39
TX_RET_TA	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	19
TX_RET_TA	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	18
TX_RET_TA	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	88
TX_RET_TA	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	256
TX_RET_TA	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	20
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	27



TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	718
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	21
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	336
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	28
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	808
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	21
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	382

Implementing Mechanism Details

Mechanism ID: 9303	Mechanism Name: DOD Mechanism
Funding Agency: DOD	Procurement Type: Cooperative Agreement
Prime Partner Name: U.S. Department of Defense (Defense)	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 670,242	
Total All Funding Sources and Applied Pipeline Amount: 670,242	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 9303			
Mechanism Name: DOD Mechanism			
Prime Partner Name: U.S. Department of Defense (Defense)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 9483	Mechanism Name: Expansion of Routine Confidential HCT and provision of basic Care in Clinics, Hospitals and HC Ivs
---------------------------	---



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Infectious Disease Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GAP	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	9483		
Mechanism Name:	Expansion of Routine Confidential HCT and provision of basic Care in		
Prime Partner Name:	Clinics, Hospitals and HC Ivs		
	Infectious Disease Institute		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 9879	Mechanism Name: STRENGTHENING TUBERCULOSIS AND HIV/AIDS RESPONSES IN THE EASTERN REGION OF UGANDA (STAR-E)
Funding Agency: USAID	Procurement Type: Cooperative Agreement



Prime Partner Name: Management Sciences for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 894,778	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 894,778	
Funding Source	Funding Amount
GHP-State	894,778

Cross-Cutting Budget Attribution(s)

Gender: GBV	376,668
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Key Populations: MSM and TG	88,334
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Key Populations: FSW	88,334
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers



Focus Area:	Collection and use of strategic information on SWs and clients
-------------	--

Budget Code Information

Mechanism ID:	9879		
Mechanism Name:	STRENGTHENING TUBERCULOSIS AND HIV/AIDS RESPONSES IN THE EASTERN REGION OF UGANDA (STAR-E)		
Prime Partner Name:	Management Sciences for Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	46,636	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	11,153	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	12,732	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	196,513	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	243,770	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVOP	275,602	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	12,894	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	91,221	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	4,257	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	9,665
PMTCT_ART_DSD	New on ART	134
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	186
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	33,520
PMTCT_ART_TA	New on ART	427
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	598
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	9,665
PMTCT_STAT_DSD	Number of new ANC and L&D clients	9,911
PMTCT_STAT_DSD	By: Known positives at entry	204
PMTCT_STAT_DSD	By: Number of new positives identified	133
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	337
PMTCT_STAT_TA	Number of pregnant women with known HIV status	33,520



	(includes women who were tested for HIV and received their results)	
PMTCT_STAT_TA	Number of new ANC and L&D clients	34,374
PMTCT_STAT_TA	By: Known positives at entry	642
PMTCT_STAT_TA	By: Number of new positives identified	433
PMTCT_STAT_TA	Sum of Positives Status disaggregates	1,075
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	23,278
VMMC_CIRC_DSD	By Age: 10-14	9,078
VMMC_CIRC_DSD	By Age: 15-19	6,750
VMMC_CIRC_DSD	By Age: 20-24	3,260
VMMC_CIRC_DSD	By Age: 25-29	1,861
VMMC_CIRC_DSD	By Age: 30-49	1,861
VMMC_CIRC_DSD	By Age: 50+	468
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	19,556
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	23,278
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	23,278
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	1,514
PP_PREV_DSD	Total number of people in the target population	4,402
PP_PREV_DSD	Aggregated Age/sex: <15 Male	319
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	413
PP_PREV_DSD	Aggregated Age/sex: <15 Female	348
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	412
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	2,174
KP_PREV_DSD	Total estimated number of key population in the catchment area	3,858
KP_PREV_DSD	By key population type: Men who have sex with men	2,151



	who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	23
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	184
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	81
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	3,593
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	36,032
HTC_TST_DSD	Age/sex: 10-14 Male	830
HTC_TST_DSD	Age/sex: 15-19 Male	3,547
HTC_TST_DSD	Age/sex: 20-24 Male	5,319
HTC_TST_DSD	Age/sex: 25-49 Male	8,156
HTC_TST_DSD	Age/sex: 50+ Male	708
HTC_TST_DSD	Age/sex: 10-14 Female	832
HTC_TST_DSD	Age/sex: 15-19 Female	3,074
HTC_TST_DSD	Age/sex: 20-24 Female	4,617
HTC_TST_DSD	Age/sex: 25-49 Female	7,077
HTC_TST_DSD	Age/sex: 50+ Female	612
HTC_TST_DSD	Sum of Age/Sex disaggregates	34,772
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	18



HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	29
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	48
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	69
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	6
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	21
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	63
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	97
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	142
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	14
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,461
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	17,730
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,461
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	15,380
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	2,922
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	33,110
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	36,032
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	31
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	152
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	32
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	316
HTC_TST_DSD	Test Result by Age: Positive: <1	6
HTC_TST_DSD	Test Result by Age: Positive: 1-9	18
HTC_TST_DSD	Age/sex: <1	296
HTC_TST_DSD	Age/sex: 1-9	964
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	4,467



HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	7,675
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	2,657
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	1,073
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	10,273
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	9,485
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	143
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	259
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	123,140
HTC_TST_TA	Age/sex: 10-14 Male	3,680
HTC_TST_TA	Age/sex: 15-19 Male	9,732
HTC_TST_TA	Age/sex: 20-24 Male	14,612
HTC_TST_TA	Age/sex: 25-49 Male	22,394
HTC_TST_TA	Age/sex: 50+ Male	1,934
HTC_TST_TA	Age/sex: 10-14 Female	3,680
HTC_TST_TA	Age/sex: 15-19 Female	12,307
HTC_TST_TA	Age/sex: 20-24 Female	18,463
HTC_TST_TA	Age/sex: 25-49 Female	28,300
HTC_TST_TA	Age/sex: 50+ Female	2,455
HTC_TST_TA	Sum of Age/Sex disaggregates	117,557
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Male	84
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Male	129
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Male	203
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Male	302
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Male	23
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Female	90
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Female	259
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Female	391
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Female	590
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Female	37
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION	6,469



	ONLY: <15 Male	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	48,672
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	6,474
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	61,525
HTC_TST_TA	Sum of Aggregated Age/Sex <15	12,943
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	110,197
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	123,140
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	128
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	657
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	137
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,277
HTC_TST_TA	Test Result by Age: Positive: <1	10
HTC_TST_TA	Test Result by Age: Positive: 1-9	81
HTC_TST_TA	Age/sex: <1	1,304
HTC_TST_TA	Age/sex: 1-9	4,279
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	21,871
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	35,979
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	12,093
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	5,154
HTC_TST_TA	Service Delivery Point (Facility): VMMC	13,005
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	32,912
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	689
HTC_TST_TA	Service Delivery Point (Facility): Index testing	1,437
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	124
TB_STAT_DSD	Total number of registered new and relapsed TB cases,	124



	during the reporting period.	
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	79
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	41
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	657
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	657
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	16
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	406
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	12
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	223
GEND_GBV_DSD	Number of people receiving post-GBV care	543
GEND_GBV_DSD	Age/Sex: <10 Male	14
GEND_GBV_DSD	Age/Sex: 10-14 Male	14
GEND_GBV_DSD	Age/Sex: 20-24 Male	26
GEND_GBV_DSD	Age/Sex: 25-49 Male	26



GEND_GBV_DSD	Age/Sex: <10 Female	26
GEND_GBV_DSD	Age/Sex: 10-14 Female	77
GEND_GBV_DSD	Age/Sex: 20-24 Female	144
GEND_GBV_DSD	Age/Sex: 25-49 Female	55
GEND_GBV_DSD	Sum of Age/Sex Disaggregates	131
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	120
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	423
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	50
GEND_GBV_DSD	Age/Sex: 15-19 Female	135
GEND_GBV_DSD	Age/Sex: 15-19 male	26
GEND_GBV_TA	Number of people receiving post-GBV care	1,882
GEND_GBV_TA	Age/Sex: <10 Male	62
GEND_GBV_TA	Age/Sex: 10-14 Male	62
GEND_GBV_TA	Age/Sex: 20-24 Male	100
GEND_GBV_TA	Age/Sex: 25-49 Male	100
GEND_GBV_TA	Age/Sex: <10 Female	100
GEND_GBV_TA	Age/Sex: 10-14 Female	268
GEND_GBV_TA	Age/Sex: 20-24 Female	440
GEND_GBV_TA	Age/Sex: 25-49 Female	194
GEND_GBV_TA	Sum of Age/Sex Disaggregates	492
GEND_GBV_TA	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	420
GEND_GBV_TA	By type of service: Sexual Violence (Post-Rape Care)	1,462
GEND_GBV_TA	By PEP service provision (related to sexual violence services provided)	173
GEND_GBV_TA	Age/Sex: 15-19 Female	468
GEND_GBV_TA	Age/Sex: 15-19 Male	88
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	37
TB_ART_DSD	The number of registered new and relapse TB cases	37



	with documented HIV-positive status during TB treatment during the reporting period	
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	27
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	10
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	196
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	196
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	146
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	49
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	6,349
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	179
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	2,027
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	207
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	3,936

TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	129
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	507
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	154
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	305
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	48
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	16,055
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	457
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	5,122
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	528
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	9,948
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	322
TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	1,286
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	390
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	775
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	121
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	210
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	61
PMTCT_EID_DSD	Sum of Infant Age disaggregates	271
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	10
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	1



PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	681
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	176
PMTCT_EID_TA	Sum of Infant Age disaggregates	857
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	34
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	6,349
TX_CURR_DSD	Age/Sex: 15-19 Male	61
TX_CURR_DSD	Age/Sex: 15-19 Female	197
TX_CURR_DSD	Sum of age/sex disaggregates	258
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	179
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	2,027
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	207
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	3,936
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	386
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	5,963
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	6,349
TX_CURR_DSD	Age/Sex: <1	15
TX_CURR_DSD	Age/Sex: <1-9	94
TX_CURR_DSD	Age/Sex: 10-14 Male	126
TX_CURR_DSD	Age/Sex: 10-14 Female	151
TX_CURR_DSD	Age/Sex: 20-24 Male	407
TX_CURR_DSD	Age/Sex: 25-49 Male	1,459
TX_CURR_DSD	Age/Sex: 50+ Male	100
TX_CURR_DSD	Age/Sex: 20-24 Female	904
TX_CURR_DSD	Age/Sex: 25-49 Female	2,638
TX_CURR_DSD	Age/Sex: 50+ Female	197
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	16,055
TX_CURR_TA	Age/Sex: 15-19 Male	153



TX_CURR_TA	Age/Sex: 15-19 Female	496
TX_CURR_TA	Sum of Age/Sex disaggregations	649
TX_CURR_TA	Aggregated Age/Sex: <15 Male	457
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	5,122
TX_CURR_TA	Aggregated Age/Sex: <15 Female	528
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	9,948
TX_CURR_TA	Sum of Aggregated Age/Sex <15	985
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	15,070
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	16,055
TX_CURR_TA	Age/Sex: <1	27
TX_CURR_TA	Age/Sex: 1-9	254
TX_CURR_TA	Age/Sex: 10-14 Male	324
TX_CURR_TA	Age/Sex: 10-14 Female	380
TX_CURR_TA	Age/Sex: 20-24 Male	1,029
TX_CURR_TA	Age/Sex: 25-49 Male	3,684
TX_CURR_TA	Age/Sex: 50+ Male	256
TX_CURR_TA	Age/Sex: 20-24 Female	2,287
TX_CURR_TA	Age/Sex: 25-49 Female	6,669
TX_CURR_TA	Age/Sex: 50+ Female	496
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	698
TX_NEW_DSD	By Age/Sex: <1	1
TX_NEW_DSD	By Age/Sex: 1-9	14
TX_NEW_DSD	By Age/Sex: 10-14 Male	16
TX_NEW_DSD	By Age/Sex: 15-19 Male	7
TX_NEW_DSD	By Age/Sex: 20-24 Male	43
TX_NEW_DSD	By Age/Sex: 25-49 Male	154
TX_NEW_DSD	By Age/Sex: 50+ Male	10
TX_NEW_DSD	By Age/Sex: 10-14 Female	23
TX_NEW_DSD	By Age/Sex: 15-19 Female	20
TX_NEW_DSD	By Age/Sex: 20-24 Female	101
TX_NEW_DSD	By Age/Sex: 25-49 Female	288



TX_NEW_DSD	By Age/Sex: 50+ Female	19
TX_NEW_DSD	Sum of Age/Sex disaggregates	681
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	23
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	214
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	31
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	428
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	696
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,571
TX_NEW_TA	By Age/Sex: 1-9	54
TX_NEW_TA	By Age/Sex: 10-14 Male	75
TX_NEW_TA	By Age/Sex: 15-19 Male	16
TX_NEW_TA	By Age/Sex: 20-24 Male	159
TX_NEW_TA	By Age/Sex: 25-49 Male	563
TX_NEW_TA	By Age/Sex: 50+ Male	42
TX_NEW_TA	By Age/Sex: 10-14 Female	121
TX_NEW_TA	By Age/Sex: 15-19 Female	73
TX_NEW_TA	By Age/Sex: 20-24 Female	355
TX_NEW_TA	By Age/Sex: 25-49 Female	1,029
TX_NEW_TA	By Age/Sex: 50+ Female	82
TX_NEW_TA	Sum of Age/Sex disaggregates	2,515
TX_NEW_TA	Aggregated Grouping by Age: <1	2
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	107
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	780
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	145
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	1,539
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	2,571

Implementing Mechanism Details

Mechanism ID: 10326	Mechanism Name: Strengthening Uganda's Systems for Treating AIDS Nationally (SUSTAIN)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University Research Corporation, LLC	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 16,332,296	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 16,332,296	
Funding Source	Funding Amount
GHP-State	16,332,296

Cross-Cutting Budget Attribution(s)

Human Resources for Health	100
Key Populations: MSM and TG	150
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG
Key Populations: FSW	150
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs



Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
-------------	--

Budget Code Information

Mechanism ID:	10326		
Mechanism Name:	Strengthening Uganda's Systems for Treating AIDS Nationally		
Prime Partner Name:	(SUSTAIN) University Research Corporation, LLC		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	2,709,138	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	461,141	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	1,029,641	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	2,578,120	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	908,485	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	455,091	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	HTXS	7,637,851	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	552,829	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	57,476
PMTCT_ART_DSD	New on ART	1,525
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	2,125
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	57,476
PMTCT_STAT_DSD	Number of new ANC and L&D clients	58,948
PMTCT_STAT_DSD	By: Known positives at entry	2,323
PMTCT_STAT_DSD	By: Number of new positives identified	1,533
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	3,856
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	128,558
VMMC_CIRC_DSD	By Age: 10-14	50,142
VMMC_CIRC_DSD	By Age: 15-19	37,278
VMMC_CIRC_DSD	By Age: 20-24	18,001
VMMC_CIRC_DSD	By Age: 25-29	10,285
VMMC_CIRC_DSD	By Age: 30-49	10,285
VMMC_CIRC_DSD	By Age: 50+	2,567
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	107,988
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	128,558
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	128,558



HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	580,902
HTC_TST_DSD	Age/sex: 10-14 Male	12,269
HTC_TST_DSD	Age/sex: 15-19 Male	64,607
HTC_TST_DSD	Age/sex: 20-24 Male	96,914
HTC_TST_DSD	Age/sex: 25-49 Male	148,596
HTC_TST_DSD	Age/sex: 50+ Male	12,918
HTC_TST_DSD	Age/sex: 10-14 Female	12,271
HTC_TST_DSD	Age/sex: 15-19 Female	42,963
HTC_TST_DSD	Age/sex: 20-24 Female	64,445
HTC_TST_DSD	Age/sex: 25-49 Female	98,814
HTC_TST_DSD	Age/sex: 50+ Female	8,590
HTC_TST_DSD	Sum of Age/Sex disaggregates	562,387
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	372
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	1,021
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	1,532
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	2,350
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	204
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	367
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	1,472
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	2,208
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	3,383
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	292
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	21,525
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	323,035
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	21,530
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	214,812
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	43,055



HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	537,847
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	580,902
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	649
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	5,107
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	644
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	7,355
HTC_TST_DSD	Test Result by Age: Positive: <1	124
HTC_TST_DSD	Test Result by Age: Positive: 1-9	430
HTC_TST_DSD	Age/sex: <1	4,308
HTC_TST_DSD	Age/sex: 1-9	14,207
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	94,691
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	182,752
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	40,046
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	30,778
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	128,558
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	56,773
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	3,247
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	44,057
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	4,597
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	4,597
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	148
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,797
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number	113



	of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,539
GEND_GBV_DSD	Number of people receiving post-GBV care	3,227
GEND_GBV_DSD	Age/Sex: <10 Male	97
GEND_GBV_DSD	Age/Sex: 10-14 Male	97
GEND_GBV_DSD	Age/Sex: 20-24 Male	161
GEND_GBV_DSD	Age/Sex: 25-49 Male	161
GEND_GBV_DSD	Age/Sex: <10 Female	161
GEND_GBV_DSD	Age/Sex: 10-14 Female	452
GEND_GBV_DSD	Age/Sex: 20-24 Female	809
GEND_GBV_DSD	Age/Sex: 25-49 Female	323
GEND_GBV_DSD	Sum of Age/Sex Disaggregates	807
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	711
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	2,516
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	291
GEND_GBV_DSD	Age/Sex: 15-19 Female	806
GEND_GBV_DSD	Age/Sex: 15-19 male	160
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,776
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,776
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	32
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with	1,110

	documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	25
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	609
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	80,284
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	2,390
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	25,560
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	2,697
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	49,637
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	1,605
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	6,421
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	1,926
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	3,853
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	642
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	2,405
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	680
PMTCT_EID_DSD	Sum of Infant Age disaggregates	3,085
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	121
PMTCT_EID_DSD	Number of infants with a positive virological test result	31



	within 12 months of birth	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	80,284
TX_CURR_DSD	Age/Sex: 15-19 Male	766
TX_CURR_DSD	Age/Sex: 15-19 Female	2,482
TX_CURR_DSD	Sum of age/sex disaggregates	3,248
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	2,390
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	25,560
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	2,697
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	49,637
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	5,087
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	75,197
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	80,284
TX_CURR_DSD	Age/Sex: <1	204
TX_CURR_DSD	Age/Sex: <1-9	1,215
TX_CURR_DSD	Age/Sex: 10-14 Male	1,697
TX_CURR_DSD	Age/Sex: 10-14 Female	1,971
TX_CURR_DSD	Age/Sex: 20-24 Male	5,112
TX_CURR_DSD	Age/Sex: 25-49 Male	18,404
TX_CURR_DSD	Age/Sex: 50+ Male	1,278
TX_CURR_DSD	Age/Sex: 20-24 Female	11,417
TX_CURR_DSD	Age/Sex: 25-49 Female	33,256
TX_CURR_DSD	Age/Sex: 50+ Female	2,482
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	19,623
TX_NEW_DSD	By Age/Sex: <1	45
TX_NEW_DSD	By Age/Sex: 1-9	288
TX_NEW_DSD	By Age/Sex: 10-14 Male	401
TX_NEW_DSD	By Age/Sex: 15-19 Male	188
TX_NEW_DSD	By Age/Sex: 20-24 Male	1,254
TX_NEW_DSD	By Age/Sex: 25-49 Male	4,509
TX_NEW_DSD	By Age/Sex: 50+ Male	315



TX_NEW_DSD	By Age/Sex: 10-14 Female	465
TX_NEW_DSD	By Age/Sex: 15-19 Female	609
TX_NEW_DSD	By Age/Sex: 20-24 Female	2,796
TX_NEW_DSD	By Age/Sex: 25-49 Female	8,146
TX_NEW_DSD	By Age/Sex: 50+ Female	607
TX_NEW_DSD	Sum of Age/Sex disaggregates	19,290
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	564
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	6,266
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	635
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	12,158
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	19,623
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	51,162
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	56,845
TX_PVLS_DSD	Numerator: Indication: Routine	51,162
TX_PVLS_DSD	Denominator: Indication: Routine	56,845
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	1,508
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	16,314
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	1,703
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	31,637
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	1,677
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	18,117
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	1,894
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	35,157
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	11,928
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	13,400



	stopped ART, and those lost to follow-up	
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	18
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	121
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	192
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	233
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	48
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,587
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,891
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	165
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	185
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	847
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,461
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults)	180



	and children who are still alive and on treatment at 12 months after initiating ART	
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	20
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	136
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	215
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	262
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,744
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,276
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART,	434



	and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	187
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	206
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	949
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,763
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	208
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	270
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7,759
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	226



TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,673
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	303
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8,716
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	255
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,126

Implementing Mechanism Details

Mechanism ID: 11479	Mechanism Name: State Department
Funding Agency: State/AF	Procurement Type: USG Core
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	



Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 11479			
Mechanism Name: State Department			
Prime Partner Name: U.S. Department of State			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	2,772
OVC_SERV_DSD	Age/Sex: 18+ Male	312
OVC_SERV_DSD	Age/Sex: 18+ Female	377
OVC_SERV_DSD	Sum of Age/Sex disaggregates	689



OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	1,005
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	1,078

Implementing Mechanism Details

Mechanism ID: 11480		Mechanism Name: US Peace Corps	
Funding Agency: PC		Procurement Type: USG Core	
Prime Partner Name: U.S. Peace Corps			
Agreement Start Date: Redacted		Agreement End Date: Redacted	
TBD: No		New Mechanism: No	
G2G: No		Managing Agency:	

Total All Funding Sources: 120,161	
Applied Pipeline Amount: 174,383	
Total All Funding Sources and Applied Pipeline Amount: 294,544	
Funding Source	Funding Amount
GHP-State	120,161

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 11480			
Mechanism Name: US Peace Corps			
Prime Partner Name: U.S. Peace Corps			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	36,716	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	83,445	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	6,501
PP_PREV_DSD	Total number of people in the target population	20,781
PP_PREV_DSD	Aggregated Age/sex: <15 Male	1,402
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	1,795
PP_PREV_DSD	Aggregated Age/sex: <15 Female	1,521
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	1,783
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	1,480
KP_PREV_DSD	Total estimated number of key population in the catchment area	2,819
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,454
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	26
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated	202



	number of key population in the catchment area	
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	88
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	2,529
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	1,078
OVC_SERV_DSD	Age/Sex: 18+ Male	122
OVC_SERV_DSD	Age/Sex: 18+ Female	147
OVC_SERV_DSD	Sum of Age/Sex disaggregates	269
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	390
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	419

Implementing Mechanism Details

Mechanism ID: 12477	Mechanism Name: Strengthening And Improving National Training Systems in the Republic of Uganda under PEPFAR
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Baylor College of Medicine Children's Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	12477		
Mechanism Name:	Strengthening And Improving National Training Systems in the Republic of Uganda under PEPFAR		
Prime Partner Name:	Baylor College of Medicine Children's Foundation		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12486	Mechanism Name: Scaling Up Community Based OVC Response (SCORE)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Associazione Volontari Per Il Servizio Internazionale, Uganda	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 2,154,750	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,154,750	
Funding Source	Funding Amount
GHP-State	2,154,750



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	12486		
Mechanism Name:	Scaling Up Community Based OVC Response (SCORE)		
Prime Partner Name:	Associazione Volontari Per Il Servizio Internazionale, Uganda		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	2,154,750	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	50,454
OVC_SERV_DSD	Age/Sex: 18+ Male	5,213
OVC_SERV_DSD	Age/Sex: 18+ Female	6,317
OVC_SERV_DSD	Sum of Age/Sex disaggregates	11,530
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	1,220
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	812
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	2,033
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	16,847
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	18,012



Implementing Mechanism Details

Mechanism ID: 12496	Mechanism Name: Monitoring and Evaluation of Emergency Plan Progress– Phase Two (MEEPP II)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Social and Scientific Systems	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,018,794	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,018,794	
Funding Source	Funding Amount
GHP-State	1,018,794

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	12496		
Mechanism Name:	Monitoring and Evaluation of Emergency Plan Progress– Phase Two (MEEPP II)		
Prime Partner Name:	Social and Scientific Systems		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	1,018,794	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and	HVSI	0	0



Systems			
---------	--	--	--

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12801	Mechanism Name: Strengthening Decentralization for Sustainability (SDS)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Cardno Emerging Markets	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,674,458	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,674,458	
Funding Source	Funding Amount
GHP-State	1,674,458

Cross-Cutting Budget Attribution(s)

Key Populations: FSW	126,678
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Gender: GBV	353,355
Focus Area:	GBV Prevention



Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Key Populations: MSM and TG	126,678
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information

Budget Code Information

Mechanism ID:	12801		
Mechanism Name:	Strengthening Decentralization for Sustainability (SDS)		
Prime Partner Name:	Cardno Emerging Markets		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	932,458	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and	HVSI	200,000	0



Systems			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	542,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12981	Mechanism Name: Strengthening capacity through improved management and coordination of laboratory, surveillance, and epidemiology activities, public health evaluations and training in Uganda – Lab Quality Assurance
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Uganda Virus Research Institute	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 2,285,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,285,000	
Funding Source	Funding Amount
GHP-State	2,285,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	12981		
Mechanism Name:	Strengthening capacity through improved management and coordination of laboratory, surveillance, and epidemiology activities, public health evaluations and training in Uganda – Lab Quality Assurance		
Prime Partner Name:	Uganda Virus Research Institute		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	1,225,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	500,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	560,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	1,342
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	1,342
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1,342
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	144
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	180
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	144

Implementing Mechanism Details

Mechanism ID: 13002	Mechanism Name: Supporting the Continuity of HIV/AIDS prevention and care programs for refugees in Uganda
Funding Agency: State/PRM	Procurement Type: Cooperative Agreement
Prime Partner Name: United Nations High Commissioner for Refugees	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 741,823	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 741,823	



Funding Source	Funding Amount
GHP-State	741,823

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13002		
Mechanism Name:	Supporting the Continuity of HIV/AIDS prevention and care programs for refugees in Uganda		
Prime Partner Name:	United Nations High Commissioner for Refugees		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	99,865	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	169,720	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	25,047	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	48,807	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	65,477	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVCT	92,350	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	30,281	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	195,226	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	15,050	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	6,370
PMTCT_ART_DSD	New on ART	146
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	203
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	6,370
PMTCT_STAT_DSD	Number of new ANC and L&D clients	6,534
PMTCT_STAT_DSD	By: Known positives at entry	193
PMTCT_STAT_DSD	By: Number of new positives identified	176
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	369
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	6,518
VMMC_CIRC_DSD	By Age: 10-14	2,540



VMMC_CIRC_DSD	By Age: 15-19	1,890
VMMC_CIRC_DSD	By Age: 20-24	912
VMMC_CIRC_DSD	By Age: 25-29	522
VMMC_CIRC_DSD	By Age: 30-49	522
VMMC_CIRC_DSD	By Age: 50+	132
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	5,474
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	6,518
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	6,518
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	771
PP_PREV_DSD	Total number of people in the target population	2,231
PP_PREV_DSD	Aggregated Age/sex: <15 Male	167
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	212
PP_PREV_DSD	Aggregated Age/sex: <15 Female	180
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	212
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	50,668
HTC_TST_DSD	Age/sex: 10-14 Male	826
HTC_TST_DSD	Age/sex: 15-19 Male	4,839
HTC_TST_DSD	Age/sex: 20-24 Male	7,258
HTC_TST_DSD	Age/sex: 25-49 Male	11,129
HTC_TST_DSD	Age/sex: 50+ Male	968
HTC_TST_DSD	Age/sex: 10-14 Female	825
HTC_TST_DSD	Age/sex: 15-19 Female	4,715
HTC_TST_DSD	Age/sex: 20-24 Female	7,073
HTC_TST_DSD	Age/sex: 25-49 Female	10,844
HTC_TST_DSD	Age/sex: 50+ Female	944
HTC_TST_DSD	Sum of Age/Sex disaggregates	49,421
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	33
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	140



HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	214
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	328
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	27
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	32
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	195
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	291
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	445
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	39
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,450
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	24,194
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,448
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	23,576
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	2,898
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	47,770
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	50,668
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	59
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	709
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	56
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	970
HTC_TST_DSD	Test Result by Age: Positive: <1	12
HTC_TST_DSD	Test Result by Age: Positive: 1-9	38
HTC_TST_DSD	Age/sex: <1	291
HTC_TST_DSD	Age/sex: 1-9	956
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	8,263
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	18,788



HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	2,496
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	2,911
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	6,518
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	9,275
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	337
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	2,080
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	173
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	173
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	5
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	107
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	4
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	57
GEND_GBV_DSD	Number of people receiving post-GBV care	379
GEND_GBV_DSD	Age/Sex: <10 Male	12
GEND_GBV_DSD	Age/Sex: 10-14 Male	12
GEND_GBV_DSD	Age/Sex: 20-24 Male	20
GEND_GBV_DSD	Age/Sex: 25-49 Male	20
GEND_GBV_DSD	Age/Sex: <10 Female	20
GEND_GBV_DSD	Age/Sex: 10-14 Female	52
GEND_GBV_DSD	Age/Sex: 20-24 Female	89
GEND_GBV_DSD	Age/Sex: 25-49 Female	38
GEND_GBV_DSD	Sum of Age/Sex Disaggregates	96
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence	85



	(Other Post-GBV Care)	
GEND_GBVDSD	By type of service: Sexual Violence (Post-Rape Care)	294
GEND_GBVDSD	By PEP service provision (related to sexual violence services provided)	35
GEND_GBVDSD	Age/Sex: 15-19 Female	96
GEND_GBVDSD	Age/Sex: 15-19 male	20
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	33
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	33
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	23
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	10
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	7,179
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	273
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	2,239
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	311
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	4,356
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	144
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	575
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	172
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	344



TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	59
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	230
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	65
PMTCT_EID_DSD	Sum of Infant Age disaggregates	295
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	11
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	2
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	7,179
TX_CURR_DSD	Age/Sex: 15-19 Male	68
TX_CURR_DSD	Age/Sex: 15-19 Female	218
TX_CURR_DSD	Sum of age/sex disaggregates	286
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	273
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	2,239
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	311
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	4,356
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	584
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	6,595
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	7,179
TX_CURR_DSD	Age/Sex: <1	22
TX_CURR_DSD	Age/Sex: <1-9	140
TX_CURR_DSD	Age/Sex: 10-14 Male	195
TX_CURR_DSD	Age/Sex: 10-14 Female	227
TX_CURR_DSD	Age/Sex: 20-24 Male	447
TX_CURR_DSD	Age/Sex: 25-49 Male	1,611
TX_CURR_DSD	Age/Sex: 50+ Male	113
TX_CURR_DSD	Age/Sex: 20-24 Female	1,002
TX_CURR_DSD	Age/Sex: 25-49 Female	2,918
TX_CURR_DSD	Age/Sex: 50+ Female	218



TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,254
TX_NEW_DSD	By Age/Sex: <1	5
TX_NEW_DSD	By Age/Sex: 1-9	34
TX_NEW_DSD	By Age/Sex: 10-14 Male	47
TX_NEW_DSD	By Age/Sex: 15-19 Male	33
TX_NEW_DSD	By Age/Sex: 20-24 Male	213
TX_NEW_DSD	By Age/Sex: 25-49 Male	764
TX_NEW_DSD	By Age/Sex: 50+ Male	51
TX_NEW_DSD	By Age/Sex: 10-14 Female	53
TX_NEW_DSD	By Age/Sex: 15-19 Female	103
TX_NEW_DSD	By Age/Sex: 20-24 Female	473
TX_NEW_DSD	By Age/Sex: 25-49 Female	1,377
TX_NEW_DSD	By Age/Sex: 50+ Female	101
TX_NEW_DSD	Sum of Age/Sex disaggregates	3,215
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	66
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,061
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	73
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	2,054
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	3,254
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	5,169
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	5,743
TX_PVLS_DSD	Numerator: Indication: Routine	5,169
TX_PVLS_DSD	Denominator: Indication: Routine	5,743
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	195
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	1,614
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	225
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	3,135



TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	219
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	1,790
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	249
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	3,485
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	800
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	899
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	14
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	15
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	376
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	129
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	14
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	13



TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	57
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	162
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	11
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	15
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	19
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	116
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	422
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of	29



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	14
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	14
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	63
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	185
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	14
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	19
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	522



TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	16
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	243
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	20
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	586
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	17
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	276

Implementing Mechanism Details

Mechanism ID: 13029	Mechanism Name: National Lab Infrastructure Initiative
Funding Agency: State/AF	Procurement Type: Cooperative Agreement
Prime Partner Name: Regional Procurement Support Office/Frankfurt	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13029		
Mechanism Name:	National Lab Infrastructure Initiative		
Prime Partner Name:	Regional Procurement Support Office/Frankfurt		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13047	Mechanism Name: Scaling up comprehensive HIV/AIDS Services at Mulago and Mbarara University Teaching Hospitals
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Makerere University School of Medicine	
Agreement Start Date: Redacted	Agreement End Date: Redacted

Approved



TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13047		
Mechanism Name:	Scaling up comprehensive HIV/AIDS Services at Mulago and Mbarara		
Prime Partner Name:	University Teaching Hospitals Makerere University School of Medicine		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	16,740
PMTCT_ART_DSD	New on ART	676
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	940



PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,671
PMTCT_ART_TA	New on ART	69
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	97
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	16,740
PMTCT_STAT_DSD	Number of new ANC and L&D clients	17,167
PMTCT_STAT_DSD	By: Known positives at entry	1,029
PMTCT_STAT_DSD	By: Number of new positives identified	680
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	1,709
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,671
PMTCT_STAT_TA	Number of new ANC and L&D clients	1,715
PMTCT_STAT_TA	By: Known positives at entry	95
PMTCT_STAT_TA	By: Number of new positives identified	78
PMTCT_STAT_TA	Sum of Positives Status disaggregates	173
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	22,729
VMMC_CIRC_DSD	By Age: 10-14	8,865
VMMC_CIRC_DSD	By Age: 15-19	6,594
VMMC_CIRC_DSD	By Age: 20-24	3,184
VMMC_CIRC_DSD	By Age: 25-29	1,817
VMMC_CIRC_DSD	By Age: 30-49	1,817
VMMC_CIRC_DSD	By Age: 50+	452
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	19,095
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	22,729
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	22,729
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the	2,960



	minimum components during the reporting period.	
PP_PREV_DSD	Total number of people in the target population	55,033
PP_PREV_DSD	Aggregated Age/sex: <15 Male	642
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	816
PP_PREV_DSD	Aggregated Age/sex: <15 Female	693
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	815
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	1,501
KP_PREV_DSD	Total estimated number of key population in the catchment area	3,845
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,356
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	145
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	1,116
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	485
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	2,244
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	84,116



HTC_TST_DSD	Age/sex: 10-14 Male	2,642
HTC_TST_DSD	Age/sex: 15-19 Male	8,301
HTC_TST_DSD	Age/sex: 20-24 Male	12,459
HTC_TST_DSD	Age/sex: 25-49 Male	19,101
HTC_TST_DSD	Age/sex: 50+ Male	1,656
HTC_TST_DSD	Age/sex: 10-14 Female	2,640
HTC_TST_DSD	Age/sex: 15-19 Female	6,667
HTC_TST_DSD	Age/sex: 20-24 Female	10,002
HTC_TST_DSD	Age/sex: 25-49 Female	15,333
HTC_TST_DSD	Age/sex: 50+ Female	1,332
HTC_TST_DSD	Sum of Age/Sex disaggregates	80,133
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	143
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	185
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	282
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	427
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	37
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	147
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	353
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	533
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	814
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	67
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	4,632
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	41,517
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	4,633
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	33,334
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	9,265
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	74,851
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	84,116



HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	250
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	931
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	256
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,767
HTC_TST_DSD	Test Result by Age: Positive: <1	48
HTC_TST_DSD	Test Result by Age: Positive: 1-9	168
HTC_TST_DSD	Age/sex: <1	929
HTC_TST_DSD	Age/sex: 1-9	3,054
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	15,783
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	10,867
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	8,268
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	3,328
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	21,167
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	17,955
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	933
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	5,815
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	6,062
HTC_TST_TA	Age/sex: 10-14 Male	231
HTC_TST_TA	Age/sex: 15-19 Male	523
HTC_TST_TA	Age/sex: 20-24 Male	783
HTC_TST_TA	Age/sex: 25-49 Male	1,200
HTC_TST_TA	Age/sex: 50+ Male	103
HTC_TST_TA	Age/sex: 10-14 Female	231
HTC_TST_TA	Age/sex: 15-19 Female	527
HTC_TST_TA	Age/sex: 20-24 Female	792
HTC_TST_TA	Age/sex: 25-49 Female	1,214
HTC_TST_TA	Age/sex: 50+ Female	106



HTC_TST_TA	Sum of Age/Sex disaggregates	5,710
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Male	14
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Male	6
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Male	14
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Male	19
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Male	3
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Female	14
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Female	28
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Female	43
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Female	65
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Female	6
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	407
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,609
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	407
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	2,639
HTC_TST_TA	Sum of Aggregated Age/Sex <15	814
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	5,248
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	6,062
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	23
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	42
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	23
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	142
HTC_TST_TA	Test Result by Age: Positive: <1	2
HTC_TST_TA	Test Result by Age: Positive: 1-9	16
HTC_TST_TA	Age/sex: <1	83



HTC_TST_TA	Age/sex: 1-9	269
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	784
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	528
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	657
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	197
HTC_TST_TA	Service Delivery Point (Facility): VMMC	1,562
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	1,923
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	67
HTC_TST_TA	Service Delivery Point (Facility): Index testing	344
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	387
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	387
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	9
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	234
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	7
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	128
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	105
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	106
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with	65

	documented HIV status, during the reporting period)	
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	35
GEND_GBV_DSD	Number of people receiving post-GBV care	939
GEND_GBV_DSD	Age/Sex: <10 Male	27
GEND_GBV_DSD	Age/Sex: 10-14 Male	27
GEND_GBV_DSD	Age/Sex: 20-24 Male	48
GEND_GBV_DSD	Age/Sex: 25-49 Male	48
GEND_GBV_DSD	Age/Sex: <10 Female	48
GEND_GBV_DSD	Age/Sex: 10-14 Female	131
GEND_GBV_DSD	Age/Sex: 20-24 Female	238
GEND_GBV_DSD	Age/Sex: 25-49 Female	94
GEND_GBV_DSD	Sum of Age/Sex Disaggregates	233
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	208
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	731
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	83
GEND_GBV_DSD	Age/Sex: 15-19 Female	234
GEND_GBV_DSD	Age/Sex: 15-19 male	44
GEND_GBV_TA	Number of people receiving post-GBV care	92
GEND_GBV_TA	Age/Sex: <10 Male	2
GEND_GBV_TA	Age/Sex: 10-14 Male	2
GEND_GBV_TA	Age/Sex: 20-24 Male	6
GEND_GBV_TA	Age/Sex: 25-49 Male	6
GEND_GBV_TA	Age/Sex: <10 Female	6
GEND_GBV_TA	Age/Sex: 10-14 Female	14
GEND_GBV_TA	Age/Sex: 20-24 Female	24
GEND_GBV_TA	Age/Sex: 25-49 Female	9



GEND_GBV_TA	Sum of Age/Sex Disaggregates	24
GEND_GBV_TA	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	19
GEND_GBV_TA	By type of service: Sexual Violence (Post-Rape Care)	73
GEND_GBV_TA	By PEP service provision (related to sexual violence services provided)	8
GEND_GBV_TA	Age/Sex: 15-19 Female	21
GEND_GBV_TA	Age/Sex: 15-19 Male	2
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	1,899
OVC_SERV_DSD	Age/Sex: 18+ Male	215
OVC_SERV_DSD	Age/Sex: 18+ Female	259
OVC_SERV_DSD	Sum of Age/Sex disaggregates	474
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	690
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	735
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	280
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	280
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	5
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	173
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3



TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	92
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	51
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	51
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	33
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	16
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	39,200
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	957
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	12,633
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	1,081
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	24,529
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	782
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent:	3,137

	Specimen sent for bacteriologic diagnosis of active TB	
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	945
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	1,882
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	310
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	2,690
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	60
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	871
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	66
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	1,693
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	55
TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	215
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	66
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	130
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	19
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,067
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	297
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,364
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	57
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	15
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	109



PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	32
PMTCT_EID_TA	Sum of Infant Age disaggregates	141
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	6
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	2
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	39,200
TX_CURR_DSD	Age/Sex: 15-19 Male	379
TX_CURR_DSD	Age/Sex: 15-19 Female	1,227
TX_CURR_DSD	Sum of age/sex disaggregates	1,606
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	957
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	12,633
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,081
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	24,529
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	2,038
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	37,162
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	39,200
TX_CURR_DSD	Age/Sex: <1	79
TX_CURR_DSD	Age/Sex: <1-9	489
TX_CURR_DSD	Age/Sex: 10-14 Male	680
TX_CURR_DSD	Age/Sex: 10-14 Female	790
TX_CURR_DSD	Age/Sex: 20-24 Male	2,525
TX_CURR_DSD	Age/Sex: 25-49 Male	9,097
TX_CURR_DSD	Age/Sex: 50+ Male	632
TX_CURR_DSD	Age/Sex: 20-24 Female	5,641
TX_CURR_DSD	Age/Sex: 25-49 Female	16,434
TX_CURR_DSD	Age/Sex: 50+ Female	1,227
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	2,690
TX_CURR_TA	Age/Sex: 15-19 Male	26



TX_CURR_TA	Age/Sex: 15-19 Female	83
TX_CURR_TA	Sum of Age/Sex disaggregations	109
TX_CURR_TA	Aggregated Age/Sex: <15 Male	60
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	871
TX_CURR_TA	Aggregated Age/Sex: <15 Female	66
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	1,693
TX_CURR_TA	Sum of Aggregated Age/Sex <15	126
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	2,564
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	2,690
TX_CURR_TA	Age/Sex: <1	4
TX_CURR_TA	Age/Sex: 1-9	33
TX_CURR_TA	Age/Sex: 10-14 Male	42
TX_CURR_TA	Age/Sex: 10-14 Female	47
TX_CURR_TA	Age/Sex: 20-24 Male	175
TX_CURR_TA	Age/Sex: 25-49 Male	626
TX_CURR_TA	Age/Sex: 50+ Male	44
TX_CURR_TA	Age/Sex: 20-24 Female	391
TX_CURR_TA	Age/Sex: 25-49 Female	1,136
TX_CURR_TA	Age/Sex: 50+ Female	83
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	4,600
TX_NEW_DSD	By Age/Sex: <1	11
TX_NEW_DSD	By Age/Sex: 1-9	79
TX_NEW_DSD	By Age/Sex: 10-14 Male	109
TX_NEW_DSD	By Age/Sex: 15-19 Male	40
TX_NEW_DSD	By Age/Sex: 20-24 Male	289
TX_NEW_DSD	By Age/Sex: 25-49 Male	1,040
TX_NEW_DSD	By Age/Sex: 50+ Male	79
TX_NEW_DSD	By Age/Sex: 10-14 Female	137
TX_NEW_DSD	By Age/Sex: 15-19 Female	141
TX_NEW_DSD	By Age/Sex: 20-24 Female	650
TX_NEW_DSD	By Age/Sex: 25-49 Female	1,884



TX_NEW_DSD	By Age/Sex: 50+ Female	141
TX_NEW_DSD	Sum of Age/Sex disaggregates	4,510
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	154
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,448
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	182
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	2,816
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	4,600
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	479
TX_NEW_TA	By Age/Sex: 1-9	9
TX_NEW_TA	By Age/Sex: 10-14 Male	13
TX_NEW_TA	By Age/Sex: 15-19 Male	4
TX_NEW_TA	By Age/Sex: 20-24 Male	31
TX_NEW_TA	By Age/Sex: 25-49 Male	107
TX_NEW_TA	By Age/Sex: 50+ Male	8
TX_NEW_TA	By Age/Sex: 10-14 Female	17
TX_NEW_TA	By Age/Sex: 15-19 Female	14
TX_NEW_TA	By Age/Sex: 20-24 Female	67
TX_NEW_TA	By Age/Sex: 25-49 Female	193
TX_NEW_TA	By Age/Sex: 50+ Female	14
TX_NEW_TA	Sum of Age/Sex disaggregates	468
TX_NEW_TA	Aggregated Grouping by Age: <1	2
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	19
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	150
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	22
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	288
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	479

Implementing Mechanism Details

Mechanism ID: 13104	Mechanism Name: Scaling up Comprehensive HIV/AIDS Services including provider initiated Testing and Counseling, TB/HIV, OVC, Care and ART for Adults and children in Eastern and West
----------------------------	--



	Nile regions in Uganda under the PEPFAR
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Baylor College of Medicine Children's Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13104		
Mechanism Name:	Scaling up Comprehensive HIV/AIDS Services including provider initiated Testing and Counseling, TB/HIV, OVC, Care and ART for Adults and children in Eastern and West Nile regions in Uganda under the		
Prime Partner Name:	PEPFAR Baylor College of Medicine Children's Foundation		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information



Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	34,808
PMTCT_ART_DSD	New on ART	412
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	577
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	12,176
PMTCT_ART_TA	New on ART	149
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	212
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	34,808
PMTCT_STAT_DSD	Number of new ANC and L&D clients	35,702
PMTCT_STAT_DSD	By: Known positives at entry	750
PMTCT_STAT_DSD	By: Number of new positives identified	296
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	1,046
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	12,176
PMTCT_STAT_TA	Number of new ANC and L&D clients	12,486
PMTCT_STAT_TA	By: Known positives at entry	267
PMTCT_STAT_TA	By: Number of new positives identified	109
PMTCT_STAT_TA	Sum of Positives Status disaggregates	376
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	12,075
VMMC_CIRC_DSD	By Age: 10-14	4,709
VMMC_CIRC_DSD	By Age: 15-19	3,502
VMMC_CIRC_DSD	By Age: 20-24	1,691
VMMC_CIRC_DSD	By Age: 25-29	965
VMMC_CIRC_DSD	By Age: 30-49	965



VMMC_CIRC_DSD	By Age: 50+	243
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	10,145
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	12,075
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	12,075
PrEP_NEW_DSD	Number of individuals who have received antiretroviral preexposure	300
PrEP_NEW_DSD	Male 15-19	74
PrEP_NEW_DSD	Male 20-24	20
PrEP_NEW_DSD	Male 25-49	27
PrEP_NEW_DSD	Male 50+	2
PrEP_NEW_DSD	Female 15-19	101
PrEP_NEW_DSD	Female 20-24	46
PrEP_NEW_DSD	Female 25-49	27
PrEP_NEW_DSD	Female 50+	3
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	849
PP_PREV_DSD	Total number of people in the target population	2,437
PP_PREV_DSD	Aggregated Age/sex: <15 Male	190
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	245
PP_PREV_DSD	Aggregated Age/sex: <15 Female	207
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	242
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	97
KP_PREV_DSD	Total estimated number of key population in the catchment area	199
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	97



KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	199
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	156,643
HTC_TST_DSD	Age/sex: 10-14 Male	4,347
HTC_TST_DSD	Age/sex: 15-19 Male	12,946
HTC_TST_DSD	Age/sex: 20-24 Male	19,417
HTC_TST_DSD	Age/sex: 25-49 Male	29,773
HTC_TST_DSD	Age/sex: 50+ Male	2,582
HTC_TST_DSD	Age/sex: 10-14 Female	4,343
HTC_TST_DSD	Age/sex: 15-19 Female	15,337
HTC_TST_DSD	Age/sex: 20-24 Female	23,002
HTC_TST_DSD	Age/sex: 25-49 Female	35,263
HTC_TST_DSD	Age/sex: 50+ Female	3,061
HTC_TST_DSD	Sum of Age/Sex disaggregates	150,071
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	96
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	205
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	306
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	468
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	39
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	102
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	296
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	444
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	678
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	53
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	7,632
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	64,718
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	7,630



HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	76,663
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	15,262
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	141,381
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	156,643
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	158
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,018
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	152
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,471
HTC_TST_DSD	Test Result by Age: Positive: <1	21
HTC_TST_DSD	Test Result by Age: Positive: 1-9	91
HTC_TST_DSD	Age/sex: <1	1,534
HTC_TST_DSD	Age/sex: 1-9	5,038
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	25,864
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	60,483
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	14,446
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	7,059
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	12,075
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	34,007
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	767
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	1,942
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	41,086
HTC_TST_TA	Age/sex: 10-14 Male	829
HTC_TST_TA	Age/sex: 15-19 Male	2,912
HTC_TST_TA	Age/sex: 20-24 Male	4,367
HTC_TST_TA	Age/sex: 25-49 Male	6,696
HTC_TST_TA	Age/sex: 50+ Male	580



HTC_TST_TA	Age/sex: 10-14 Female	827
HTC_TST_TA	Age/sex: 15-19 Female	4,728
HTC_TST_TA	Age/sex: 20-24 Female	7,090
HTC_TST_TA	Age/sex: 25-49 Female	10,865
HTC_TST_TA	Age/sex: 50+ Female	939
HTC_TST_TA	Sum of Age/Sex disaggregates	39,833
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Male	19
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Male	54
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Male	82
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Male	123
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Male	10
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Female	26
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Female	88
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Female	131
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Female	201
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Female	18
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,455
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	14,555
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,454
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	23,622
HTC_TST_TA	Sum of Aggregated Age/Sex <15	2,909
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	38,177
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	41,086
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	28
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	269
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	32



HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	438
HTC_TST_TA	Test Result by Age: Positive: 1-9	15
HTC_TST_TA	Age/sex: <1	295
HTC_TST_TA	Age/sex: 1-9	958
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	7,960
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	15,323
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	2,611
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	1,975
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	11,901
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	219
HTC_TST_TA	Service Delivery Point (Facility): Index testing	1,097
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	722
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	722
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	16
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	448
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	12
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	246
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	73
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	73
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with	48



	documented HIV status, during the reporting period)	
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	25
GEND_GBV_DSD	Number of people receiving post-GBV care	1,952
GEND_GBV_DSD	Age/Sex: <10 Male	59
GEND_GBV_DSD	Age/Sex: 10-14 Male	59
GEND_GBV_DSD	Age/Sex: 20-24 Male	98
GEND_GBV_DSD	Age/Sex: 25-49 Male	98
GEND_GBV_DSD	Age/Sex: <10 Female	98
GEND_GBV_DSD	Age/Sex: 10-14 Female	276
GEND_GBV_DSD	Age/Sex: 20-24 Female	475
GEND_GBV_DSD	Age/Sex: 25-49 Female	199
GEND_GBV_DSD	Sum of Age/Sex Disaggregates	492
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	428
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	1,524
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	176
GEND_GBV_DSD	Age/Sex: 15-19 Female	494
GEND_GBV_DSD	Age/Sex: 15-19 male	96
GEND_GBV_TA	Number of people receiving post-GBV care	684
GEND_GBV_TA	Age/Sex: <10 Male	23
GEND_GBV_TA	Age/Sex: 10-14 Male	23
GEND_GBV_TA	Age/Sex: 20-24 Male	38
GEND_GBV_TA	Age/Sex: 25-49 Male	38
GEND_GBV_TA	Age/Sex: <10 Female	38
GEND_GBV_TA	Age/Sex: 10-14 Female	96
GEND_GBV_TA	Age/Sex: 20-24 Female	157
GEND_GBV_TA	Age/Sex: 25-49 Female	65
GEND_GBV_TA	Sum of Age/Sex Disaggregates	180
GEND_GBV_TA	By type of service: Physical and/or Emotional Violence	151



	(Other Post-GBV Care)	
GEND_GBV_TA	By type of service: Sexual Violence (Post-Rape Care)	533
GEND_GBV_TA	By PEP service provision (related to sexual violence services provided)	63
GEND_GBV_TA	Age/Sex: 15-19 Female	174
GEND_GBV_TA	Age/Sex: 15-19 Male	32
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	3,478
OVC_SERV_DSD	Age/Sex: 18+ Male	390
OVC_SERV_DSD	Age/Sex: 18+ Female	476
OVC_SERV_DSD	Sum of Age/Sex disaggregates	866
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	1,263
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	1,349
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	173
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	173
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	131
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	42
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	24
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	24



TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	20
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	25,177
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	854
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	7,937
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	962
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	15,424
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	503
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	2,016
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	609
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	1,212
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	195
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	3,395
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	136
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	1,056
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	153
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	2,050
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	67
TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	272

TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	80
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	163
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	29
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	649
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	185
PMTCT_EID_DSD	Sum of Infant Age disaggregates	834
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	34
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	240
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	55
PMTCT_EID_TA	Sum of Infant Age disaggregates	295
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	10
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	25,177
TX_CURR_DSD	Age/Sex: 15-19 Male	240
TX_CURR_DSD	Age/Sex: 15-19 Female	776
TX_CURR_DSD	Sum of age/sex disaggregates	1,016
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	854
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	7,937
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	962
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	15,424
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,816
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	23,361
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	25,177
TX_CURR_DSD	Age/Sex: <1	63



TX_CURR_DSD	Age/Sex: <1-9	443
TX_CURR_DSD	Age/Sex: 10-14 Male	609
TX_CURR_DSD	Age/Sex: 10-14 Female	701
TX_CURR_DSD	Age/Sex: 20-24 Male	1,591
TX_CURR_DSD	Age/Sex: 25-49 Male	5,708
TX_CURR_DSD	Age/Sex: 50+ Male	398
TX_CURR_DSD	Age/Sex: 20-24 Female	3,550
TX_CURR_DSD	Age/Sex: 25-49 Female	10,322
TX_CURR_DSD	Age/Sex: 50+ Female	776
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	3,395
TX_CURR_TA	Age/Sex: 15-19 Male	30
TX_CURR_TA	Age/Sex: 15-19 Female	104
TX_CURR_TA	Sum of Age/Sex disaggregations	134
TX_CURR_TA	Aggregated Age/Sex: <15 Male	136
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	1,056
TX_CURR_TA	Aggregated Age/Sex: <15 Female	153
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	2,050
TX_CURR_TA	Sum of Aggregated Age/Sex <15	289
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	3,106
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	3,395
TX_CURR_TA	Age/Sex: <1	4
TX_CURR_TA	Age/Sex: 1-9	76
TX_CURR_TA	Age/Sex: 10-14 Male	97
TX_CURR_TA	Age/Sex: 10-14 Female	112
TX_CURR_TA	Age/Sex: 20-24 Male	210
TX_CURR_TA	Age/Sex: 25-49 Male	761
TX_CURR_TA	Age/Sex: 50+ Male	55
TX_CURR_TA	Age/Sex: 20-24 Female	473
TX_CURR_TA	Age/Sex: 25-49 Female	1,369
TX_CURR_TA	Age/Sex: 50+ Female	104
TX_NEW_DSD	Number of adults and children newly enrolled on	3,542



	antiretroviral therapy (ART)	
TX_NEW_DSD	By Age/Sex: <1	2
TX_NEW_DSD	By Age/Sex: 1-9	72
TX_NEW_DSD	By Age/Sex: 10-14 Male	98
TX_NEW_DSD	By Age/Sex: 15-19 Male	30
TX_NEW_DSD	By Age/Sex: 20-24 Male	221
TX_NEW_DSD	By Age/Sex: 25-49 Male	792
TX_NEW_DSD	By Age/Sex: 50+ Male	53
TX_NEW_DSD	By Age/Sex: 10-14 Female	142
TX_NEW_DSD	By Age/Sex: 15-19 Female	109
TX_NEW_DSD	By Age/Sex: 20-24 Female	493
TX_NEW_DSD	By Age/Sex: 25-49 Female	1,427
TX_NEW_DSD	By Age/Sex: 50+ Female	103
TX_NEW_DSD	Sum of Age/Sex disaggregates	3,468
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	138
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,096
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	176
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	2,132
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	3,542
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	946
TX_NEW_TA	By Age/Sex: 1-9	6
TX_NEW_TA	By Age/Sex: 10-14 Male	14
TX_NEW_TA	By Age/Sex: 15-19 Male	6
TX_NEW_TA	By Age/Sex: 20-24 Male	62
TX_NEW_TA	By Age/Sex: 25-49 Male	219
TX_NEW_TA	By Age/Sex: 50+ Male	17
TX_NEW_TA	By Age/Sex: 10-14 Female	31
TX_NEW_TA	By Age/Sex: 15-19 Female	31
TX_NEW_TA	By Age/Sex: 20-24 Female	137
TX_NEW_TA	By Age/Sex: 25-49 Female	395
TX_NEW_TA	By Age/Sex: 50+ Female	28



TX_NEW_TA	Sum of Age/Sex disaggregates	940
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	18
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	304
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	33
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	591
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	946

Implementing Mechanism Details

Mechanism ID: 13136	Mechanism Name: Scaling up comprehensive HIV/ Aids Services Including Provider Initiated Testing and Counseling (PITC), MARPI, SGBV at KCC Clinics
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Infectious Disease Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 13136



Mechanism Name: Scaling up comprehensive HIV/ Aids Services Including Provider			
Prime Partner Name: Initiated Testing and Counseling (PITC), MARPI, SGBV at KCC Clinics			
		Infectious Disease Institute	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	PDTX	0	0
-----------	------	---	---

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	14,745
PMTCT_ART_DSD	New on ART	589
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	822
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	14,745
PMTCT_STAT_DSD	Number of new ANC and L&D clients	15,125
PMTCT_STAT_DSD	By: Known positives at entry	962
PMTCT_STAT_DSD	By: Number of new positives identified	530
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	1,492
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	1,326
VMMC_CIRC_DSD	By Age: 10-14	517
VMMC_CIRC_DSD	By Age: 15-19	384
VMMC_CIRC_DSD	By Age: 20-24	185
VMMC_CIRC_DSD	By Age: 25-29	106
VMMC_CIRC_DSD	By Age: 30-49	106
VMMC_CIRC_DSD	By Age: 50+	28
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	1,114
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	1,326
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	1,326
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the	61



	minimum components during the reporting period.	
PP_PREV_DSD	Total number of people in the target population	1,127
PP_PREV_DSD	Aggregated Age/sex: <15 Male	14
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	17
PP_PREV_DSD	Aggregated Age/sex: <15 Female	16
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	17
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	57
KP_PREV_DSD	Total estimated number of key population in the catchment area	156
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	50
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	7
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	45
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	21
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	90
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	78,798



HTC_TST_DSD	Age/sex: 10-14 Male	2,893
HTC_TST_DSD	Age/sex: 15-19 Male	6,134
HTC_TST_DSD	Age/sex: 20-24 Male	9,203
HTC_TST_DSD	Age/sex: 25-49 Male	14,110
HTC_TST_DSD	Age/sex: 50+ Male	1,227
HTC_TST_DSD	Age/sex: 10-14 Female	2,894
HTC_TST_DSD	Age/sex: 15-19 Female	7,594
HTC_TST_DSD	Age/sex: 20-24 Female	11,390
HTC_TST_DSD	Age/sex: 25-49 Female	17,465
HTC_TST_DSD	Age/sex: 50+ Female	1,517
HTC_TST_DSD	Sum of Age/Sex disaggregates	74,427
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	144
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	263
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	394
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	604
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	52
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	142
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	414
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	622
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	953
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	84
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	5,078
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	30,674
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	5,080
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	37,966
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	10,158
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	68,640
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	78,798



HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	253
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,313
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	254
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	2,073
HTC_TST_DSD	Test Result by Age: Positive: <1	51
HTC_TST_DSD	Test Result by Age: Positive: 1-9	170
HTC_TST_DSD	Age/sex: <1	1,018
HTC_TST_DSD	Age/sex: 1-9	3,353
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	23,735
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	16,447
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	8,995
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	4,557
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	1,326
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	14,606
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	1,132
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	8,000
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	380
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	380
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	12
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	228
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	10



TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	130
GEND_GBV_DSD	Number of people receiving post-GBV care	827
GEND_GBV_DSD	Age/Sex: <10 Male	24
GEND_GBV_DSD	Age/Sex: 10-14 Male	24
GEND_GBV_DSD	Age/Sex: 20-24 Male	40
GEND_GBV_DSD	Age/Sex: 25-49 Male	40
GEND_GBV_DSD	Age/Sex: <10 Female	40
GEND_GBV_DSD	Age/Sex: 10-14 Female	116
GEND_GBV_DSD	Age/Sex: 20-24 Female	211
GEND_GBV_DSD	Age/Sex: 25-49 Female	83
GEND_GBV_DSD	Sum of Age/Sex Disaggregates	204
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	182
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	645
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	73
GEND_GBV_DSD	Age/Sex: 15-19 Female	207
GEND_GBV_DSD	Age/Sex: 15-19 male	42
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	181
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	181
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	113



TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	65
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	44,156
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	981
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	14,285
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	1,118
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	27,772
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	883
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	3,534
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	1,060
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	2,122
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	352
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	931
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	262
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,193
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	48
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	11
TX_CURR_DSD	Number of adults and children receiving antiretroviral	44,156



	therapy (ART)	
TX_CURR_DSD	Age/Sex: 15-19 Male	430
TX_CURR_DSD	Age/Sex: 15-19 Female	1,390
TX_CURR_DSD	Sum of age/sex disaggregates	1,820
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	981
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	14,285
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,118
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	27,772
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	2,099
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	42,057
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	44,156
TX_CURR_DSD	Age/Sex: <1	83
TX_CURR_DSD	Age/Sex: <1-9	504
TX_CURR_DSD	Age/Sex: 10-14 Male	696
TX_CURR_DSD	Age/Sex: 10-14 Female	816
TX_CURR_DSD	Age/Sex: 20-24 Male	2,856
TX_CURR_DSD	Age/Sex: 25-49 Male	10,284
TX_CURR_DSD	Age/Sex: 50+ Male	715
TX_CURR_DSD	Age/Sex: 20-24 Female	6,387
TX_CURR_DSD	Age/Sex: 25-49 Female	18,605
TX_CURR_DSD	Age/Sex: 50+ Female	1,390
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	6,267
TX_NEW_DSD	By Age/Sex: <1	22
TX_NEW_DSD	By Age/Sex: 1-9	145
TX_NEW_DSD	By Age/Sex: 10-14 Male	199
TX_NEW_DSD	By Age/Sex: 15-19 Male	57
TX_NEW_DSD	By Age/Sex: 20-24 Male	387
TX_NEW_DSD	By Age/Sex: 25-49 Male	1,390
TX_NEW_DSD	By Age/Sex: 50+ Male	96
TX_NEW_DSD	By Age/Sex: 10-14 Female	231
TX_NEW_DSD	By Age/Sex: 15-19 Female	188



TX_NEW_DSD	By Age/Sex: 20-24 Female	861
TX_NEW_DSD	By Age/Sex: 25-49 Female	2,506
TX_NEW_DSD	By Age/Sex: 50+ Female	185
TX_NEW_DSD	Sum of Age/Sex disaggregates	6,100
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	281
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,930
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	316
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	3,740
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	6,267

Implementing Mechanism Details

Mechanism ID: 13161	Mechanism Name: Enhanced Prevention
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Uganda Virus Research Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 13161



Mechanism Name: Enhanced Prevention			
Prime Partner Name: Uganda Virus Research Institute			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	55
PMTCT_ART_DSD	New on ART	3
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	3
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	55
PMTCT_STAT_DSD	Number of new ANC and L&D clients	57
PMTCT_STAT_DSD	By: Known positives at entry	4
PMTCT_STAT_DSD	By: Number of new positives identified	2
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	6
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	34
KP_PREV_DSD	Total estimated number of key population in the catchment area	145
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	29
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	5
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	42
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total)	18



	estimated number of key population in the catchment area)	
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	85
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	4,017
HTC_TST_DSD	Age/sex: 10-14 Male	163
HTC_TST_DSD	Age/sex: 15-19 Male	370
HTC_TST_DSD	Age/sex: 20-24 Male	555
HTC_TST_DSD	Age/sex: 25-49 Male	851
HTC_TST_DSD	Age/sex: 50+ Male	74
HTC_TST_DSD	Age/sex: 10-14 Female	163
HTC_TST_DSD	Age/sex: 15-19 Female	319
HTC_TST_DSD	Age/sex: 20-24 Female	479
HTC_TST_DSD	Age/sex: 25-49 Female	734
HTC_TST_DSD	Age/sex: 50+ Female	63
HTC_TST_DSD	Sum of Age/Sex disaggregates	3,771
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	8
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	16
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	24
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	37
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	3
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	8
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	20
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	30
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	46
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	3
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	286
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,850



HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	286
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,595
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	572
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	3,445
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	4,017
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	14
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	80
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	15
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	99
HTC_TST_DSD	Test Result by Age: Positive: <1	3
HTC_TST_DSD	Test Result by Age: Positive: 1-9	10
HTC_TST_DSD	Age/sex: <1	58
HTC_TST_DSD	Age/sex: 1-9	188
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	2,531
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	567
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	287
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	55
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	72
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	505
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	7
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	7
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	4
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number	3

	of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
GEND_GBVDSD	Number of people receiving post-GBV care	3
GEND_GBVDSD	Age/Sex: 20-24 Female	3
GEND_GBVDSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	1
GEND_GBVDSD	By type of service: Sexual Violence (Post-Rape Care)	2
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	3
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	3
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	530
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	10
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	50
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	12
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	458
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	11
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	42
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	13
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert	25

	MTB/RIF assay	
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	4
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	4
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	1
PMTCT_EID_DSD	Sum of Infant Age disaggregates	5
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	530
TX_CURR_DSD	Age/Sex: 15-19 Male	2
TX_CURR_DSD	Age/Sex: 15-19 Female	23
TX_CURR_DSD	Sum of age/sex disaggregates	25
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	10
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	50
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	12
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	458
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	22
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	508
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	530
TX_CURR_DSD	Age/Sex: <1-9	6
TX_CURR_DSD	Age/Sex: 10-14 Male	7
TX_CURR_DSD	Age/Sex: 10-14 Female	9
TX_CURR_DSD	Age/Sex: 20-24 Male	10
TX_CURR_DSD	Age/Sex: 25-49 Male	35
TX_CURR_DSD	Age/Sex: 50+ Male	3
TX_CURR_DSD	Age/Sex: 20-24 Female	105
TX_CURR_DSD	Age/Sex: 25-49 Female	307
TX_CURR_DSD	Age/Sex: 50+ Female	23
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	180
TX_NEW_DSD	By Age/Sex: 1-9	4



TX_NEW_DSD	By Age/Sex: 10-14 Male	7
TX_NEW_DSD	By Age/Sex: 15-19 Male	1
TX_NEW_DSD	By Age/Sex: 20-24 Male	3
TX_NEW_DSD	By Age/Sex: 25-49 Male	12
TX_NEW_DSD	By Age/Sex: 50+ Male	1
TX_NEW_DSD	By Age/Sex: 10-14 Female	8
TX_NEW_DSD	By Age/Sex: 15-19 Female	7
TX_NEW_DSD	By Age/Sex: 20-24 Female	33
TX_NEW_DSD	By Age/Sex: 25-49 Female	96
TX_NEW_DSD	By Age/Sex: 50+ Female	8
TX_NEW_DSD	Sum of Age/Sex disaggregates	176
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	9
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	17
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	10
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	144
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	180

Implementing Mechanism Details

Mechanism ID: 13170	Mechanism Name: Surveillance - Epi
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Makerere University School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 250,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 250,000	
Funding Source	Funding Amount
GHP-State	250,000

Cross-Cutting Budget Attribution(s)

Approved



(No data provided.)

Budget Code Information

Mechanism ID: 13170			
Mechanism Name: Surveillance - Epi			
Prime Partner Name: Makerere University School of Public Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	200,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13226	Mechanism Name: Procurement and Logistics Management of Health-related Commodities for HHS/CDC funded HIV/AIDS Programs
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Medical Access Uganda Limited (MAUL)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
-------------------------------------	--



Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13226		
Mechanism Name:	Procurement and Logistics Management of Health-related Commodities		
Prime Partner Name:	for HHS/CDC funded HIV/AIDS Programs Medical Access Uganda Limited (MAUL)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13317	Mechanism Name: Targeted HIV/AIDS and Laboratory Services (THALAS)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Joint Clinical Research Center, Uganda	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,857,988	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,857,988	
Funding Source	Funding Amount
GHP-State	1,857,988



Cross-Cutting Budget Attribution(s)

Human Resources for Health	100,000
Key Populations: FSW	50,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs

Budget Code Information

Mechanism ID: 13317			
Mechanism Name: Targeted HIV/AIDS and Laboratory Services (THALAS)			
Prime Partner Name: Joint Clinical Research Center, Uganda			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	508,150	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	122,743	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	161,355	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Prevention	HVCT	8,140	0
Prevention	MTCT	613	0
Treatment	HTXS	998,877	0
Treatment	PDTX	58,110	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	160
PMTCT_ART_DSD	New on ART	5
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	8
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	160
PMTCT_STAT_DSD	Number of new ANC and L&D clients	165
PMTCT_STAT_DSD	By: Known positives at entry	7
PMTCT_STAT_DSD	By: Number of new positives identified	7
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	14
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12	3,187



	months	
HTC_TST_DSD	Age/sex: 10-14 Male	102
HTC_TST_DSD	Age/sex: 15-19 Male	292
HTC_TST_DSD	Age/sex: 20-24 Male	438
HTC_TST_DSD	Age/sex: 25-49 Male	672
HTC_TST_DSD	Age/sex: 50+ Male	58
HTC_TST_DSD	Age/sex: 10-14 Female	103
HTC_TST_DSD	Age/sex: 15-19 Female	273
HTC_TST_DSD	Age/sex: 20-24 Female	410
HTC_TST_DSD	Age/sex: 25-49 Female	629
HTC_TST_DSD	Age/sex: 50+ Female	55
HTC_TST_DSD	Sum of Age/Sex disaggregates	3,032
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	5
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	12
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	18
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	28
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	3
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	6
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	16
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	24
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	37
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	4
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	179
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,460
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	181
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,367
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	360
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	2,827



HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	3,187
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	9
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	61
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	10
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	81
HTC_TST_DSD	Test Result by Age: Positive: <1	2
HTC_TST_DSD	Test Result by Age: Positive: 1-9	6
HTC_TST_DSD	Age/sex: <1	36
HTC_TST_DSD	Age/sex: 1-9	119
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	505
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	1,079
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	349
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	391
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	160
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	28
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	675
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	9
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	9
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	7
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	4



TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	4
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	22,367
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	739
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	7,068
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	834
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	13,726
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	447
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	1,789
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	537
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	1,073
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	179
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	9
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	3
PMTCT_EID_DSD	Sum of Infant Age disaggregates	12
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	22,367



TX_CURR_DSD	Age/Sex: 15-19 Male	212
TX_CURR_DSD	Age/Sex: 15-19 Female	686
TX_CURR_DSD	Sum of age/sex disaggregates	898
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	739
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	7,068
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	834
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	13,726
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,573
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	20,794
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	22,367
TX_CURR_DSD	Age/Sex: <1	63
TX_CURR_DSD	Age/Sex: <1-9	376
TX_CURR_DSD	Age/Sex: 10-14 Male	525
TX_CURR_DSD	Age/Sex: 10-14 Female	609
TX_CURR_DSD	Age/Sex: 20-24 Male	1,414
TX_CURR_DSD	Age/Sex: 25-49 Male	5,089
TX_CURR_DSD	Age/Sex: 50+ Male	353
TX_CURR_DSD	Age/Sex: 20-24 Female	3,157
TX_CURR_DSD	Age/Sex: 25-49 Female	9,197
TX_CURR_DSD	Age/Sex: 50+ Female	686
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,600
TX_NEW_DSD	By Age/Sex: <1	4
TX_NEW_DSD	By Age/Sex: 1-9	21
TX_NEW_DSD	By Age/Sex: 10-14 Male	29
TX_NEW_DSD	By Age/Sex: 15-19 Male	15
TX_NEW_DSD	By Age/Sex: 20-24 Male	103
TX_NEW_DSD	By Age/Sex: 25-49 Male	370
TX_NEW_DSD	By Age/Sex: 50+ Male	26
TX_NEW_DSD	By Age/Sex: 10-14 Female	34
TX_NEW_DSD	By Age/Sex: 15-19 Female	50
TX_NEW_DSD	By Age/Sex: 20-24 Female	230



TX_NEW_DSD	By Age/Sex: 25-49 Female	669
TX_NEW_DSD	By Age/Sex: 50+ Female	49
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,575
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	41
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	514
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	47
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	998
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,600
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	16,105
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	17,894
TX_PVLS_DSD	Numerator: Indication: Routine	16,105
TX_PVLS_DSD	Denominator: Indication: Routine	17,894
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	532
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	5,094
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	600
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	9,879
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	591
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	5,658
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	667
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	10,978
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	851
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	956
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after	2



	initiating ART	
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	9
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	13
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	17
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	399
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	135
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	11
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	13
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	60
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	176
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	13
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and	2



	children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	15
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	19
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	125
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	449
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	30
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months	13



	prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	15
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	68
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	197
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	14
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	19
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	554
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	16
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	262



TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	21
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	623
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	18
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	294

Implementing Mechanism Details

Mechanism ID: 13325	Mechanism Name: Provision of comprehensive, community-based HIV/AIDS services and Capacity Building of Indigenous Organizations in the Republic Of Uganda
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Reach Out Mbuya	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	



Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13325		
Mechanism Name:	Provision of comprehensive, community-based HIV/AIDS services and Capacity Building of Indigenous Organizations in the Republic Of		
Prime Partner Name:	Uganda Reach Out Mbuya		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	715
PMTCT_ART_DSD	New on ART	28
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	36
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	715
PMTCT_STAT_DSD	Number of new ANC and L&D clients	732
PMTCT_STAT_DSD	By: Known positives at entry	39
PMTCT_STAT_DSD	By: Number of new positives identified	27
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	66
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	1,833
PP_PREV_DSD	Total number of people in the target population	17,821
PP_PREV_DSD	Aggregated Age/sex: <15 Male	397



PP_PREV_DSD	Aggregated Age/sex: 15+ Male	506
PP_PREV_DSD	Aggregated Age/sex: <15 Female	428
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	504
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	65
KP_PREV_DSD	Total estimated number of key population in the catchment area	242
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	56
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	9
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	70
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	30
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	142
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	14,580
HTC_TST_DSD	Age/sex: 10-14 Male	816
HTC_TST_DSD	Age/sex: 15-19 Male	1,204
HTC_TST_DSD	Age/sex: 20-24 Male	1,808



HTC_TST_DSD	Age/sex: 25-49 Male	2,772
HTC_TST_DSD	Age/sex: 50+ Male	242
HTC_TST_DSD	Age/sex: 10-14 Female	815
HTC_TST_DSD	Age/sex: 15-19 Female	1,138
HTC_TST_DSD	Age/sex: 20-24 Female	1,708
HTC_TST_DSD	Age/sex: 25-49 Female	2,619
HTC_TST_DSD	Age/sex: 50+ Female	227
HTC_TST_DSD	Sum of Age/Sex disaggregates	13,349
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	40
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	51
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	76
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	117
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	10
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	39
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	68
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	102
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	156
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	13
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,431
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	6,026
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,431
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	5,692
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	2,862
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	11,718
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	14,580
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	71
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	254



HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	70
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	339
HTC_TST_DSD	Test Result by Age: Positive: <1	16
HTC_TST_DSD	Test Result by Age: Positive: 1-9	46
HTC_TST_DSD	Age/sex: <1	286
HTC_TST_DSD	Age/sex: 1-9	945
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	365
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	7,798
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	2,809
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	995
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	711
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	252
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	1,650
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	71
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	71
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	41
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	25
GEND_GBV_DSD	Number of people receiving post-GBV care	40
GEND_GBV_DSD	Age/Sex: <10 Male	1



GEND_GBV_DSD	Age/Sex: 10-14 Male	1
GEND_GBV_DSD	Age/Sex: 20-24 Male	2
GEND_GBV_DSD	Age/Sex: 25-49 Male	2
GEND_GBV_DSD	Age/Sex: <10 Female	2
GEND_GBV_DSD	Age/Sex: 10-14 Female	6
GEND_GBV_DSD	Age/Sex: 20-24 Female	14
GEND_GBV_DSD	Age/Sex: 25-49 Female	4
GEND_GBV_DSD	Sum of Age/Sex Disaggregates	10
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	9
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	31
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	4
GEND_GBV_DSD	Age/Sex: 15-19 Female	8
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	3,690
OVC_SERV_DSD	Age/Sex: 18+ Male	415
OVC_SERV_DSD	Age/Sex: 18+ Female	502
OVC_SERV_DSD	Sum of Age/Sex disaggregates	917
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	1,340
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	1,433
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	33
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	33
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	23
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The	10

	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	7,743
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	172
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	2,507
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	196
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	4,868
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	155
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	620
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	187
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	372
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	61
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	43
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	10
PMTCT_EID_DSD	Sum of Infant Age disaggregates	53
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	3
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	7,743
TX_CURR_DSD	Age/Sex: 15-19 Male	75
TX_CURR_DSD	Age/Sex: 15-19 Female	244
TX_CURR_DSD	Sum of age/sex disaggregates	319
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	172
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	2,507



TX_CURR_DSD	Aggregated Age/Sex: <15 Female	196
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	4,868
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	368
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	7,375
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	7,743
TX_CURR_DSD	Age/Sex: <1	15
TX_CURR_DSD	Age/Sex: <1-9	88
TX_CURR_DSD	Age/Sex: 10-14 Male	122
TX_CURR_DSD	Age/Sex: 10-14 Female	143
TX_CURR_DSD	Age/Sex: 20-24 Male	502
TX_CURR_DSD	Age/Sex: 25-49 Male	1,805
TX_CURR_DSD	Age/Sex: 50+ Male	125
TX_CURR_DSD	Age/Sex: 20-24 Female	1,119
TX_CURR_DSD	Age/Sex: 25-49 Female	3,261
TX_CURR_DSD	Age/Sex: 50+ Female	244
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,064
TX_NEW_DSD	By Age/Sex: <1	6
TX_NEW_DSD	By Age/Sex: 1-9	36
TX_NEW_DSD	By Age/Sex: 10-14 Male	47
TX_NEW_DSD	By Age/Sex: 15-19 Male	10
TX_NEW_DSD	By Age/Sex: 20-24 Male	62
TX_NEW_DSD	By Age/Sex: 25-49 Male	225
TX_NEW_DSD	By Age/Sex: 50+ Male	15
TX_NEW_DSD	By Age/Sex: 10-14 Female	57
TX_NEW_DSD	By Age/Sex: 15-19 Female	30
TX_NEW_DSD	By Age/Sex: 20-24 Female	139
TX_NEW_DSD	By Age/Sex: 25-49 Female	406
TX_NEW_DSD	By Age/Sex: 50+ Female	31
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,022
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	68
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	312



TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	78
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	606
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,064

Implementing Mechanism Details

Mechanism ID: 13383	Mechanism Name: Supporting the Scale-up of Comprehensive HIV/AIDS Prevention Services in the Republic of Uganda under the Presidents Emergency Plan for AIDS Relief
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Medical and Research Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13383
Mechanism Name:	Supporting the Scale-up of Comprehensive HIV/AIDS Prevention Services in the Republic of Uganda under the Presidents Emergency
Prime Partner Name:	Plan for AIDS Relief African Medical and Research Foundation



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	30,340
VMMC_CIRC_DSD	By Age: 10-14	11,831
VMMC_CIRC_DSD	By Age: 15-19	8,800
VMMC_CIRC_DSD	By Age: 20-24	4,248
VMMC_CIRC_DSD	By Age: 25-29	2,429
VMMC_CIRC_DSD	By Age: 30-49	2,429
VMMC_CIRC_DSD	By Age: 50+	603
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	25,482
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	30,340
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	30,340

Implementing Mechanism Details

Mechanism ID: 13416	Mechanism Name: Scaling up comprehensive HIV/AIDS services including PICT, TB/HIV, OVC, ART (including pregnant women) & children through public university teaching hospitals, regional referral hospitals & public & private-not-for-profit health facilities in Uganda under PEPFAR.
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Mildmay International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: Mechanism Name: Prime Partner Name:	13416 Scaling up comprehensive HIV/AIDS services including PICT,TB/HIV,OVC,ART (including pregnant women)&children through public university teaching hospitals, regional referral hospitals& public& private-not-for-profit health facilities in Uganda under PEPFAR. Mildmay International		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	31,731
PMTCT_ART_DSD	New on ART	1,160



PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,611
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	19,722
PMTCT_ART_TA	New on ART	673
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	935
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	31,731
PMTCT_STAT_DSD	Number of new ANC and L&D clients	32,542
PMTCT_STAT_DSD	By: Known positives at entry	1,602
PMTCT_STAT_DSD	By: Number of new positives identified	1,310
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	2,912
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	19,722
PMTCT_STAT_TA	Number of new ANC and L&D clients	20,224
PMTCT_STAT_TA	By: Known positives at entry	902
PMTCT_STAT_TA	By: Number of new positives identified	795
PMTCT_STAT_TA	Sum of Positives Status disaggregates	1,697
PrEP_NEW_DSD	Number of individuals who have received antiretroviral preexposure	489
PrEP_NEW_DSD	Male 15-19	122
PrEP_NEW_DSD	Male 20-24	32
PrEP_NEW_DSD	Male 25-49	44
PrEP_NEW_DSD	Male 50+	4
PrEP_NEW_DSD	Female 15-19	164
PrEP_NEW_DSD	Female 20-24	75
PrEP_NEW_DSD	Female 25-49	44
PrEP_NEW_DSD	Female 50+	4
PrEP_NEW_TA	Number of adult women and adolescent girls newly enrolled on oral or topical PrEP	100
PrEP_NEW_TA	Male 15-19	25

PrEP_NEW_TA	Male 20-24	7
PrEP_NEW_TA	Male 25-49	9
PrEP_NEW_TA	Male 50+	1
PrEP_NEW_TA	Female 15-19	33
PrEP_NEW_TA	Female 20-24	15
PrEP_NEW_TA	Female 25-49	9
PrEP_NEW_TA	Female 50+	1
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	75,523
PP_PREV_DSD	Total number of people in the target population	456,069
PP_PREV_DSD	Aggregated Age/sex: <15 Male	10,750
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	13,712
PP_PREV_DSD	Aggregated Age/sex: <15 Female	11,745
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	39,338
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	2,283
KP_PREV_DSD	Total estimated number of key population in the catchment area	4,738
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,219
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	64
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	496



KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	216
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	4,026
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	195,747
HTC_TST_DSD	Age/sex: 10-14 Male	6,007
HTC_TST_DSD	Age/sex: 15-19 Male	15,760
HTC_TST_DSD	Age/sex: 20-24 Male	23,640
HTC_TST_DSD	Age/sex: 25-49 Male	36,246
HTC_TST_DSD	Age/sex: 50+ Male	3,145
HTC_TST_DSD	Age/sex: 10-14 Female	6,020
HTC_TST_DSD	Age/sex: 15-19 Female	19,168
HTC_TST_DSD	Age/sex: 20-24 Female	28,756
HTC_TST_DSD	Age/sex: 25-49 Female	44,083
HTC_TST_DSD	Age/sex: 50+ Female	3,821
HTC_TST_DSD	Sum of Age/Sex disaggregates	186,646
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	312
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	490
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	741
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	1,133
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	95
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	305
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	1,002
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	1,505
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	2,297
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	198
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	10,562



HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	78,791
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	10,566
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	95,828
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	21,128
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	174,619
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	195,747
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	511
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	2,459
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	518
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	5,002
HTC_TST_DSD	Test Result by Age: Positive: <1	81
HTC_TST_DSD	Test Result by Age: Positive: 1-9	331
HTC_TST_DSD	Age/sex: <1	2,125
HTC_TST_DSD	Age/sex: 1-9	6,976
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	29,925
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	43,665
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	17,345
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	12,834
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	23,598
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	53,534
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	1,442
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	13,404
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	189,355
HTC_TST_TA	Age/sex: 10-14 Male	7,159



HTC_TST_TA	Age/sex: 15-19 Male	12,414
HTC_TST_TA	Age/sex: 20-24 Male	18,626
HTC_TST_TA	Age/sex: 25-49 Male	28,546
HTC_TST_TA	Age/sex: 50+ Male	2,467
HTC_TST_TA	Age/sex: 10-14 Female	7,149
HTC_TST_TA	Age/sex: 15-19 Female	20,430
HTC_TST_TA	Age/sex: 20-24 Female	30,660
HTC_TST_TA	Age/sex: 25-49 Female	46,994
HTC_TST_TA	Age/sex: 50+ Female	4,060
HTC_TST_TA	Sum of Age/Sex disaggregates	178,505
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Male	371
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Male	453
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Male	683
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Male	1,029
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Male	90
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Female	355
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Female	1,019
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Female	1,557
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Female	2,368
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Female	188
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	12,594
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	62,053
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	12,564
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	102,144
HTC_TST_TA	Sum of Aggregated Age/Sex <15	25,158
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	164,197
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	189,355
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15	603



	Male	
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	2,255
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	592
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	5,132
HTC_TST_TA	Test Result by Age: Positive: <1	86
HTC_TST_TA	Test Result by Age: Positive: 1-9	383
HTC_TST_TA	Age/sex: <1	2,539
HTC_TST_TA	Age/sex: 1-9	8,311
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	28,446
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	44,092
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	21,049
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	12,418
HTC_TST_TA	Service Delivery Point (Facility): VMMC	6,742
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	60,097
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	1,279
HTC_TST_TA	Service Delivery Point (Facility): Index testing	15,232
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,788
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,788
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	52
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,092
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	41
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number	603

	of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,181
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	1,181
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	31
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	741
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	22
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	387
GEND_GBV_DSD	Number of people receiving post-GBV care	2,267
GEND_GBV_DSD	Age/Sex: <10 Male	66
GEND_GBV_DSD	Age/Sex: 10-14 Male	66
GEND_GBV_DSD	Age/Sex: 20-24 Male	113
GEND_GBV_DSD	Age/Sex: 25-49 Male	113
GEND_GBV_DSD	Age/Sex: <10 Female	113
GEND_GBV_DSD	Age/Sex: 10-14 Female	319
GEND_GBV_DSD	Age/Sex: 20-24 Female	577
GEND_GBV_DSD	Age/Sex: 25-49 Female	226
GEND_GBV_DSD	Sum of Age/Sex Disaggregates	564
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	495
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	1,772
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	204
GEND_GBV_DSD	Age/Sex: 15-19 Female	564



GEND_GBV_DSD	Age/Sex: 15-19 male	110
GEND_GBV_TA	Number of people receiving post-GBV care	1,448
GEND_GBV_TA	Age/Sex: <10 Male	39
GEND_GBV_TA	Age/Sex: 10-14 Male	39
GEND_GBV_TA	Age/Sex: 20-24 Male	71
GEND_GBV_TA	Age/Sex: 25-49 Male	71
GEND_GBV_TA	Age/Sex: <10 Female	71
GEND_GBV_TA	Age/Sex: 10-14 Female	205
GEND_GBV_TA	Age/Sex: 20-24 Female	369
GEND_GBV_TA	Age/Sex: 25-49 Female	144
GEND_GBV_TA	Sum of Age/Sex Disaggregates	354
GEND_GBV_TA	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	320
GEND_GBV_TA	By type of service: Sexual Violence (Post-Rape Care)	1,128
GEND_GBV_TA	By PEP service provision (related to sexual violence services provided)	124
GEND_GBV_TA	Age/Sex: 15-19 Female	365
GEND_GBV_TA	Age/Sex: 15-19 Male	74
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	25,985
OVC_SERV_DSD	Age/Sex: 18+ Male	1,694
OVC_SERV_DSD	Age/Sex: 18+ Female	2,050
OVC_SERV_DSD	Sum of Age/Sex disaggregates	3,744
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	3,264
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	2,170
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	5,504
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	5,464
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	5,839
TB_ART_DSD	The number of registered new and relapse TB cases	819

	with documented HIV-positive status who are on ART during TB treatment during the reporting period	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	819
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	10
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	533
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	5
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	271
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	530
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	530
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	356



TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	169
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	73,169
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	2,850
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	22,804
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	3,227
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	44,288
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	1,462
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	5,852
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	1,757
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	3,510
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	585
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	44,748
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	1,639
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	14,009
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	1,858
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	27,242
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	895
TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	3,582



TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	1,082
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	2,153
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	347
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,843
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	493
PMTCT_EID_DSD	Sum of Infant Age disaggregates	2,336
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	94
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	15
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	1,066
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	293
PMTCT_EID_TA	Sum of Infant Age disaggregates	1,359
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	53
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	5
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	73,169
TX_CURR_DSD	Age/Sex: 15-19 Male	685
TX_CURR_DSD	Age/Sex: 15-19 Female	2,213
TX_CURR_DSD	Sum of age/sex disaggregates	2,898
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	2,850
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	22,804
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	3,227
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	44,288



TX_CURR_DSD	Sum of Aggregated Age/Sex <15	6,077
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	67,092
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	73,169
TX_CURR_DSD	Age/Sex: <1	228
TX_CURR_DSD	Age/Sex: <1-9	1,464
TX_CURR_DSD	Age/Sex: 10-14 Male	2,026
TX_CURR_DSD	Age/Sex: 10-14 Female	2,359
TX_CURR_DSD	Age/Sex: 20-24 Male	4,558
TX_CURR_DSD	Age/Sex: 25-49 Male	16,418
TX_CURR_DSD	Age/Sex: 50+ Male	1,143
TX_CURR_DSD	Age/Sex: 20-24 Female	10,191
TX_CURR_DSD	Age/Sex: 25-49 Female	29,671
TX_CURR_DSD	Age/Sex: 50+ Female	2,213
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	44,748
TX_CURR_TA	Age/Sex: 15-19 Male	424
TX_CURR_TA	Age/Sex: 15-19 Female	1,365
TX_CURR_TA	Sum of Age/Sex disaggregations	1,789
TX_CURR_TA	Aggregated Age/Sex: <15 Male	1,639
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	14,009
TX_CURR_TA	Aggregated Age/Sex: <15 Female	1,858
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	27,242
TX_CURR_TA	Sum of Aggregated Age/Sex <15	3,497
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	41,251
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	44,748
TX_CURR_TA	Age/Sex: <1	122
TX_CURR_TA	Age/Sex: 1-9	852
TX_CURR_TA	Age/Sex: 10-14 Male	1,167
TX_CURR_TA	Age/Sex: 10-14 Female	1,356
TX_CURR_TA	Age/Sex: 20-24 Male	2,799
TX_CURR_TA	Age/Sex: 25-49 Male	10,082
TX_CURR_TA	Age/Sex: 50+ Male	704



TX_CURR_TA	Age/Sex: 20-24 Female	6,272
TX_CURR_TA	Age/Sex: 25-49 Female	18,240
TX_CURR_TA	Age/Sex: 50+ Female	1,365
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	11,722
TX_NEW_DSD	By Age/Sex: <1	23
TX_NEW_DSD	By Age/Sex: 1-9	202
TX_NEW_DSD	By Age/Sex: 10-14 Male	281
TX_NEW_DSD	By Age/Sex: 15-19 Male	111
TX_NEW_DSD	By Age/Sex: 20-24 Male	739
TX_NEW_DSD	By Age/Sex: 25-49 Male	2,657
TX_NEW_DSD	By Age/Sex: 50+ Male	187
TX_NEW_DSD	By Age/Sex: 10-14 Female	343
TX_NEW_DSD	By Age/Sex: 15-19 Female	355
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,655
TX_NEW_DSD	By Age/Sex: 25-49 Female	4,808
TX_NEW_DSD	By Age/Sex: 50+ Female	361
TX_NEW_DSD	Sum of Age/Sex disaggregates	11,497
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	396
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	3,694
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	453
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	7,179
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	11,722
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	9,383
TX_NEW_TA	By Age/Sex: 1-9	182
TX_NEW_TA	By Age/Sex: 10-14 Male	259
TX_NEW_TA	By Age/Sex: 15-19 Male	81
TX_NEW_TA	By Age/Sex: 20-24 Male	584
TX_NEW_TA	By Age/Sex: 25-49 Male	2,105
TX_NEW_TA	By Age/Sex: 50+ Male	143
TX_NEW_TA	By Age/Sex: 10-14 Female	335



TX_NEW_TA	By Age/Sex: 15-19 Female	284
TX_NEW_TA	By Age/Sex: 20-24 Female	1,312
TX_NEW_TA	By Age/Sex: 25-49 Female	3,811
TX_NEW_TA	By Age/Sex: 50+ Female	272
TX_NEW_TA	Sum of Age/Sex disaggregates	9,186
TX_NEW_TA	Aggregated Grouping by Age: <1	15
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	363
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	2,913
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	428
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	5,679
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	9,383

Implementing Mechanism Details

Mechanism ID: 13466	Mechanism Name: Provision of Comprehensive HIV/AIDS Care, Treatment and Prevention services in Track 1.0 Health Facilities in Uganda
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Uganda Protestant Medical Board	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,920,238	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,920,238	
Funding Source	Funding Amount
GHP-State	1,920,238

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID:	13466		
Mechanism Name:	Provision of Comprehensive HIV/AIDS Care, Treatment and Prevention services in Track 1.0 Health Facilities in Uganda		
Prime Partner Name:	Uganda Protestant Medical Board		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	365,082	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	174,425	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	87,691	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	140,343	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	249,118	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	30,808	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	70,166	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	754,082	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	48,523	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	11,937
PMTCT_ART_DSD	New on ART	243
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	358
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	11,937
PMTCT_STAT_DSD	Number of new ANC and L&D clients	12,244



PMTCT_STAT_DSD	By: Known positives at entry	371
PMTCT_STAT_DSD	By: Number of new positives identified	257
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	628
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	1,955
PP_PREV_DSD	Total number of people in the target population	9,241
PP_PREV_DSD	Aggregated Age/sex: <15 Male	422
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	540
PP_PREV_DSD	Aggregated Age/sex: <15 Female	457
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	536
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	707
KP_PREV_DSD	Total estimated number of key population in the catchment area	1,412
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	707
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	1,412
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	102,248
HTC_TST_DSD	Age/sex: 10-14 Male	2,720
HTC_TST_DSD	Age/sex: 15-19 Male	8,901
HTC_TST_DSD	Age/sex: 20-24 Male	13,351
HTC_TST_DSD	Age/sex: 25-49 Male	20,472
HTC_TST_DSD	Age/sex: 50+ Male	1,780
HTC_TST_DSD	Age/sex: 10-14 Female	2,719



HTC_TST_DSD	Age/sex: 15-19 Female	9,640
HTC_TST_DSD	Age/sex: 20-24 Female	14,459
HTC_TST_DSD	Age/sex: 25-49 Female	22,171
HTC_TST_DSD	Age/sex: 50+ Female	1,928
HTC_TST_DSD	Sum of Age/Sex disaggregates	98,141
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	109
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	255
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	382
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	584
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	50
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	105
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	362
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	542
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	832
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	71
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	4,774
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	44,504
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	4,772
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	48,198
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	9,546
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	92,702
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	102,248
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	188
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,271
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	186
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+	1,807



	Female	
HTC_TST_DSD	Test Result by Age: Positive: <1	35
HTC_TST_DSD	Test Result by Age: Positive: 1-9	125
HTC_TST_DSD	Age/sex: <1	957
HTC_TST_DSD	Age/sex: 1-9	3,150
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	22,449
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	43,502
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	9,053
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	6,818
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	11,768
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	772
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	7,886
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	450
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	450
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	14
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	277
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	10
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	149
GEND_GBV_DSD	Number of people receiving post-GBV care	669
GEND_GBV_DSD	Age/Sex: <10 Male	20
GEND_GBV_DSD	Age/Sex: 10-14 Male	20
GEND_GBV_DSD	Age/Sex: 20-24 Male	32
GEND_GBV_DSD	Age/Sex: 25-49 Male	32



GEND_GBV_DSD	Age/Sex: <10 Female	32
GEND_GBV_DSD	Age/Sex: 10-14 Female	94
GEND_GBV_DSD	Age/Sex: 20-24 Female	166
GEND_GBV_DSD	Age/Sex: 25-49 Female	68
GEND_GBV_DSD	Sum of Age/Sex Disaggregates	166
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	146
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	523
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	63
GEND_GBV_DSD	Age/Sex: 15-19 Female	167
GEND_GBV_DSD	Age/Sex: 15-19 male	38
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	2,995
OVC_SERV_DSD	Age/Sex: 18+ Male	337
OVC_SERV_DSD	Age/Sex: 18+ Female	407
OVC_SERV_DSD	Sum of Age/Sex disaggregates	744
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	1,088
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	1,163
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	164
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	164
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	107



TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	55
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	14,842
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	432
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	4,733
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	487
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	9,190
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	296
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	1,188
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	354
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	714
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	120
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	396
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	105
PMTCT_EID_DSD	Sum of Infant Age disaggregates	501
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	19
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	5
TX_CURR_DSD	Number of adults and children receiving antiretroviral	14,842



	therapy (ART)	
TX_CURR_DSD	Age/Sex: 15-19 Male	144
TX_CURR_DSD	Age/Sex: 15-19 Female	459
TX_CURR_DSD	Sum of age/sex disaggregates	603
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	432
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	4,733
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	487
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	9,190
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	919
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	13,923
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	14,842
TX_CURR_DSD	Age/Sex: <1	38
TX_CURR_DSD	Age/Sex: <1-9	218
TX_CURR_DSD	Age/Sex: 10-14 Male	307
TX_CURR_DSD	Age/Sex: 10-14 Female	356
TX_CURR_DSD	Age/Sex: 20-24 Male	946
TX_CURR_DSD	Age/Sex: 25-49 Male	3,405
TX_CURR_DSD	Age/Sex: 50+ Male	238
TX_CURR_DSD	Age/Sex: 20-24 Female	2,114
TX_CURR_DSD	Age/Sex: 25-49 Female	6,158
TX_CURR_DSD	Age/Sex: 50+ Female	459
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,863
TX_NEW_DSD	By Age/Sex: <1	5
TX_NEW_DSD	By Age/Sex: 1-9	54
TX_NEW_DSD	By Age/Sex: 10-14 Male	74
TX_NEW_DSD	By Age/Sex: 15-19 Male	26
TX_NEW_DSD	By Age/Sex: 20-24 Male	180
TX_NEW_DSD	By Age/Sex: 25-49 Male	649
TX_NEW_DSD	By Age/Sex: 50+ Male	45
TX_NEW_DSD	By Age/Sex: 10-14 Female	91
TX_NEW_DSD	By Age/Sex: 15-19 Female	87



TX_NEW_DSD	By Age/Sex: 20-24 Female	402
TX_NEW_DSD	By Age/Sex: 25-49 Female	1,164
TX_NEW_DSD	By Age/Sex: 50+ Female	86
TX_NEW_DSD	Sum of Age/Sex disaggregates	2,804
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	103
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	900
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	121
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,739
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	2,863
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	10,687
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	11,874
TX_PVLS_DSD	Numerator: Indication: Routine	10,687
TX_PVLS_DSD	Denominator: Indication: Routine	11,874
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	311
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	3,410
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	349
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	6,617
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	345
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	3,789
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	389
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	7,351
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,631
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,957
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and	27



	children who are still alive and on treatment at 12 months after initiating ART	
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	43
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	51
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,232
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	418
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	40
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	41
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	188
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	544
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	37
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who	1



	have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	29
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	49
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	57
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	384
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,385
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	96
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART,	44



	and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	46
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	209
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	612
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	45
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	59
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,711
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	51
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	810
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the	67



	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,922
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	56
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	912

Implementing Mechanism Details

Mechanism ID: 13486	Mechanism Name: Scaling Up Integrated, Effective and Sustainable Services for the Prevention of Mother to Child Transmission of HIV (PMTCT) in Uganda
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Protecting Families from AIDS, Uganda	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13486		
Mechanism Name:	Scaling Up Integrated, Effective and Sustainable Services for the		
Prime Partner Name:	Prevention of Mother to Child Transmission of HIV (PMTCT) in Uganda		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information



Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	21,834
PMTCT_ART_DSD	New on ART	780
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,044
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	40,480
PMTCT_ART_TA	New on ART	1,414
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	1,946
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	21,834
PMTCT_STAT_DSD	Number of new ANC and L&D clients	22,397
PMTCT_STAT_DSD	By: Known positives at entry	1,025
PMTCT_STAT_DSD	By: Number of new positives identified	865
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	1,890
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	40,480
PMTCT_STAT_TA	Number of new ANC and L&D clients	41,514
PMTCT_STAT_TA	By: Known positives at entry	1,890
PMTCT_STAT_TA	By: Number of new positives identified	1,635
PMTCT_STAT_TA	Sum of Positives Status disaggregates	3,525
GEND_GBV_DSD	Number of people receiving post-GBV care	1,225
GEND_GBV_DSD	Age/Sex: <10 Male	35
GEND_GBV_DSD	Age/Sex: 10-14 Male	35
GEND_GBV_DSD	Age/Sex: 20-24 Male	60
GEND_GBV_DSD	Age/Sex: 25-49 Male	60
GEND_GBV_DSD	Age/Sex: <10 Female	60
GEND_GBV_DSD	Age/Sex: 10-14 Female	172
GEND_GBV_DSD	Age/Sex: 20-24 Female	314



GEND_GBV_DSD	Age/Sex: 25-49 Female	127
GEND_GBV_DSD	Sum of Age/Sex Disaggregates	302
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	270
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	955
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	113
GEND_GBV_DSD	Age/Sex: 15-19 Female	306
GEND_GBV_DSD	Age/Sex: 15-19 male	56
GEND_GBV_TA	Number of people receiving post-GBV care	2,270
GEND_GBV_TA	Age/Sex: <10 Male	65
GEND_GBV_TA	Age/Sex: 10-14 Male	65
GEND_GBV_TA	Age/Sex: 20-24 Male	113
GEND_GBV_TA	Age/Sex: 25-49 Male	113
GEND_GBV_TA	Age/Sex: <10 Female	113
GEND_GBV_TA	Age/Sex: 10-14 Female	317
GEND_GBV_TA	Age/Sex: 20-24 Female	585
GEND_GBV_TA	Age/Sex: 25-49 Female	231
GEND_GBV_TA	Sum of Age/Sex Disaggregates	560
GEND_GBV_TA	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	502
GEND_GBV_TA	By type of service: Sexual Violence (Post-Rape Care)	1,768
GEND_GBV_TA	By PEP service provision (related to sexual violence services provided)	209
GEND_GBV_TA	Age/Sex: 15-19 Female	566
GEND_GBV_TA	Age/Sex: 15-19 Male	102
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,190
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	321
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,511
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	60



PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	9
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	2,218
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	601
PMTCT_EID_TA	Sum of Infant Age disaggregates	2,819
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	115
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	18

Implementing Mechanism Details

Mechanism ID: 13717	Mechanism Name: Provision of Comprehensive CARE, Treatment and Prevention Services in Indigenous Health Facilities - AIDS Care and Treatment
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Registered Trustees for the Uganda Episcopal Conference	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 7,180,310	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 7,180,310	
Funding Source	Funding Amount
GHP-State	7,180,310

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID:	13717		
Mechanism Name:	Provision of Comprehensive CARE, Treatment and Prevention Services		
Prime Partner Name:	in Indigenous Health Facilities - AIDS Care and Treatment		
	Registered Trustees for the Uganda Episcopal Conference		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	1,539,404	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	491,350	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	367,792	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	480,849	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	177,927	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	529,868	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	54,289	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	288,616	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	3,094,319	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	155,898	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	39,197
PMTCT_ART_DSD	New on ART	1,420
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,971
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	39,197
PMTCT_STAT_DSD	Number of new ANC and L&D clients	40,204
PMTCT_STAT_DSD	By: Known positives at entry	2,152
PMTCT_STAT_DSD	By: Number of new positives identified	1,425
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	3,577
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	27,500
VMMC_CIRC_DSD	By Age: 10-14	10,724
VMMC_CIRC_DSD	By Age: 15-19	7,975
VMMC_CIRC_DSD	By Age: 20-24	3,849
VMMC_CIRC_DSD	By Age: 25-29	2,201



VMMC_CIRC_DSD	By Age: 30-49	2,201
VMMC_CIRC_DSD	By Age: 50+	550
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	23,098
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	27,500
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	27,500
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	1,768
PP_PREV_DSD	Total number of people in the target population	6,090
PP_PREV_DSD	Aggregated Age/sex: <15 Male	383
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	490
PP_PREV_DSD	Aggregated Age/sex: <15 Female	416
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	488
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	2,636
KP_PREV_DSD	Total estimated number of key population in the catchment area	3,353
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,636
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	3,353
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	231,584
HTC_TST_DSD	Age/sex: 10-14 Male	7,805
HTC_TST_DSD	Age/sex: 15-19 Male	20,844
HTC_TST_DSD	Age/sex: 20-24 Male	31,267
HTC_TST_DSD	Age/sex: 25-49 Male	47,941



HTC_TST_DSD	Age/sex: 50+ Male	4,168
HTC_TST_DSD	Age/sex: 10-14 Female	7,807
HTC_TST_DSD	Age/sex: 15-19 Female	19,994
HTC_TST_DSD	Age/sex: 20-24 Female	29,990
HTC_TST_DSD	Age/sex: 25-49 Female	45,985
HTC_TST_DSD	Age/sex: 50+ Female	3,998
HTC_TST_DSD	Sum of Age/Sex disaggregates	219,799
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	351
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	593
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	890
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	1,363
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	119
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	356
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	929
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	1,397
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	2,139
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	185
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	13,694
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	104,220
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	13,703
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	99,967
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	27,397
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	204,187
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	231,584
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	615
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	2,965
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15	620



	Female	
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	4,650
HTC_TST_DSD	Test Result by Age: Positive: <1	120
HTC_TST_DSD	Test Result by Age: Positive: 1-9	408
HTC_TST_DSD	Age/sex: <1	2,743
HTC_TST_DSD	Age/sex: 1-9	9,042
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	47,469
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	60,132
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	24,600
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	13,940
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	27,500
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	38,933
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	1,941
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	17,069
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	3,364
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	3,364
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	107
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,046
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	82
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,129
GEND_GBV_DSD	Number of people receiving post-GBV care	2,201
GEND_GBV_DSD	Age/Sex: <10 Male	66



GEND_GBV_DSD	Age/Sex: 10-14 Male	66
GEND_GBV_DSD	Age/Sex: 20-24 Male	110
GEND_GBV_DSD	Age/Sex: 25-49 Male	110
GEND_GBV_DSD	Age/Sex: <10 Female	110
GEND_GBV_DSD	Age/Sex: 10-14 Female	309
GEND_GBV_DSD	Age/Sex: 20-24 Female	550
GEND_GBV_DSD	Age/Sex: 25-49 Female	220
GEND_GBV_DSD	Sum of Age/Sex Disaggregates	551
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	483
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	1,718
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	198
GEND_GBV_DSD	Age/Sex: 15-19 Female	548
GEND_GBV_DSD	Age/Sex: 15-19 male	112
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	7,757
OVC_SERV_DSD	Age/Sex: 18+ Male	873
OVC_SERV_DSD	Age/Sex: 18+ Female	1,055
OVC_SERV_DSD	Sum of Age/Sex disaggregates	1,928
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	2,814
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	3,015
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,303
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,303
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	23

TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	816
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	17
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	447
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	68,174
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	2,064
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	21,681
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	2,329
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	42,100
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	1,363
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	5,454
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	1,637
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	3,271
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	546
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	2,236
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	625
PMTCT_EID_DSD	Sum of Infant Age disaggregates	2,861
PMTCT_EID_DSD	Number of infants with a positive virological test result	112

	within 2 months of birth	
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	28
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	68,174
TX_CURR_DSD	Age/Sex: 15-19 Male	651
TX_CURR_DSD	Age/Sex: 15-19 Female	2,106
TX_CURR_DSD	Sum of age/sex disaggregates	2,757
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	2,064
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	21,681
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	2,329
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	42,100
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	4,393
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	63,781
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	68,174
TX_CURR_DSD	Age/Sex: <1	174
TX_CURR_DSD	Age/Sex: <1-9	1,054
TX_CURR_DSD	Age/Sex: 10-14 Male	1,465
TX_CURR_DSD	Age/Sex: 10-14 Female	1,700
TX_CURR_DSD	Age/Sex: 20-24 Male	4,335
TX_CURR_DSD	Age/Sex: 25-49 Male	15,612
TX_CURR_DSD	Age/Sex: 50+ Male	1,083
TX_CURR_DSD	Age/Sex: 20-24 Female	9,682
TX_CURR_DSD	Age/Sex: 25-49 Female	28,206
TX_CURR_DSD	Age/Sex: 50+ Female	2,106
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	12,416
TX_NEW_DSD	By Age/Sex: <1	40
TX_NEW_DSD	By Age/Sex: 1-9	256
TX_NEW_DSD	By Age/Sex: 10-14 Male	357
TX_NEW_DSD	By Age/Sex: 15-19 Male	116
TX_NEW_DSD	By Age/Sex: 20-24 Male	774



TX_NEW_DSD	By Age/Sex: 25-49 Male	2,784
TX_NEW_DSD	By Age/Sex: 50+ Male	190
TX_NEW_DSD	By Age/Sex: 10-14 Female	413
TX_NEW_DSD	By Age/Sex: 15-19 Female	375
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,722
TX_NEW_DSD	By Age/Sex: 25-49 Female	5,016
TX_NEW_DSD	By Age/Sex: 50+ Female	373
TX_NEW_DSD	Sum of Age/Sex disaggregates	12,120
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	502
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	3,864
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	564
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	7,486
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	12,416
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	49,087
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	54,540
TX_PVLS_DSD	Numerator: Indication: Routine	49,087
TX_PVLS_DSD	Denominator: Indication: Routine	54,540
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	1,484
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	15,628
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	1,675
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	30,300
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	1,653
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	17,353
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	1,862
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	33,672
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	11,701
TX_RET_DSD	Total number of adults and children who initiated ART	13,149



	in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	18
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	121
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	186
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	231
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	45
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,478
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,855
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	163
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	182
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	830
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12	2,415



	months after initiating ART	
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	177
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	22
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	132
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	210
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	258
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,712
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,157
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of	422



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	186
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	202
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	929
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,714
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	205
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	263
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7,609



TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	225
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,604
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	296
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8,549
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	254
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,050

Implementing Mechanism Details

Mechanism ID: 13833	Mechanism Name: TRACK TB
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Management Sciences for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



Total All Funding Sources: 1,200,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,200,000	
Funding Source	Funding Amount
GHP-State	1,200,000

Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	5,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

Budget Code Information

Mechanism ID:	13833		
Mechanism Name:	TRACK TB		
Prime Partner Name:	Management Sciences for Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	1,200,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details



Mechanism ID: 13835	Mechanism Name: Strengthening National Pediatric HIV/AIDS and Scaling up Comprehensive HIV/AIDS Services in the Republic of Uganda under The President's Emergency Plan For AIDS Relief
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Baylor College of Medicine Children's Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 14,231,103	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 14,231,103	
Funding Source	Funding Amount
GHP-State	14,231,103

Cross-Cutting Budget Attribution(s)

Gender: GBV	300,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

Budget Code Information

Mechanism ID:	13835
Mechanism Name:	Strengthening National Pediatric HIV/AIDS and Scaling up Comprehensive HIV/AIDS Services in the Republic of Uganda under The President's Emergency Plan For AIDS Relief
Prime Partner Name:	



Baylor College of Medicine Children's Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	1,807,401	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	1,209,415	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	488,743	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	1,428,196	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	55,700	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	1,349,862	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,503,142	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	702,131	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	683,753	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	HTXS	4,266,420	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	736,340	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	86,662
PMTCT_ART_DSD	New on ART	2,194
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	3,047
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	27,498
PMTCT_ART_TA	New on ART	748
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	1,034
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	86,662
PMTCT_STAT_DSD	Number of new ANC and L&D clients	88,887
PMTCT_STAT_DSD	By: Known positives at entry	3,246
PMTCT_STAT_DSD	By: Number of new positives identified	2,284
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	5,530
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	27,498
PMTCT_STAT_TA	Number of new ANC and L&D clients	28,197
PMTCT_STAT_TA	By: Known positives at entry	1,097
PMTCT_STAT_TA	By: Number of new positives identified	784
PMTCT_STAT_TA	Sum of Positives Status disaggregates	1,881

VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	46,681
VMMC_CIRC_DSD	By Age: 10-14	18,206
VMMC_CIRC_DSD	By Age: 15-19	13,537
VMMC_CIRC_DSD	By Age: 20-24	6,536
VMMC_CIRC_DSD	By Age: 25-29	3,735
VMMC_CIRC_DSD	By Age: 30-49	3,735
VMMC_CIRC_DSD	By Age: 50+	932
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	39,211
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	46,681
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	46,681
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	36,328
PP_PREV_DSD	Total number of people in the target population	166,564
PP_PREV_DSD	Aggregated Age/sex: <15 Male	7,845
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	10,007
PP_PREV_DSD	Aggregated Age/sex: <15 Female	8,497
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	9,978
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	2,209
KP_PREV_DSD	Total estimated number of key population in the catchment area	5,022
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,209
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	5,022



HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	543,439
HTC_TST_DSD	Age/sex: 10-14 Male	9,004
HTC_TST_DSD	Age/sex: 15-19 Male	52,276
HTC_TST_DSD	Age/sex: 20-24 Male	78,425
HTC_TST_DSD	Age/sex: 25-49 Male	120,242
HTC_TST_DSD	Age/sex: 50+ Male	10,459
HTC_TST_DSD	Age/sex: 10-14 Female	9,023
HTC_TST_DSD	Age/sex: 15-19 Female	50,077
HTC_TST_DSD	Age/sex: 20-24 Female	75,124
HTC_TST_DSD	Age/sex: 25-49 Female	115,181
HTC_TST_DSD	Age/sex: 50+ Female	10,006
HTC_TST_DSD	Sum of Age/Sex disaggregates	529,817
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	307
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	1,257
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	1,886
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	2,892
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	247
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	324
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	1,779
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	2,669
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	4,090
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	355
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	15,812
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	261,402
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	15,837
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	250,388
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	31,649



HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	511,790
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	543,439
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	534
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	6,282
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	565
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	8,893
HTC_TST_DSD	Test Result by Age: Positive: <1	103
HTC_TST_DSD	Test Result by Age: Positive: 1-9	365
HTC_TST_DSD	Age/sex: <1	3,174
HTC_TST_DSD	Age/sex: 1-9	10,448
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	94,036
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	231,375
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	28,084
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	32,321
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	46,681
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	75,958
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	3,030
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	31,954
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	168,842
HTC_TST_TA	Age/sex: 10-14 Male	2,711
HTC_TST_TA	Age/sex: 15-19 Male	14,605
HTC_TST_TA	Age/sex: 20-24 Male	21,914
HTC_TST_TA	Age/sex: 25-49 Male	33,595
HTC_TST_TA	Age/sex: 50+ Male	2,909
HTC_TST_TA	Age/sex: 10-14 Female	2,719
HTC_TST_TA	Age/sex: 15-19 Female	17,256
HTC_TST_TA	Age/sex: 20-24 Female	25,889



HTC_TST_TA	Age/sex: 25-49 Female	39,688
HTC_TST_TA	Age/sex: 50+ Female	3,449
HTC_TST_TA	Sum of Age/Sex disaggregates	164,735
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Male	89
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Male	395
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Male	593
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Male	908
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Male	77
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Female	97
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Female	639
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Female	964
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Female	1,475
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Female	123
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	4,760
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	73,023
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	4,777
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	86,282
HTC_TST_TA	Sum of Aggregated Age/Sex <15	9,537
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	159,305
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	168,842
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	153
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,973
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	167
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	3,201
HTC_TST_TA	Test Result by Age: Positive: <1	27



HTC_TST_TA	Test Result by Age: Positive: 1-9	107
HTC_TST_TA	Age/sex: <1	956
HTC_TST_TA	Age/sex: 1-9	3,151
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	28,667
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	80,919
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	8,058
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	11,024
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	27,206
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	953
HTC_TST_TA	Service Delivery Point (Facility): Index testing	12,015
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,063
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	2,063
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	65
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,254
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	46
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	698
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	222
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	222
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	8
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of	137



	registered new and relapsed TB cases with documented HIV status, during the reporting period)	
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	74
GEND_GBV_DSD	Number of people receiving post-GBV care	4,312
GEND_GBV_DSD	Age/Sex: <10 Male	133
GEND_GBV_DSD	Age/Sex: 10-14 Male	133
GEND_GBV_DSD	Age/Sex: 20-24 Male	217
GEND_GBV_DSD	Age/Sex: 25-49 Male	217
GEND_GBV_DSD	Age/Sex: <10 Female	217
GEND_GBV_DSD	Age/Sex: 10-14 Female	601
GEND_GBV_DSD	Age/Sex: 20-24 Female	1,052
GEND_GBV_DSD	Age/Sex: 25-49 Female	438
GEND_GBV_DSD	Sum of Age/Sex Disaggregates	1,084
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	953
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	3,359
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	390
GEND_GBV_DSD	Age/Sex: 15-19 Female	1,080
GEND_GBV_DSD	Age/Sex: 15-19 male	224
GEND_GBV_TA	Number of people receiving post-GBV care	1,542
GEND_GBV_TA	Age/Sex: <10 Male	46
GEND_GBV_TA	Age/Sex: 10-14 Male	46
GEND_GBV_TA	Age/Sex: 20-24 Male	81
GEND_GBV_TA	Age/Sex: 25-49 Male	81
GEND_GBV_TA	Age/Sex: <10 Female	81
GEND_GBV_TA	Age/Sex: 10-14 Female	216
GEND_GBV_TA	Age/Sex: 20-24 Female	373



GEND_GBV_TA	Age/Sex: 25-49 Female	155
GEND_GBV_TA	Sum of Age/Sex Disaggregates	389
GEND_GBV_TA	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	339
GEND_GBV_TA	By type of service: Sexual Violence (Post-Rape Care)	1,203
GEND_GBV_TA	By PEP service provision (related to sexual violence services provided)	140
GEND_GBV_TA	Age/Sex: 15-19 Female	387
GEND_GBV_TA	Age/Sex: 15-19 Male	76
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	20,331
OVC_SERV_DSD	Age/Sex: 18+ Male	2,284
OVC_SERV_DSD	Age/Sex: 18+ Female	2,766
OVC_SERV_DSD	Sum of Age/Sex disaggregates	5,050
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	7,389
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	7,892
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	471
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	471
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	318
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	150



	TB treatment during the reporting period)	
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	56
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	56
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	38
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	18
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	70,523
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	4,357
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	20,821
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	4,909
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	40,436
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	1,413
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	5,643
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	1,698
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	3,388
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	557
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	12,670

TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	435
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	3,993
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	494
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	7,748
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	252
TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	1,013
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	304
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	608
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	101
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	3,464
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	965
PMTCT_EID_DSD	Sum of Infant Age disaggregates	4,429
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	173
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	41
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	1,178
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	329
PMTCT_EID_TA	Sum of Infant Age disaggregates	1,507
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	57
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	11
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	70,523
TX_CURR_DSD	Age/Sex: 15-19 Male	623



TX_CURR_DSD	Age/Sex: 15-19 Female	2,023
TX_CURR_DSD	Sum of age/sex disaggregates	2,646
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	4,357
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	20,821
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	4,909
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	40,436
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	9,266
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	61,257
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	70,523
TX_CURR_DSD	Age/Sex: <1	363
TX_CURR_DSD	Age/Sex: <1-9	2,223
TX_CURR_DSD	Age/Sex: 10-14 Male	3,096
TX_CURR_DSD	Age/Sex: 10-14 Female	3,584
TX_CURR_DSD	Age/Sex: 20-24 Male	4,163
TX_CURR_DSD	Age/Sex: 25-49 Male	14,995
TX_CURR_DSD	Age/Sex: 50+ Male	1,040
TX_CURR_DSD	Age/Sex: 20-24 Female	9,300
TX_CURR_DSD	Age/Sex: 25-49 Female	27,090
TX_CURR_DSD	Age/Sex: 50+ Female	2,023
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	12,670
TX_CURR_TA	Age/Sex: 15-19 Male	117
TX_CURR_TA	Age/Sex: 15-19 Female	389
TX_CURR_TA	Sum of Age/Sex disaggregations	506
TX_CURR_TA	Aggregated Age/Sex: <15 Male	435
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	3,993
TX_CURR_TA	Aggregated Age/Sex: <15 Female	494
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	7,748
TX_CURR_TA	Sum of Aggregated Age/Sex <15	929
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	11,741
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	12,670
TX_CURR_TA	Age/Sex: <1	34



TX_CURR_TA	Age/Sex: 1-9	229
TX_CURR_TA	Age/Sex: 10-14 Male	309
TX_CURR_TA	Age/Sex: 10-14 Female	357
TX_CURR_TA	Age/Sex: 20-24 Male	798
TX_CURR_TA	Age/Sex: 25-49 Male	2,875
TX_CURR_TA	Age/Sex: 50+ Male	203
TX_CURR_TA	Age/Sex: 20-24 Female	1,783
TX_CURR_TA	Age/Sex: 25-49 Female	5,187
TX_CURR_TA	Age/Sex: 50+ Female	389
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	22,208
TX_NEW_DSD	By Age/Sex: <1	35
TX_NEW_DSD	By Age/Sex: 1-9	287
TX_NEW_DSD	By Age/Sex: 10-14 Male	389
TX_NEW_DSD	By Age/Sex: 15-19 Male	211
TX_NEW_DSD	By Age/Sex: 20-24 Male	1,423
TX_NEW_DSD	By Age/Sex: 25-49 Male	5,148
TX_NEW_DSD	By Age/Sex: 50+ Male	369
TX_NEW_DSD	By Age/Sex: 10-14 Female	465
TX_NEW_DSD	By Age/Sex: 15-19 Female	695
TX_NEW_DSD	By Age/Sex: 20-24 Female	3,196
TX_NEW_DSD	By Age/Sex: 25-49 Female	9,299
TX_NEW_DSD	By Age/Sex: 50+ Female	691
TX_NEW_DSD	Sum of Age/Sex disaggregates	21,886
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	548
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	7,151
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	628
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	13,881
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	22,208
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	5,609
TX_NEW_TA	By Age/Sex: 1-9	49



TX_NEW_TA	By Age/Sex: 10-14 Male	62
TX_NEW_TA	By Age/Sex: 15-19 Male	51
TX_NEW_TA	By Age/Sex: 20-24 Male	366
TX_NEW_TA	By Age/Sex: 25-49 Male	1,323
TX_NEW_TA	By Age/Sex: 50+ Male	98
TX_NEW_TA	By Age/Sex: 10-14 Female	90
TX_NEW_TA	By Age/Sex: 15-19 Female	176
TX_NEW_TA	By Age/Sex: 20-24 Female	821
TX_NEW_TA	By Age/Sex: 25-49 Female	2,392
TX_NEW_TA	By Age/Sex: 50+ Female	181
TX_NEW_TA	Sum of Age/Sex disaggregates	5,560
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	88
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	1,838
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	113
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	3,570
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	5,609
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	50,778
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	56,420
TX_PVLS_DSD	Numerator: Indication: Routine	50,778
TX_PVLS_DSD	Denominator: Indication: Routine	56,420
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	3,140
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	15,000
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	3,534
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	29,104
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	3,488
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	16,660
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	3,930



TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	32,342
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	9,123
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	10,135
TX_PVLS_TA	Numerator: Indication: Routine	9,123
TX_PVLS_TA	Denominator: Indication: Routine	10,135
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	313
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	2,877
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	356
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	5,577
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	350
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	3,190
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	399
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	6,196
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	12,235
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	13,748
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	9
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	122
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	206
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults	236



	and children who are still alive and on treatment at 12 months after initiating ART	
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	42
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,693
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,936
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	190
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	188
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	875
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,549
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	189
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	12
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those	136



	lost to follow-up)	
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	224
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	264
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,773
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,395
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	449
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	209
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	212



TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	987
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,867
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	220
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	286
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7,907
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	241
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,801
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	315
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	8,881



	including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	266
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,286
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,863
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,093
TX_RET_TA	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	14
TX_RET_TA	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	29
TX_RET_TA	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	33
TX_RET_TA	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1
TX_RET_TA	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	886
TX_RET_TA	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12	309



	months after initiating ART)	
TX_RET_TA	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	35
TX_RET_TA	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	27
TX_RET_TA	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	125
TX_RET_TA	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	375
TX_RET_TA	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	29
TX_RET_TA	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	14
TX_RET_TA	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	29
TX_RET_TA	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	39
TX_RET_TA	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART,	276



	and those lost to follow-up)	
TX_RET_TA	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	991
TX_RET_TA	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	72
TX_RET_TA	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	35
TX_RET_TA	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	31
TX_RET_TA	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	142
TX_RET_TA	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	421
TX_RET_TA	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	43



TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	42
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,229
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	36
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	556
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	42
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,378
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	36
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	637

Implementing Mechanism Details

Mechanism ID: 13837	Mechanism Name: Monitoring, Evaluation and Learning Program
----------------------------	--

Approved



Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: QED Group, LLC	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,821,639	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,821,639	
Funding Source	Funding Amount
GHP-State	1,821,639

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 13837			
Mechanism Name: Monitoring, Evaluation and Learning Program			
Prime Partner Name: QED Group, LLC			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	521,639	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	1,300,000	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 13841	Mechanism Name: CDC-WHO collaboration
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: World Health Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 320,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 320,000	
Funding Source	Funding Amount
GHP-State	320,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13841		
Mechanism Name:	CDC-WHO collaboration		
Prime Partner Name:	World Health Organization		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	120,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	200,000	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13864	Mechanism Name: Ministry of Health, Uganda
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health, Uganda	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 2,030,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,030,000	
Funding Source	Funding Amount
GHP-State	2,030,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13864		
Mechanism Name:	Ministry of Health, Uganda		
Prime Partner Name:	Ministry of Health, Uganda		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	730,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	1,300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMIN	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13874	Mechanism Name: Advocacy for Better Health
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Program for Appropriate Technology in Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 430,357	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 430,357	
Funding Source	Funding Amount
GHP-State	430,357

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13874		
Mechanism Name:	Advocacy for Better Health		
Prime Partner Name:	Program for Appropriate Technology in Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	OHSS	147,212	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	80,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	103,145	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13877	Mechanism Name: New Hope Project – Provision of Comprehensive HIV/AIDS Care, Treatment and Prevention services in Track 1.0 Health Facilities in Uganda		
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement		
Prime Partner Name: Children's AIDS Fund			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
G2G: No	Managing Agency:		

Total All Funding Sources: 3,022,837	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 3,022,837	
Funding Source	Funding Amount
GHP-State	3,022,837



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 13877 Mechanism Name: New Hope Project – Provision of Comprehensive HIV/AIDS Care, Treatment and Prevention services in Track 1.0 Health Facilities in Prime Partner Name: Uganda Children's AIDS Fund			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	671,210	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	546,365	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	159,491	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	164,278	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	84,791	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	19,166	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,318,742	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	PDX	58,794	0
-----------	-----	--------	---

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,341
PMTCT_ART_DSD	New on ART	34
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	45
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,341
PMTCT_STAT_DSD	Number of new ANC and L&D clients	1,374
PMTCT_STAT_DSD	By: Known positives at entry	48
PMTCT_STAT_DSD	By: Number of new positives identified	37
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	85
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	36,598
HTC_TST_DSD	Age/sex: 10-14 Male	1,235
HTC_TST_DSD	Age/sex: 15-19 Male	3,382
HTC_TST_DSD	Age/sex: 20-24 Male	5,075
HTC_TST_DSD	Age/sex: 25-49 Male	7,779
HTC_TST_DSD	Age/sex: 50+ Male	676
HTC_TST_DSD	Age/sex: 10-14 Female	1,239
HTC_TST_DSD	Age/sex: 15-19 Female	3,070
HTC_TST_DSD	Age/sex: 20-24 Female	4,604
HTC_TST_DSD	Age/sex: 25-49 Female	7,059
HTC_TST_DSD	Age/sex: 50+ Female	613
HTC_TST_DSD	Sum of Age/Sex disaggregates	34,732
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	53



HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	119
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	182
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	276
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	24
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	56
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	156
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	233
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	357
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	30
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,166
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	16,912
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,174
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	15,346
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	4,340
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	32,258
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	36,598
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	93
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	601
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	99
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	776
HTC_TST_DSD	Test Result by Age: Positive: <1	20
HTC_TST_DSD	Test Result by Age: Positive: 1-9	63
HTC_TST_DSD	Age/sex: <1	432
HTC_TST_DSD	Age/sex: 1-9	1,434
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	11,803



HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	10,778
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	4,272
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	3,135
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	1,327
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	458
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	4,825
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	296
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	296
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	10
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	181
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	7
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	98
GEND_GBV_DSD	Number of people receiving post-GBV care	77
GEND_GBV_DSD	Age/Sex: <10 Male	1
GEND_GBV_DSD	Age/Sex: 10-14 Male	1
GEND_GBV_DSD	Age/Sex: 20-24 Male	2
GEND_GBV_DSD	Age/Sex: 25-49 Male	2
GEND_GBV_DSD	Age/Sex: <10 Female	2
GEND_GBV_DSD	Age/Sex: 10-14 Female	11
GEND_GBV_DSD	Age/Sex: 20-24 Female	29
GEND_GBV_DSD	Age/Sex: 25-49 Female	8
GEND_GBV_DSD	Sum of Age/Sex Disaggregates	15
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence	17



	(Other Post-GBV Care)	
GEND_GBVDSD	By type of service: Sexual Violence (Post-Rape Care)	60
GEND_GBVDSD	By PEP service provision (related to sexual violence services provided)	6
GEND_GBVDSD	Age/Sex: 15-19 Female	19
GEND_GBVDSD	Age/Sex: 15-19 male	2
OVC_SERVDSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	8,597
OVC_SERVDSD	Age/Sex: 18+ Male	965
OVC_SERVDSD	Age/Sex: 18+ Female	1,172
OVC_SERVDSD	Sum of Age/Sex disaggregates	2,137
OVC_SERVDSD	By Aggregated Age/Sex: <18 Male	3,122
OVC_SERVDSD	By Aggregated Age/Sex: <18 Female	3,338
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	128
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	128
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	84
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	41
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during	29,476

	the reporting period.	
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	792
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	9,447
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	893
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	18,344
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	589
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	2,358
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	708
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	1,415
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	235
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	55
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	14
PMTCT_EID_DSD	Sum of Infant Age disaggregates	69
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	1
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	29,476
TX_CURR_DSD	Age/Sex: 15-19 Male	283
TX_CURR_DSD	Age/Sex: 15-19 Female	916
TX_CURR_DSD	Sum of age/sex disaggregates	1,199
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	792
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	9,447
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	893
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	18,344
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,685
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	27,791
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	29,476



TX_CURR_DSD	Age/Sex: <1	67
TX_CURR_DSD	Age/Sex: <1-9	404
TX_CURR_DSD	Age/Sex: 10-14 Male	562
TX_CURR_DSD	Age/Sex: 10-14 Female	652
TX_CURR_DSD	Age/Sex: 20-24 Male	1,890
TX_CURR_DSD	Age/Sex: 25-49 Male	6,802
TX_CURR_DSD	Age/Sex: 50+ Male	472
TX_CURR_DSD	Age/Sex: 20-24 Female	4,219
TX_CURR_DSD	Age/Sex: 25-49 Female	12,293
TX_CURR_DSD	Age/Sex: 50+ Female	916
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,433
TX_NEW_DSD	By Age/Sex: <1	10
TX_NEW_DSD	By Age/Sex: 1-9	68
TX_NEW_DSD	By Age/Sex: 10-14 Male	91
TX_NEW_DSD	By Age/Sex: 15-19 Male	32
TX_NEW_DSD	By Age/Sex: 20-24 Male	215
TX_NEW_DSD	By Age/Sex: 25-49 Male	774
TX_NEW_DSD	By Age/Sex: 50+ Male	54
TX_NEW_DSD	By Age/Sex: 10-14 Female	107
TX_NEW_DSD	By Age/Sex: 15-19 Female	105
TX_NEW_DSD	By Age/Sex: 20-24 Female	479
TX_NEW_DSD	By Age/Sex: 25-49 Female	1,395
TX_NEW_DSD	By Age/Sex: 50+ Female	103
TX_NEW_DSD	Sum of Age/Sex disaggregates	3,355
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	129
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,075
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	147
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	2,082
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	3,433
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml)	21,222



	documented in the medical records and /or supporting laboratory results within the past 12 months.	
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	23,580
TX_PVLS_DSD	Numerator: Indication: Routine	21,222
TX_PVLS_DSD	Denominator: Indication: Routine	23,580
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	571
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	6,806
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	643
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	13,202
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	634
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	7,560
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	715
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	14,671
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	4,296
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	4,826
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	4
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	42
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	72
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	86
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults	18



	and children who are still alive and on treatment at 12 months after initiating ART	
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,013
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	677
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	62
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	68
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	304
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	885
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	65
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	48
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months	79



	prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	94
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	627
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,260
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	159
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	68
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	74
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including	343



	those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	996
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	73
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	98
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,794
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	82
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,322
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	109
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,140
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total	91



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,486

Implementing Mechanism Details

Mechanism ID: 13880	Mechanism Name: Provision of Comprehensive HIV/AIDS Services and Health Work Force Development for Managing Health Programs in the Republic of Uganda under the President's Plan for AIDS Relief
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Makerere University School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 3,697,229	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 3,697,229	
Funding Source	Funding Amount
GHP-State	3,697,229

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID:		13880	
Mechanism Name:		Provision of Comprehensive HIV/AIDS Services and Health Work Force Development for Managing Health Programs in the Republic of Uganda	
Prime Partner Name:		under the President's Plan for AIDS Relief Makerere University School of Public Health	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	529,739	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	128,366	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	209,218	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	540,952	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	335,971	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVOP	399,844	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	217,371	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,073,772	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	61,996	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	23,739
PMTCT_ART_DSD	New on ART	1,026
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,428
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	23,739
PMTCT_STAT_DSD	Number of new ANC and L&D clients	24,346
PMTCT_STAT_DSD	By: Known positives at entry	1,721
PMTCT_STAT_DSD	By: Number of new positives identified	872
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	2,593
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	63,535
VMMC_CIRC_DSD	By Age: 10-14	24,782
VMMC_CIRC_DSD	By Age: 15-19	18,427
VMMC_CIRC_DSD	By Age: 20-24	8,902



VMMC_CIRC_DSD	By Age: 25-29	5,079
VMMC_CIRC_DSD	By Age: 30-49	5,079
VMMC_CIRC_DSD	By Age: 50+	1,266
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	53,377
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	63,535
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	57,174
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	6,361
PrEP_NEW_DSD	Number of individuals who have received antiretroviral preexposure	1,503
PrEP_NEW_DSD	Male 15-19	372
PrEP_NEW_DSD	Male 20-24	99
PrEP_NEW_DSD	Male 25-49	136
PrEP_NEW_DSD	Male 50+	12
PrEP_NEW_DSD	Female 15-19	504
PrEP_NEW_DSD	Female 20-24	231
PrEP_NEW_DSD	Female 25-49	136
PrEP_NEW_DSD	Female 50+	13
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	24,212
PP_PREV_DSD	Total number of people in the target population	38,246
PP_PREV_DSD	Aggregated Age/sex: <15 Male	741
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	947
PP_PREV_DSD	Aggregated Age/sex: <15 Female	803
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	21,722
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	658
KP_PREV_DSD	Total estimated number of key population in the catchment area	1,162
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key	658



	populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	1,162
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	180,012
HTC_TST_DSD	Age/sex: 10-14 Male	2,974
HTC_TST_DSD	Age/sex: 15-19 Male	21,931
HTC_TST_DSD	Age/sex: 20-24 Male	32,895
HTC_TST_DSD	Age/sex: 25-49 Male	50,441
HTC_TST_DSD	Age/sex: 50+ Male	4,384
HTC_TST_DSD	Age/sex: 10-14 Female	2,984
HTC_TST_DSD	Age/sex: 15-19 Female	11,979
HTC_TST_DSD	Age/sex: 20-24 Female	17,971
HTC_TST_DSD	Age/sex: 25-49 Female	27,555
HTC_TST_DSD	Age/sex: 50+ Female	2,393
HTC_TST_DSD	Sum of Age/Sex disaggregates	175,507
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	123
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	400
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	604
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	921
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	75
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	119
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	592
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	894
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	1,366
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	113
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	5,225
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION	109,651



	ONLY: 15+ Male	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	5,238
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	59,898
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	10,463
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	169,549
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	180,012
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	219
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	2,000
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	218
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	2,965
HTC_TST_DSD	Test Result by Age: Positive: <1	48
HTC_TST_DSD	Test Result by Age: Positive: 1-9	147
HTC_TST_DSD	Age/sex: <1	1,050
HTC_TST_DSD	Age/sex: 1-9	3,455
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	26,135
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	36,257
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	8,440
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	10,954
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	63,535
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	23,496
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	980
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	10,215
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	517
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	517
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of	14



	registered new and relapsed TB cases with documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	320
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	11
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	172
GEND_GBV_DSD	Number of people receiving post-GBV care	1,834
GEND_GBV_DSD	Age/Sex: <10 Male	56
GEND_GBV_DSD	Age/Sex: 10-14 Male	56
GEND_GBV_DSD	Age/Sex: 20-24 Male	93
GEND_GBV_DSD	Age/Sex: 25-49 Male	93
GEND_GBV_DSD	Age/Sex: <10 Female	93
GEND_GBV_DSD	Age/Sex: 10-14 Female	257
GEND_GBV_DSD	Age/Sex: 20-24 Female	457
GEND_GBV_DSD	Age/Sex: 25-49 Female	186
GEND_GBV_DSD	Sum of Age/Sex Disaggregates	462
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	402
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	1,432
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	166
GEND_GBV_DSD	Age/Sex: 15-19 Female	455
GEND_GBV_DSD	Age/Sex: 15-19 male	88
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	6,268
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	1,888



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	1,246
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	3,134
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	177
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	177
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	119
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	56
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	24,157
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	776
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	7,647
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	880
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	14,854
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	481



TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	1,932
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	579
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	1,161
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	192
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,619
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	452
PMTCT_EID_DSD	Sum of Infant Age disaggregates	2,071
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	81
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	18
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	24,157
TX_CURR_DSD	Age/Sex: 15-19 Male	229
TX_CURR_DSD	Age/Sex: 15-19 Female	740
TX_CURR_DSD	Sum of age/sex disaggregates	969
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	776
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	7,647
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	880
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	14,854
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,656
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	22,501
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	24,157
TX_CURR_DSD	Age/Sex: <1	60
TX_CURR_DSD	Age/Sex: <1-9	406
TX_CURR_DSD	Age/Sex: 10-14 Male	551
TX_CURR_DSD	Age/Sex: 10-14 Female	639



TX_CURR_DSD	Age/Sex: 20-24 Male	1,528
TX_CURR_DSD	Age/Sex: 25-49 Male	5,506
TX_CURR_DSD	Age/Sex: 50+ Male	384
TX_CURR_DSD	Age/Sex: 20-24 Female	3,415
TX_CURR_DSD	Age/Sex: 25-49 Female	9,959
TX_CURR_DSD	Age/Sex: 50+ Female	740
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	6,445
TX_NEW_DSD	By Age/Sex: <1	9
TX_NEW_DSD	By Age/Sex: 1-9	82
TX_NEW_DSD	By Age/Sex: 10-14 Male	111
TX_NEW_DSD	By Age/Sex: 15-19 Male	65
TX_NEW_DSD	By Age/Sex: 20-24 Male	414
TX_NEW_DSD	By Age/Sex: 25-49 Male	1,496
TX_NEW_DSD	By Age/Sex: 50+ Male	104
TX_NEW_DSD	By Age/Sex: 10-14 Female	136
TX_NEW_DSD	By Age/Sex: 15-19 Female	199
TX_NEW_DSD	By Age/Sex: 20-24 Female	925
TX_NEW_DSD	By Age/Sex: 25-49 Female	2,699
TX_NEW_DSD	By Age/Sex: 50+ Female	205
TX_NEW_DSD	Sum of Age/Sex disaggregates	6,354
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	158
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	2,079
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	180
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	4,028
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	6,445
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	17,396
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	19,326



TX_PVLS_DSD	Numerator: Indication: Routine	17,396
TX_PVLS_DSD	Denominator: Indication: Routine	19,326
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	557
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	5,516
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	632
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	10,691
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	623
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	6,121
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	703
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	11,879
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,442
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	3,865
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	31
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	58
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	69
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,614
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	549



TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	61
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	52
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	242
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	707
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	51
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	35
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	61
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	75



TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	507
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,809
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	122
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	64
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	63
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	273
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	800
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of	55



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	81
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,240
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	69
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,052
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	87
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,513
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	74
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	1,191



	stopped ART, and those lost to follow-up)	
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	115
HRH_PRE	By Graduates: Other	115
HRH_PRE	Sum of Graduates disaggreagtes	115

Implementing Mechanism Details

Mechanism ID: 13892	Mechanism Name: School Health and Reading Program (SHRP)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Research Triangle International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,000	
Funding Source	Funding Amount
GHP-State	1,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13892
Mechanism Name:	School Health and Reading Program (SHRP)
Prime Partner Name:	Research Triangle International



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	1,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	111,728
PP_PREV_DSD	Total number of people in the target population	422,760
PP_PREV_DSD	Aggregated Age/sex: <15 Male	20,323
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	25,915
PP_PREV_DSD	Aggregated Age/sex: <15 Female	35,162
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	30,328

Implementing Mechanism Details

Mechanism ID: 13897	Mechanism Name: Public Health Workforce and Systems
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Field Epidemiology Network	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 13897			
Mechanism Name: Public Health Workforce and Systems			
Prime Partner Name: African Field Epidemiology Network			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13901	Mechanism Name: Communication for Healthy Communities (CHC)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 2,002,161	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,002,161	
Funding Source	Funding Amount
GHP-State	2,002,161

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	40,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and



	operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	80,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Gender: GBV	30,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	25,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Condom programming	100,000



Budget Code Information

Mechanism ID: 13901			
Mechanism Name: Communication for Healthy Communities (CHC)			
Prime Partner Name: FHI 360			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	55,761	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	500,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	246,400	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	600,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	300,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13924	Mechanism Name: Production for Improved Nutrition (PIN) Project
Funding Agency: USAID	Procurement Type: Cooperative Agreement



Prime Partner Name: RECO Industries	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 203,260	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 203,260	
Funding Source	Funding Amount
GHP-State	203,260

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13924		
Mechanism Name:	Production for Improved Nutrition (PIN) Project		
Prime Partner Name:	RECO Industries		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	203,260	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	3,775
OVC_SERV_DSD	Age/Sex: 18+ Male	426
OVC_SERV_DSD	Age/Sex: 18+ Female	515
OVC_SERV_DSD	Sum of Age/Sex disaggregates	941
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	1,367
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	1,467

Implementing Mechanism Details

Mechanism ID: 16594	Mechanism Name: MEASURE Evaluation Phase IV
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: University of North Carolina at Chapel Hill, Carolina Population Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 960,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 960,000	
Funding Source	Funding Amount
GHP-State	960,000



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	16594		
Mechanism Name:	MEASURE Evaluation Phase IV		
Prime Partner Name:	University of North Carolina at Chapel Hill, Carolina Population Center		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	960,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16626	Mechanism Name: Uganda Private Health Support Program (PHS)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Cardno Emerging Markets	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 6,635,668	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 6,635,668	
Funding Source	Funding Amount



GHP-State	6,635,668
-----------	-----------

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 16626			
Mechanism Name: Uganda Private Health Support Program (PHS)			
Prime Partner Name: Cardno Emerging Markets			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	777,694	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	2,655,020	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	187,617	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	242,473	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	246,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	504,400	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	229,239	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	HTXS	1,721,129	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	72,096	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	33,406
PMTCT_ART_DSD	New on ART	925
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,294
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	7,266
PMTCT_ART_TA	New on ART	246
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	345
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	33,406
PMTCT_STAT_DSD	Number of new ANC and L&D clients	34,276
PMTCT_STAT_DSD	By: Known positives at entry	1,342
PMTCT_STAT_DSD	By: Number of new positives identified	999
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	2,341
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	7,266
PMTCT_STAT_TA	Number of new ANC and L&D clients	7,444
PMTCT_STAT_TA	By: Known positives at entry	368
PMTCT_STAT_TA	By: Number of new positives identified	254



PMTCT_STAT_TA	Sum of Positives Status disaggregates	622
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	45,448
VMMC_CIRC_DSD	By Age: 10-14	17,723
VMMC_CIRC_DSD	By Age: 15-19	13,178
VMMC_CIRC_DSD	By Age: 20-24	6,363
VMMC_CIRC_DSD	By Age: 25-29	3,635
VMMC_CIRC_DSD	By Age: 30-49	3,635
VMMC_CIRC_DSD	By Age: 50+	914
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	38,178
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	45,448
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	45,448
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	286,389
HTC_TST_DSD	Age/sex: 10-14 Male	8,582
HTC_TST_DSD	Age/sex: 15-19 Male	27,337
HTC_TST_DSD	Age/sex: 20-24 Male	41,010
HTC_TST_DSD	Age/sex: 25-49 Male	62,877
HTC_TST_DSD	Age/sex: 50+ Male	5,464
HTC_TST_DSD	Age/sex: 10-14 Female	8,628
HTC_TST_DSD	Age/sex: 15-19 Female	23,903
HTC_TST_DSD	Age/sex: 20-24 Female	35,851
HTC_TST_DSD	Age/sex: 25-49 Female	54,967
HTC_TST_DSD	Age/sex: 50+ Female	4,774
HTC_TST_DSD	Sum of Age/Sex disaggregates	273,393
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	346
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	788
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	1,184
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	1,809
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	155



HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	371
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	1,040
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	1,569
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	2,398
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	204
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	15,064
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	136,688
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	15,142
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	119,495
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	30,206
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	256,183
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	286,389
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	604
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	3,936
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	653
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	5,211
HTC_TST_DSD	Test Result by Age: Positive: <1	120
HTC_TST_DSD	Test Result by Age: Positive: 1-9	420
HTC_TST_DSD	Age/sex: <1	3,025
HTC_TST_DSD	Age/sex: 1-9	9,971
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	70,149
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	81,731
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	28,358
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	18,227
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	30,730



HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	33,230
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	2,736
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	21,228
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	66,315
HTC_TST_TA	Age/sex: 10-14 Male	1,587
HTC_TST_TA	Age/sex: 15-19 Male	7,231
HTC_TST_TA	Age/sex: 20-24 Male	10,843
HTC_TST_TA	Age/sex: 25-49 Male	16,629
HTC_TST_TA	Age/sex: 50+ Male	1,448
HTC_TST_TA	Age/sex: 10-14 Female	1,608
HTC_TST_TA	Age/sex: 15-19 Female	4,913
HTC_TST_TA	Age/sex: 20-24 Female	7,365
HTC_TST_TA	Age/sex: 25-49 Female	11,294
HTC_TST_TA	Age/sex: 50+ Female	978
HTC_TST_TA	Sum of Age/Sex disaggregates	63,896
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Male	65
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Male	147
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Male	229
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Male	347
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Male	27
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Female	80
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Female	224
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Female	342
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Female	520
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Female	46
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,788
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	36,151
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION	2,826



	ONLY: <15 Female	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	24,550
HTC_TST_TA	Sum of Aggregated Age/Sex <15	5,614
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	60,701
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	66,315
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	112
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	750
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	138
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,132
HTC_TST_TA	Test Result by Age: Positive: <1	19
HTC_TST_TA	Test Result by Age: Positive: 1-9	86
HTC_TST_TA	Age/sex: <1	569
HTC_TST_TA	Age/sex: 1-9	1,850
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	11,502
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	18,344
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	5,122
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	3,517
HTC_TST_TA	Service Delivery Point (Facility): VMMC	14,718
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	7,206
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	463
HTC_TST_TA	Service Delivery Point (Facility): Index testing	5,443
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,025
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,025
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	30



TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	625
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	24
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	344
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	195
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	195
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	5
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	120
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	4
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	66
GEND_GBV_DSD	Number of people receiving post-GBV care	1,883
GEND_GBV_DSD	Age/Sex: <10 Male	54
GEND_GBV_DSD	Age/Sex: 10-14 Male	54
GEND_GBV_DSD	Age/Sex: 20-24 Male	93
GEND_GBV_DSD	Age/Sex: 25-49 Male	93
GEND_GBV_DSD	Age/Sex: <10 Female	93
GEND_GBV_DSD	Age/Sex: 10-14 Female	260
GEND_GBV_DSD	Age/Sex: 20-24 Female	481
GEND_GBV_DSD	Age/Sex: 25-49 Female	191



GEND_GBV_DSD	Sum of Age/Sex Disaggregates	461
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	413
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	1,470
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	169
GEND_GBV_DSD	Age/Sex: 15-19 Female	470
GEND_GBV_DSD	Age/Sex: 15-19 male	94
GEND_GBV_TA	Number of people receiving post-GBV care	408
GEND_GBV_TA	Age/Sex: <10 Male	11
GEND_GBV_TA	Age/Sex: 10-14 Male	11
GEND_GBV_TA	Age/Sex: 20-24 Male	20
GEND_GBV_TA	Age/Sex: 25-49 Male	20
GEND_GBV_TA	Age/Sex: <10 Female	20
GEND_GBV_TA	Age/Sex: 10-14 Female	56
GEND_GBV_TA	Age/Sex: 20-24 Female	112
GEND_GBV_TA	Age/Sex: 25-49 Female	42
GEND_GBV_TA	Sum of Age/Sex Disaggregates	98
GEND_GBV_TA	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	91
GEND_GBV_TA	By type of service: Sexual Violence (Post-Rape Care)	317
GEND_GBV_TA	By PEP service provision (related to sexual violence services provided)	37
GEND_GBV_TA	Age/Sex: 15-19 Female	98
GEND_GBV_TA	Age/Sex: 15-19 Male	18
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	43,823
OVC_SERV_DSD	Age/Sex: 18+ Male	4,926
OVC_SERV_DSD	Age/Sex: 18+ Female	5,963
OVC_SERV_DSD	Sum of Age/Sex disaggregates	10,889
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	15,919
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	17,015



TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	369
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	369
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	239
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	123
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	84
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	84
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	58

	TB treatment during the reporting period)	
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	24
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	37,475
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	1,114
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	11,924
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	1,263
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	23,174
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	749
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	2,997
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	901
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	1,798
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	298
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	5,883
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	257
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	1,811
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	300
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	3,515
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	117
TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent:	473



	Specimen sent for bacteriologic diagnosis of active TB	
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	144
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	283
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	46
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,472
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	400
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,872
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	75
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	13
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	388
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	114
PMTCT_EID_TA	Sum of Infant Age disaggregates	502
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	17
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	2
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	37,341
TX_CURR_DSD	Age/Sex: 15-19 Male	358
TX_CURR_DSD	Age/Sex: 15-19 Female	1,161
TX_CURR_DSD	Sum of age/sex disaggregates	1,519
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,114
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	11,924
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,263



TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	23,174
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	2,377
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	35,098
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	37,475
TX_CURR_DSD	Age/Sex: <1	90
TX_CURR_DSD	Age/Sex: <1-9	574
TX_CURR_DSD	Age/Sex: 10-14 Male	792
TX_CURR_DSD	Age/Sex: 10-14 Female	921
TX_CURR_DSD	Age/Sex: 20-24 Male	2,374
TX_CURR_DSD	Age/Sex: 25-49 Male	8,556
TX_CURR_DSD	Age/Sex: 50+ Male	592
TX_CURR_DSD	Age/Sex: 20-24 Female	5,328
TX_CURR_DSD	Age/Sex: 25-49 Female	15,524
TX_CURR_DSD	Age/Sex: 50+ Female	1,161
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	5,883
TX_CURR_TA	Age/Sex: 15-19 Male	52
TX_CURR_TA	Age/Sex: 15-19 Female	178
TX_CURR_TA	Sum of Age/Sex disaggregations	230
TX_CURR_TA	Aggregated Age/Sex: <15 Male	257
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	1,811
TX_CURR_TA	Aggregated Age/Sex: <15 Female	300
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	3,515
TX_CURR_TA	Sum of Aggregated Age/Sex <15	557
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	5,326
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	5,883
TX_CURR_TA	Age/Sex: <1	20
TX_CURR_TA	Age/Sex: 1-9	138
TX_CURR_TA	Age/Sex: 10-14 Male	182
TX_CURR_TA	Age/Sex: 10-14 Female	217
TX_CURR_TA	Age/Sex: 20-24 Male	365
TX_CURR_TA	Age/Sex: 25-49 Male	1,303



TX_CURR_TA	Age/Sex: 50+ Male	91
TX_CURR_TA	Age/Sex: 20-24 Female	807
TX_CURR_TA	Age/Sex: 25-49 Female	2,352
TX_CURR_TA	Age/Sex: 50+ Female	178
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	8,063
TX_NEW_DSD	By Age/Sex: <1	19
TX_NEW_DSD	By Age/Sex: 1-9	156
TX_NEW_DSD	By Age/Sex: 10-14 Male	221
TX_NEW_DSD	By Age/Sex: 15-19 Male	77
TX_NEW_DSD	By Age/Sex: 20-24 Male	501
TX_NEW_DSD	By Age/Sex: 25-49 Male	1,807
TX_NEW_DSD	By Age/Sex: 50+ Male	128
TX_NEW_DSD	By Age/Sex: 10-14 Female	269
TX_NEW_DSD	By Age/Sex: 15-19 Female	243
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,121
TX_NEW_DSD	By Age/Sex: 25-49 Female	3,275
TX_NEW_DSD	By Age/Sex: 50+ Female	246
TX_NEW_DSD	Sum of Age/Sex disaggregates	7,888
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	308
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	2,513
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	357
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	4,885
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	8,063
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,322
TX_NEW_TA	By Age/Sex: 1-9	28
TX_NEW_TA	By Age/Sex: 10-14 Male	47
TX_NEW_TA	By Age/Sex: 15-19 Male	18
TX_NEW_TA	By Age/Sex: 20-24 Male	146
TX_NEW_TA	By Age/Sex: 25-49 Male	534
TX_NEW_TA	By Age/Sex: 50+ Male	43



TX_NEW_TA	By Age/Sex: 10-14 Female	60
TX_NEW_TA	By Age/Sex: 15-19 Female	72
TX_NEW_TA	By Age/Sex: 20-24 Female	330
TX_NEW_TA	By Age/Sex: 25-49 Female	967
TX_NEW_TA	By Age/Sex: 50+ Female	74
TX_NEW_TA	Sum of Age/Sex disaggregates	2,291
TX_NEW_TA	Aggregated Grouping by Age: <1	3
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	62
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	741
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	76
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	1,443
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	2,322
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	26,887
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	29,873
TX_PVLS_DSD	Numerator: Indication: Routine	26,887
TX_PVLS_DSD	Denominator: Indication: Routine	29,873
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	801
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	8,560
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	907
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	16,619
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	890
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	9,502
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	1,014
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	18,467
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	4,234



TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	4,706
TX_PVLS_TA	Numerator: Indication: Routine	4,234
TX_PVLS_TA	Denominator: Indication: Routine	4,706
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	184
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	1,306
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	215
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	2,529
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	207
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	1,444
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	243
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	2,812
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	5,651
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	6,350
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	57
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	95
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	104
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	19



TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,640
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	902
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	89
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	84
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	405
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,170
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	83
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	64
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART,	104



	and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	121
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	825
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,966
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	210
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	98
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	94
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	448



TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,311
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	105
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	132
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,665
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	112
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,742
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	147
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,122
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	123



	including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,958
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,445
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,624
TX_RET_TA	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	12
TX_RET_TA	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	24
TX_RET_TA	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	27
TX_RET_TA	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5
TX_RET_TA	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	674
TX_RET_TA	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	230
TX_RET_TA	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	22
TX_RET_TA	Age/Sex: 15-19 Female (Numerator: Number of adults	22



	and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_TA	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	103
TX_RET_TA	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	304
TX_RET_TA	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	22
TX_RET_TA	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	12
TX_RET_TA	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	27
TX_RET_TA	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	30
TX_RET_TA	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	213
TX_RET_TA	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART,	761



	and those lost to follow-up)	
TX_RET_TA	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	51
TX_RET_TA	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	23
TX_RET_TA	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	25
TX_RET_TA	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	114
TX_RET_TA	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	340
TX_RET_TA	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	28
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	31
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of	936



	adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	27
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	451
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	34
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,055
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	28
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	507

Implementing Mechanism Details

Mechanism ID: 17063	Mechanism Name: Social Marketing Program
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Uganda Health Marketing Group	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No

Approved



G2G: No	Managing Agency:
Total All Funding Sources: 1,500,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,500,000	
Funding Source	Funding Amount
GHP-State	1,500,000

Cross-Cutting Budget Attribution(s)

Condom programming	1,500,000
--------------------	-----------

Budget Code Information

Mechanism ID: 17063			
Mechanism Name: Social Marketing Program			
Prime Partner Name: Uganda Health Marketing Group			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	1,500,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17065	Mechanism Name: Sustainable Outcomes for Children and Youth Central and Western Uganda (SOCY)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Relief Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
G2G: No	Managing Agency:
Total All Funding Sources: 6,281,620	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 6,281,620	
Funding Source	Funding Amount
GHP-State	6,281,620

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17065		
Mechanism Name:	Sustainable Outcomes for Children and Youth Central and Western		
Prime Partner Name:	Uganda (SOCY) Catholic Relief Services		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	6,281,620	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	104,939
OVC_SERV_DSD	Age/Sex: 18+ Male	10,655
OVC_SERV_DSD	Age/Sex: 18+ Female	12,912



OVC_SERV_DSD	Sum of Age/Sex disaggregates	23,567
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	3,032
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	2,018
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	5,054
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	34,446
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	36,822

Implementing Mechanism Details

Mechanism ID: 17066	Mechanism Name: HIV/Health Initiatives in Workplaces Activity (HIWA)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: World Vision	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,066,311	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,066,311	
Funding Source	Funding Amount
GHP-State	1,066,311

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	110,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information



Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs
Gender: GBV	100,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Gender: Gender Equality	100,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research

Budget Code Information



Mechanism ID: 17066			
Mechanism Name: HIV/Health Initiatives in Workplaces Activity (HIWA)			
Prime Partner Name: World Vision			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	23,178	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	6,568	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	25,278	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	492,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	74,768	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	355,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	38,420	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	44,638	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	6,461	0

Implementing Mechanism Indicator Information



Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	10,276
PMTCT_ART_DSD	New on ART	200
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	273
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	10,276
PMTCT_STAT_DSD	Number of new ANC and L&D clients	10,540
PMTCT_STAT_DSD	By: Known positives at entry	385
PMTCT_STAT_DSD	By: Number of new positives identified	116
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	501
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	17,029
VMMC_CIRC_DSD	By Age: 10-14	6,640
VMMC_CIRC_DSD	By Age: 15-19	4,939
VMMC_CIRC_DSD	By Age: 20-24	2,385
VMMC_CIRC_DSD	By Age: 25-29	1,362
VMMC_CIRC_DSD	By Age: 30-49	1,362
VMMC_CIRC_DSD	By Age: 50+	341
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	14,305
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	17,029
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	17,029
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	30,718
PP_PREV_DSD	Total number of people in the target population	33,039
PP_PREV_DSD	Aggregated Age/sex: <15 Male	6,588
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	8,515
PP_PREV_DSD	Aggregated Age/sex: <15 Female	7,187
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	8,428



HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	55,330
HTC_TST_DSD	Age/sex: 10-14 Male	1,655
HTC_TST_DSD	Age/sex: 15-19 Male	5,899
HTC_TST_DSD	Age/sex: 20-24 Male	8,849
HTC_TST_DSD	Age/sex: 25-49 Male	13,566
HTC_TST_DSD	Age/sex: 50+ Male	1,179
HTC_TST_DSD	Age/sex: 10-14 Female	1,648
HTC_TST_DSD	Age/sex: 15-19 Female	4,008
HTC_TST_DSD	Age/sex: 20-24 Female	6,010
HTC_TST_DSD	Age/sex: 25-49 Female	9,216
HTC_TST_DSD	Age/sex: 50+ Female	801
HTC_TST_DSD	Sum of Age/Sex disaggregates	52,831
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	83
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	99
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	146
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	225
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	20
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	74
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	142
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	214
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	329
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	29
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,906
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	29,493
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,896
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	20,035
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	5,802



HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	49,528
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	55,330
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	141
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	490
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	132
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	714
HTC_TST_DSD	Test Result by Age: Positive: <1	27
HTC_TST_DSD	Test Result by Age: Positive: 1-9	89
HTC_TST_DSD	Age/sex: <1	580
HTC_TST_DSD	Age/sex: 1-9	1,919
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	648
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	15,748
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	5,410
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	2,713
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	17,029
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	10,031
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	584
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	3,167
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	401
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	401
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	14
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	243
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number	10



	of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	134
GEND_GBV_DSD	Number of people receiving post-GBV care	575
GEND_GBV_DSD	Age/Sex: <10 Male	16
GEND_GBV_DSD	Age/Sex: 10-14 Male	16
GEND_GBV_DSD	Age/Sex: 20-24 Male	28
GEND_GBV_DSD	Age/Sex: 25-49 Male	28
GEND_GBV_DSD	Age/Sex: <10 Female	28
GEND_GBV_DSD	Age/Sex: 10-14 Female	81
GEND_GBV_DSD	Age/Sex: 20-24 Female	147
GEND_GBV_DSD	Age/Sex: 25-49 Female	59
GEND_GBV_DSD	Sum of Age/Sex Disaggregates	141
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	125
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	450
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	53
GEND_GBV_DSD	Age/Sex: 15-19 Female	142
GEND_GBV_DSD	Age/Sex: 15-19 male	30
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	3,691
OVC_SERV_DSD	Age/Sex: 18+ Male	413
OVC_SERV_DSD	Age/Sex: 18+ Female	503
OVC_SERV_DSD	Sum of Age/Sex disaggregates	916
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	1,343
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	1,432
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	101

TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	101
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	63
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	35
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	2,459
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	260
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	647
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	296
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	1,256
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	48
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	197
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	60
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	118
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other	19



	(not Xpert)	
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	312
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	88
PMTCT_EID_DSD	Sum of Infant Age disaggregates	400
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	13
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	1
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	2,459
TX_CURR_DSD	Age/Sex: 15-19 Male	19
TX_CURR_DSD	Age/Sex: 15-19 Female	63
TX_CURR_DSD	Sum of age/sex disaggregates	82
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	260
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	647
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	296
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	1,256
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	556
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	1,903
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	2,459
TX_CURR_DSD	Age/Sex: <1	22
TX_CURR_DSD	Age/Sex: <1-9	132
TX_CURR_DSD	Age/Sex: 10-14 Male	185
TX_CURR_DSD	Age/Sex: 10-14 Female	217
TX_CURR_DSD	Age/Sex: 20-24 Male	129
TX_CURR_DSD	Age/Sex: 25-49 Male	468
TX_CURR_DSD	Age/Sex: 50+ Male	31
TX_CURR_DSD	Age/Sex: 20-24 Female	289
TX_CURR_DSD	Age/Sex: 25-49 Female	841
TX_CURR_DSD	Age/Sex: 50+ Female	63



TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	777
TX_NEW_DSD	By Age/Sex: <1	2
TX_NEW_DSD	By Age/Sex: 1-9	20
TX_NEW_DSD	By Age/Sex: 10-14 Male	24
TX_NEW_DSD	By Age/Sex: 15-19 Male	5
TX_NEW_DSD	By Age/Sex: 20-24 Male	48
TX_NEW_DSD	By Age/Sex: 25-49 Male	174
TX_NEW_DSD	By Age/Sex: 50+ Male	13
TX_NEW_DSD	By Age/Sex: 10-14 Female	29
TX_NEW_DSD	By Age/Sex: 15-19 Female	24
TX_NEW_DSD	By Age/Sex: 20-24 Female	107
TX_NEW_DSD	By Age/Sex: 25-49 Female	309
TX_NEW_DSD	By Age/Sex: 50+ Female	22
TX_NEW_DSD	Sum of Age/Sex disaggregates	755
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	35
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	240
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	40
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	462
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	777
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	1,771
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,967
TX_PVLS_DSD	Numerator: Indication: Routine	1,771
TX_PVLS_DSD	Denominator: Indication: Routine	1,967
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	188
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	465
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	214
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	904



TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	207
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	518
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	237
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	1,005
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	772
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	867
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	12
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	18
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	13
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	327
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	112
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	17
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	13



TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	62
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	182
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	14
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	13
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	19
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	14
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	104
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of	369



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	24
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	19
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	14
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	70
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	204
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	15
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment)	24



	at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	454
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	23
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	271
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	27
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	511
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	26
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	303

Implementing Mechanism Details

Mechanism ID: 17078	Mechanism Name: Applying Science to Strengthen and Improve Systems (ASSIST) Project
Funding Agency: USAID	Procurement Type: Cooperative Agreement



Prime Partner Name: University Research Council	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 10,872,533	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 10,872,533	
Funding Source	Funding Amount
GHP-State	10,872,533

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	30,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Gender: Gender Equality	50,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Implementation
Focus Area:	Equity in HIV prevention, care, treatment and



	support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: GBV	50,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

Budget Code Information

Mechanism ID: 17078			
Mechanism Name: Applying Science to Strengthen and Improve Systems (ASSIST) Project			
Prime Partner Name: University Research Council			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	2,020,682	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	100,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	451,857	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	921,611	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	395,591	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	637,364	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	886,168	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	811,975	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	4,252,017	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	395,268	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status	82,379



	(includes women who were tested for HIV and received their results)	
PMTCT_ART_DSD	New on ART	2,435
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	3,423
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	51,898
PMTCT_ART_TA	New on ART	1,514
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	2,153
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	82,379
PMTCT_STAT_DSD	Number of new ANC and L&D clients	84,481
PMTCT_STAT_DSD	By: Known positives at entry	3,467
PMTCT_STAT_DSD	By: Number of new positives identified	2,698
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	6,165
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	51,898
PMTCT_STAT_TA	Number of new ANC and L&D clients	53,231
PMTCT_STAT_TA	By: Known positives at entry	2,149
PMTCT_STAT_TA	By: Number of new positives identified	1,708
PMTCT_STAT_TA	Sum of Positives Status disaggregates	3,857
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	27,021
PP_PREV_DSD	Total number of people in the target population	37,723
PP_PREV_DSD	Aggregated Age/sex: <15 Male	939
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	1,194
PP_PREV_DSD	Aggregated Age/sex: <15 Female	1,009
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	23,879
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions	788



	that are based on evidence and/or meet the minimum standards required	
KP_PREV_DSD	Total estimated number of key population in the catchment area	1,871
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	770
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	18
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	137
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	58
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	1,676
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	268,748
HTC_TST_DSD	Age/sex: 10-14 Male	7,341
HTC_TST_DSD	Age/sex: 15-19 Male	18,123
HTC_TST_DSD	Age/sex: 20-24 Male	27,187
HTC_TST_DSD	Age/sex: 25-49 Male	41,682
HTC_TST_DSD	Age/sex: 50+ Male	3,620
HTC_TST_DSD	Age/sex: 10-14 Female	7,344
HTC_TST_DSD	Age/sex: 15-19 Female	30,473



HTC_TST_DSD	Age/sex: 20-24 Female	45,716
HTC_TST_DSD	Age/sex: 25-49 Female	70,095
HTC_TST_DSD	Age/sex: 50+ Female	6,094
HTC_TST_DSD	Sum of Age/Sex disaggregates	257,675
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	329
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	963
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	1,452
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	2,224
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	188
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	327
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	1,323
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	1,990
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	3,046
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	264
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	12,878
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	90,612
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	12,880
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	152,378
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	25,758
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	242,990
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	268,748
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	579
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	4,827
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	584
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	6,623



HTC_TST_DSD	Test Result by Age: Positive: <1	120
HTC_TST_DSD	Test Result by Age: Positive: 1-9	387
HTC_TST_DSD	Age/sex: <1	2,574
HTC_TST_DSD	Age/sex: 1-9	8,499
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	60,457
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	73,776
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	20,931
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	16,690
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	81,758
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	2,038
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	13,098
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	183,640
HTC_TST_TA	Age/sex: 10-14 Male	5,669
HTC_TST_TA	Age/sex: 15-19 Male	12,577
HTC_TST_TA	Age/sex: 20-24 Male	18,871
HTC_TST_TA	Age/sex: 25-49 Male	28,928
HTC_TST_TA	Age/sex: 50+ Male	2,516
HTC_TST_TA	Age/sex: 10-14 Female	5,670
HTC_TST_TA	Age/sex: 15-19 Female	20,164
HTC_TST_TA	Age/sex: 20-24 Female	30,257
HTC_TST_TA	Age/sex: 25-49 Female	46,391
HTC_TST_TA	Age/sex: 50+ Female	4,030
HTC_TST_TA	Sum of Age/Sex disaggregates	175,073
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Male	242
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Male	432
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Male	646
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Male	989
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Male	86
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Female	249
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Female	868



HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Female	1,307
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Female	2,000
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Female	175
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	9,951
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	62,892
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	9,955
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	100,842
HTC_TST_TA	Sum of Aggregated Age/Sex <15	19,906
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	163,734
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	183,640
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	424
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	2,153
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	432
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	4,350
HTC_TST_TA	Test Result by Age: Positive: <1	83
HTC_TST_TA	Test Result by Age: Positive: 1-9	282
HTC_TST_TA	Age/sex: <1	2,000
HTC_TST_TA	Age/sex: 1-9	6,567
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	36,703
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	60,991
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	16,888
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	10,109
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	51,515
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	1,368
HTC_TST_TA	Service Delivery Point (Facility): Index testing	6,066



TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	4,093
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	4,093
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	128
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,491
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	99
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,375
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,809
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	1,809
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	53
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,106
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	43
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	607
GEND_GBV_DSD	Number of people receiving post-GBV care	5,677
GEND_GBV_DSD	Age/Sex: <10 Male	168



GEND_GBVDSD	Age/Sex: 10-14 Male	168
GEND_GBVDSD	Age/Sex: 20-24 Male	286
GEND_GBVDSD	Age/Sex: 25-49 Male	286
GEND_GBVDSD	Age/Sex: <10 Female	286
GEND_GBVDSD	Age/Sex: 10-14 Female	797
GEND_GBVDSD	Age/Sex: 20-24 Female	1,413
GEND_GBVDSD	Age/Sex: 25-49 Female	571
GEND_GBVDSD	Sum of Age/Sex Disaggregates	1,419
GEND_GBVDSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	1,249
GEND_GBVDSD	By type of service: Sexual Violence (Post-Rape Care)	4,428
GEND_GBVDSD	By PEP service provision (related to sexual violence services provided)	514
GEND_GBVDSD	Age/Sex: 15-19 Female	1,412
GEND_GBVDSD	Age/Sex: 15-19 male	290
GEND_GBVTATA	Number of people receiving post-GBV care	2,991
GEND_GBVTATA	Age/Sex: <10 Male	93
GEND_GBVTATA	Age/Sex: 10-14 Male	93
GEND_GBVTATA	Age/Sex: 20-24 Male	149
GEND_GBVTATA	Age/Sex: 25-49 Male	149
GEND_GBVTATA	Age/Sex: <10 Female	149
GEND_GBVTATA	Age/Sex: 10-14 Female	421
GEND_GBVTATA	Age/Sex: 20-24 Female	743
GEND_GBVTATA	Age/Sex: 25-49 Female	301
GEND_GBVTATA	Sum of Age/Sex Disaggregates	756
GEND_GBVTATA	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	657
GEND_GBVTATA	By type of service: Sexual Violence (Post-Rape Care)	2,334
GEND_GBVTATA	By PEP service provision (related to sexual violence services provided)	272
GEND_GBVTATA	Age/Sex: 15-19 Female	745
GEND_GBVTATA	Age/Sex: 15-19 Male	148



TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,278
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,278
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	19
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	814
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	14
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	431
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	572
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	572
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	7
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	374



	TB treatment during the reporting period)	
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	188
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	55,186
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	1,768
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	17,482
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	1,986
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	33,950
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	1,105
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	4,415
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	1,334
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	2,648
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	433
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	27,917
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	1,213
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	8,609
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	1,368
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	16,727
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	558
TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent:	2,234



	Specimen sent for bacteriologic diagnosis of active TB	
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	676
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	1,339
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	219
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	3,859
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	1,073
PMTCT_EID_DSD	Sum of Infant Age disaggregates	4,932
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	194
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	56
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	2,416
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	671
PMTCT_EID_TA	Sum of Infant Age disaggregates	3,087
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	127
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	35
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	55,186
TX_CURR_DSD	Age/Sex: 15-19 Male	524
TX_CURR_DSD	Age/Sex: 15-19 Female	1,696
TX_CURR_DSD	Sum of age/sex disaggregates	2,220
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,768
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	17,482
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,986



TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	33,950
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	3,754
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	51,432
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	55,186
TX_CURR_DSD	Age/Sex: <1	139
TX_CURR_DSD	Age/Sex: <1-9	905
TX_CURR_DSD	Age/Sex: 10-14 Male	1,258
TX_CURR_DSD	Age/Sex: 10-14 Female	1,452
TX_CURR_DSD	Age/Sex: 20-24 Male	3,494
TX_CURR_DSD	Age/Sex: 25-49 Male	12,590
TX_CURR_DSD	Age/Sex: 50+ Male	874
TX_CURR_DSD	Age/Sex: 20-24 Female	7,808
TX_CURR_DSD	Age/Sex: 25-49 Female	22,750
TX_CURR_DSD	Age/Sex: 50+ Female	1,696
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	27,917
TX_CURR_TA	Age/Sex: 15-19 Male	258
TX_CURR_TA	Age/Sex: 15-19 Female	837
TX_CURR_TA	Sum of Age/Sex disaggregations	1,095
TX_CURR_TA	Aggregated Age/Sex: <15 Male	1,213
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	8,609
TX_CURR_TA	Aggregated Age/Sex: <15 Female	1,368
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	16,727
TX_CURR_TA	Sum of Aggregated Age/Sex <15	2,581
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	25,336
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	27,917
TX_CURR_TA	Age/Sex: <1	94
TX_CURR_TA	Age/Sex: 1-9	627
TX_CURR_TA	Age/Sex: 10-14 Male	862
TX_CURR_TA	Age/Sex: 10-14 Female	998
TX_CURR_TA	Age/Sex: 20-24 Male	1,721
TX_CURR_TA	Age/Sex: 25-49 Male	6,197



TX_CURR_TA	Age/Sex: 50+ Male	433
TX_CURR_TA	Age/Sex: 20-24 Female	3,848
TX_CURR_TA	Age/Sex: 25-49 Female	11,205
TX_CURR_TA	Age/Sex: 50+ Female	837
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	15,437
TX_NEW_DSD	By Age/Sex: <1	26
TX_NEW_DSD	By Age/Sex: 1-9	217
TX_NEW_DSD	By Age/Sex: 10-14 Male	299
TX_NEW_DSD	By Age/Sex: 15-19 Male	148
TX_NEW_DSD	By Age/Sex: 20-24 Male	988
TX_NEW_DSD	By Age/Sex: 25-49 Male	3,561
TX_NEW_DSD	By Age/Sex: 50+ Male	247
TX_NEW_DSD	By Age/Sex: 10-14 Female	362
TX_NEW_DSD	By Age/Sex: 15-19 Female	478
TX_NEW_DSD	By Age/Sex: 20-24 Female	2,207
TX_NEW_DSD	By Age/Sex: 25-49 Female	6,429
TX_NEW_DSD	By Age/Sex: 50+ Female	475
TX_NEW_DSD	Sum of Age/Sex disaggregates	15,194
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	424
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	4,944
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	480
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	9,589
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	15,437
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	9,494
TX_NEW_TA	By Age/Sex: 1-9	142
TX_NEW_TA	By Age/Sex: 10-14 Male	185
TX_NEW_TA	By Age/Sex: 15-19 Male	93
TX_NEW_TA	By Age/Sex: 20-24 Male	610
TX_NEW_TA	By Age/Sex: 25-49 Male	2,188
TX_NEW_TA	By Age/Sex: 50+ Male	152



TX_NEW_TA	By Age/Sex: 10-14 Female	236
TX_NEW_TA	By Age/Sex: 15-19 Female	294
TX_NEW_TA	By Age/Sex: 20-24 Female	1,352
TX_NEW_TA	By Age/Sex: 25-49 Female	3,933
TX_NEW_TA	By Age/Sex: 50+ Female	293
TX_NEW_TA	Sum of Age/Sex disaggregates	9,336
TX_NEW_TA	Aggregated Grouping by Age: <1	16
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	268
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	3,043
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	311
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	5,872
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	9,494
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	39,735
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	44,148
TX_PVLS_DSD	Numerator: Indication: Routine	39,735
TX_PVLS_DSD	Denominator: Indication: Routine	44,148
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	1,275
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	12,599
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	1,430
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	24,431
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	1,417
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	13,988
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	1,594
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	27,149
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	20,101



TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	22,331
TX_PVLS_TA	Numerator: Indication: Routine	20,101
TX_PVLS_TA	Denominator: Indication: Routine	22,331
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	875
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	6,208
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	983
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	12,035
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	971
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	6,888
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	1,096
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	13,376
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	9,542
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	10,723
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	6
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	92
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	160
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	185
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	33



TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,472
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,518
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	149
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	144
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	677
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,956
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	150
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	101
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART,	178



	and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	208
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,393
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,021
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	351
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	163
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	167
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	760



TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,211
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	164
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	220
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,208
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	187
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,927
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	242
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,973
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	206



	including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,302
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	4,897
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	5,501
TX_RET_TA	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	46
TX_RET_TA	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	82
TX_RET_TA	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	94
TX_RET_TA	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	14
TX_RET_TA	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,294
TX_RET_TA	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	784
TX_RET_TA	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	79
TX_RET_TA	Age/Sex: 15-19 Female (Numerator: Number of adults	74



	and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_TA	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	347
TX_RET_TA	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,003
TX_RET_TA	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	80
TX_RET_TA	Age/Sex: <1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1
TX_RET_TA	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	51
TX_RET_TA	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	87
TX_RET_TA	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	106
TX_RET_TA	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART,	719



	and those lost to follow-up)	
TX_RET_TA	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,577
TX_RET_TA	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	180
TX_RET_TA	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	85
TX_RET_TA	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	82
TX_RET_TA	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	389
TX_RET_TA	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,133
TX_RET_TA	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	91



TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	112
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,186
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	95
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,504
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	122
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,582
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	102
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,695

Implementing Mechanism Details

Mechanism ID: 17090	Mechanism Name: OVC PIE (Performance and Impact Evaluation of OVC Programs)
----------------------------	--

Approved



Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Measure Evaluation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17090			
Mechanism Name: OVC PIE (Performance and Impact Evaluation of OVC Programs)			
Prime Partner Name: Measure Evaluation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17094	Mechanism Name: Uganda Health Supply Chain
Funding Agency: USAID	Procurement Type: Cooperative Agreement

Approved



Prime Partner Name: Management Sciences for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 6,650,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 6,650,000	
Funding Source	Funding Amount
GHP-State	6,650,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17094		
Mechanism Name:	Uganda Health Supply Chain		
Prime Partner Name:	Management Sciences for Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	6,650,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 17649	Mechanism Name: Regional Health Integration to Enhance Services in East Central Region (RHITES EC)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University Research Council	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 11,408,310	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 11,408,310	
Funding Source	Funding Amount
GHP-State	11,408,310

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	143,765
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Key Populations: FSW	143,765
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Gender: GBV	287,529



Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building

Budget Code Information

Mechanism ID:	17649		
Mechanism Name:	Regional Health Integration to Enhance Services in East Central Region (RHITES EC)		
Prime Partner Name:	University Research Council		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	2,219,234	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	525,157	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	704,254	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	990,888	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,159,824	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVOP	589,042	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	406,320	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	4,580,276	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	233,315	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	58,807
PMTCT_ART_DSD	New on ART	785
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,091
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	94,474
PMTCT_ART_TA	New on ART	1,170
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	1,621
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	58,807
PMTCT_STAT_DSD	Number of new ANC and L&D clients	60,313
PMTCT_STAT_DSD	By: Known positives at entry	1,026
PMTCT_STAT_DSD	By: Number of new positives identified	944
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	1,970
PMTCT_STAT_TA	Number of pregnant women with known HIV status	94,474



	(includes women who were tested for HIV and received their results)	
PMTCT_STAT_TA	Number of new ANC and L&D clients	96,898
PMTCT_STAT_TA	By: Known positives at entry	1,559
PMTCT_STAT_TA	By: Number of new positives identified	1,376
PMTCT_STAT_TA	Sum of Positives Status disaggregates	2,935
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	97,997
VMMC_CIRC_DSD	By Age: 10-14	38,217
VMMC_CIRC_DSD	By Age: 15-19	28,417
VMMC_CIRC_DSD	By Age: 20-24	13,717
VMMC_CIRC_DSD	By Age: 25-29	7,839
VMMC_CIRC_DSD	By Age: 30-49	7,839
VMMC_CIRC_DSD	By Age: 50+	1,968
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	82,319
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	97,997
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	97,997
PrEP_NEW_TA	Number of adult women and adolescent girls newly enrolled on oral or topical PrEP	200
PrEP_NEW_TA	Male 15-19	50
PrEP_NEW_TA	Male 20-24	14
PrEP_NEW_TA	Male 25-49	18
PrEP_NEW_TA	Male 50+	2
PrEP_NEW_TA	Female 15-19	66
PrEP_NEW_TA	Female 20-24	30
PrEP_NEW_TA	Female 25-49	18
PrEP_NEW_TA	Female 50+	2
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	46,882
PP_PREV_DSD	Total number of people in the target population	199,713
PP_PREV_DSD	Aggregated Age/sex: <15 Male	10,125



PP_PREV_DSD	Aggregated Age/sex: 15+ Male	12,910
PP_PREV_DSD	Aggregated Age/sex: <15 Female	10,970
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	12,877
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	5,284
KP_PREV_DSD	Total estimated number of key population in the catchment area	7,829
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	5,284
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	7,829
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	380,484
HTC_TST_DSD	Age/sex: 10-14 Male	9,202
HTC_TST_DSD	Age/sex: 15-19 Male	38,501
HTC_TST_DSD	Age/sex: 20-24 Male	57,755
HTC_TST_DSD	Age/sex: 25-49 Male	88,557
HTC_TST_DSD	Age/sex: 50+ Male	7,701
HTC_TST_DSD	Age/sex: 10-14 Female	9,208
HTC_TST_DSD	Age/sex: 15-19 Female	31,135
HTC_TST_DSD	Age/sex: 20-24 Female	46,703
HTC_TST_DSD	Age/sex: 25-49 Female	71,610
HTC_TST_DSD	Age/sex: 50+ Female	6,223
HTC_TST_DSD	Sum of Age/Sex disaggregates	366,595
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	287
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	742



HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	1,117
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	1,706
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	147
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	288
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	843
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	1,265
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	1,935
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	169
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	16,146
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	192,514
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	16,153
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	155,671
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	32,299
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	348,185
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	380,484
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	501
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	3,712
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	503
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	4,212
HTC_TST_DSD	Test Result by Age: Positive: <1	98
HTC_TST_DSD	Test Result by Age: Positive: 1-9	331
HTC_TST_DSD	Age/sex: <1	3,230
HTC_TST_DSD	Age/sex: 1-9	10,659
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	57,013
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	124,841



HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	30,752
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	19,718
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	72,399
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	57,856
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	2,468
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	15,437
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	424,892
HTC_TST_TA	Age/sex: 10-14 Male	12,015
HTC_TST_TA	Age/sex: 15-19 Male	34,303
HTC_TST_TA	Age/sex: 20-24 Male	51,459
HTC_TST_TA	Age/sex: 25-49 Male	78,892
HTC_TST_TA	Age/sex: 50+ Male	6,846
HTC_TST_TA	Age/sex: 10-14 Female	12,004
HTC_TST_TA	Age/sex: 15-19 Female	42,245
HTC_TST_TA	Age/sex: 20-24 Female	63,369
HTC_TST_TA	Age/sex: 25-49 Female	97,165
HTC_TST_TA	Age/sex: 50+ Female	8,445
HTC_TST_TA	Sum of Age/Sex disaggregates	406,743
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Male	332
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Male	624
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Male	936
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Male	1,430
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Male	123
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Female	325
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Female	1,041
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Female	1,568
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Female	2,387
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Female	200
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	21,093



HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	171,500
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	21,075
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	211,224
HTC_TST_TA	Sum of Aggregated Age/Sex <15	42,168
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	382,724
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	424,892
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	569
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	3,113
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	556
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	5,196
HTC_TST_TA	Test Result by Age: Positive: <1	98
HTC_TST_TA	Test Result by Age: Positive: 1-9	370
HTC_TST_TA	Age/sex: <1	4,226
HTC_TST_TA	Age/sex: 1-9	13,923
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	65,245
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	159,416
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	39,854
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	23,231
HTC_TST_TA	Service Delivery Point (Facility): VMMC	25,598
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	92,887
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	2,671
HTC_TST_TA	Service Delivery Point (Facility): Index testing	15,990
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,539
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,539



TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	49
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	936
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	37
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	517
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,247
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	1,247
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	32
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	776
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	22
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	417
GEND_GBV_DSD	Number of people receiving post-GBV care	3,300
GEND_GBV_DSD	Age/Sex: <10 Male	99
GEND_GBV_DSD	Age/Sex: 10-14 Male	99
GEND_GBV_DSD	Age/Sex: 20-24 Male	163
GEND_GBV_DSD	Age/Sex: 25-49 Male	163
GEND_GBV_DSD	Age/Sex: <10 Female	163



GEND_GBVDSD	Age/Sex: 10-14 Female	463
GEND_GBVDSD	Age/Sex: 20-24 Female	823
GEND_GBVDSD	Age/Sex: 25-49 Female	335
GEND_GBVDSD	Sum of Age/Sex Disaggregates	824
GEND_GBVDSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	726
GEND_GBVDSD	By type of service: Sexual Violence (Post-Rape Care)	2,574
GEND_GBVDSD	By PEP service provision (related to sexual violence services provided)	298
GEND_GBVDSD	Age/Sex: 15-19 Female	830
GEND_GBVDSD	Age/Sex: 15-19 male	162
GEND_GBVTATA	Number of people receiving post-GBV care	5,305
GEND_GBVTATA	Age/Sex: <10 Male	153
GEND_GBVTATA	Age/Sex: 10-14 Male	153
GEND_GBVTATA	Age/Sex: 20-24 Male	269
GEND_GBVTATA	Age/Sex: 25-49 Male	269
GEND_GBVTATA	Age/Sex: <10 Female	269
GEND_GBVTATA	Age/Sex: 10-14 Female	745
GEND_GBVTATA	Age/Sex: 20-24 Female	1,311
GEND_GBVTATA	Age/Sex: 25-49 Female	537
GEND_GBVTATA	Sum of Age/Sex Disaggregates	1,320
GEND_GBVTATA	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	1,169
GEND_GBVTATA	By type of service: Sexual Violence (Post-Rape Care)	4,136
GEND_GBVTATA	By PEP service provision (related to sexual violence services provided)	473
GEND_GBVTATA	Age/Sex: 15-19 Female	1,325
GEND_GBVTATA	Age/Sex: 15-19 Male	274
TB_ARTDSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	419
TB_ARTDSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB	419



	treatment during the reporting period	
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	5
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	274
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	138
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	308
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	308
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	215
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	91

TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	57,323
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	1,690
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	18,264
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	1,904
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	35,465
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	1,148
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	4,588
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	1,379
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	2,754
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	455
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	43,244
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	1,278
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	13,776
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	1,449
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	26,741
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	869
TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	3,458
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	1,043
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	2,075
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	340
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,234



PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	336
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,570
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	59
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	11
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	1,845
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	506
PMTCT_EID_TA	Sum of Infant Age disaggregates	2,351
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	89
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	9
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	57,323
TX_CURR_DSD	Age/Sex: 15-19 Male	547
TX_CURR_DSD	Age/Sex: 15-19 Female	1,776
TX_CURR_DSD	Sum of age/sex disaggregates	2,323
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,690
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	18,264
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,904
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	35,465
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	3,594
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	53,729
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	57,323
TX_CURR_DSD	Age/Sex: <1	138
TX_CURR_DSD	Age/Sex: <1-9	869
TX_CURR_DSD	Age/Sex: 10-14 Male	1,198
TX_CURR_DSD	Age/Sex: 10-14 Female	1,389
TX_CURR_DSD	Age/Sex: 20-24 Male	3,650



TX_CURR_DSD	Age/Sex: 25-49 Male	13,153
TX_CURR_DSD	Age/Sex: 50+ Male	914
TX_CURR_DSD	Age/Sex: 20-24 Female	8,155
TX_CURR_DSD	Age/Sex: 25-49 Female	23,758
TX_CURR_DSD	Age/Sex: 50+ Female	1,776
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	43,244
TX_CURR_TA	Age/Sex: 15-19 Male	411
TX_CURR_TA	Age/Sex: 15-19 Female	1,338
TX_CURR_TA	Sum of Age/Sex disaggregations	1,749
TX_CURR_TA	Aggregated Age/Sex: <15 Male	1,278
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	13,776
TX_CURR_TA	Aggregated Age/Sex: <15 Female	1,449
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	26,741
TX_CURR_TA	Sum of Aggregated Age/Sex <15	2,727
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	40,517
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	43,244
TX_CURR_TA	Age/Sex: <1	93
TX_CURR_TA	Age/Sex: 1-9	671
TX_CURR_TA	Age/Sex: 10-14 Male	908
TX_CURR_TA	Age/Sex: 10-14 Female	1,055
TX_CURR_TA	Age/Sex: 20-24 Male	2,751
TX_CURR_TA	Age/Sex: 25-49 Male	9,920
TX_CURR_TA	Age/Sex: 50+ Male	694
TX_CURR_TA	Age/Sex: 20-24 Female	6,147
TX_CURR_TA	Age/Sex: 25-49 Female	17,918
TX_CURR_TA	Age/Sex: 50+ Female	1,338
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	11,624
TX_NEW_DSD	By Age/Sex: <1	33
TX_NEW_DSD	By Age/Sex: 1-9	221
TX_NEW_DSD	By Age/Sex: 10-14 Male	310



TX_NEW_DSD	By Age/Sex: 15-19 Male	110
TX_NEW_DSD	By Age/Sex: 20-24 Male	729
TX_NEW_DSD	By Age/Sex: 25-49 Male	2,619
TX_NEW_DSD	By Age/Sex: 50+ Male	176
TX_NEW_DSD	By Age/Sex: 10-14 Female	367
TX_NEW_DSD	By Age/Sex: 15-19 Female	353
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,622
TX_NEW_DSD	By Age/Sex: 25-49 Female	4,730
TX_NEW_DSD	By Age/Sex: 50+ Female	354
TX_NEW_DSD	Sum of Age/Sex disaggregates	11,370
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	439
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	3,634
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	492
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	7,059
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	11,624
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	11,576
TX_NEW_TA	By Age/Sex: 1-9	198
TX_NEW_TA	By Age/Sex: 10-14 Male	276
TX_NEW_TA	By Age/Sex: 15-19 Male	103
TX_NEW_TA	By Age/Sex: 20-24 Male	730
TX_NEW_TA	By Age/Sex: 25-49 Male	2,620
TX_NEW_TA	By Age/Sex: 50+ Male	187
TX_NEW_TA	By Age/Sex: 10-14 Female	338
TX_NEW_TA	By Age/Sex: 15-19 Female	359
TX_NEW_TA	By Age/Sex: 20-24 Female	1,630
TX_NEW_TA	By Age/Sex: 25-49 Female	4,758
TX_NEW_TA	By Age/Sex: 50+ Female	354
TX_NEW_TA	Sum of Age/Sex disaggregates	11,355
TX_NEW_TA	Aggregated Grouping by Age: <1	23
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	389
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	3,640



TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	446
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	7,101
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	11,576
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	41,271
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	45,859
TX_PVLS_DSD	Numerator: Indication: Routine	41,271
TX_PVLS_DSD	Denominator: Indication: Routine	45,859
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	1,216
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	13,159
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	1,369
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	25,527
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	1,354
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	14,615
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	1,525
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	28,365
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	31,139
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	34,596
TX_PVLS_TA	Numerator: Indication: Routine	31,139
TX_PVLS_TA	Denominator: Indication: Routine	34,596
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	920
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	9,932
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	1,041
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	19,246



TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	1,020
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	11,025
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	1,162
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	21,389
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	12,368
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	13,897
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	13
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	126
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	194
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	240
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	45
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,786
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,967
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	182



TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	192
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	880
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,556
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	187
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	18
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	138
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	222
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	271
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including	1,804



	those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,498
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	455
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	202
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	215
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	988
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,872
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART,	214



	and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	275
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8,038
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	240
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,815
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	311
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9,028
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	269
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,289
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	11,228



TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	12,617
TX_RET_TA	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5
TX_RET_TA	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	105
TX_RET_TA	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	193
TX_RET_TA	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	221
TX_RET_TA	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	37
TX_RET_TA	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,260
TX_RET_TA	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,791
TX_RET_TA	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	176
TX_RET_TA	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	172
TX_RET_TA	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	792
TX_RET_TA	Age/Sex: 25-49 Female (Numerator: Number of adults	2,300



	and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_TA	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	176
TX_RET_TA	Age/Sex: <1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9
TX_RET_TA	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	119
TX_RET_TA	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	203
TX_RET_TA	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	248
TX_RET_TA	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,644
TX_RET_TA	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,917



TX_RET_TA	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	405
TX_RET_TA	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	188
TX_RET_TA	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	201
TX_RET_TA	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	893
TX_RET_TA	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,603
TX_RET_TA	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	187
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	260
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7,309



TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	219
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,440
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	282
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8,214
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	237
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,884

Implementing Mechanism Details

Mechanism ID: 17651	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17654	Mechanism Name: Regional Health Integration to Enhance Services in South West Region
----------------------------	---



	(RHITES-SW)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 15,293,346	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 15,293,346	
Funding Source	Funding Amount
GHP-State	15,293,346

Cross-Cutting Budget Attribution(s)

Key Populations: FSW	219,008
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Gender: GBV	438,016
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Key Populations: MSM and TG	219,008
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions



	for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information

Budget Code Information

Mechanism ID:	17654		
Mechanism Name:	Regional Health Integration to Enhance Services in South West Region (RHITES-SW)		
Prime Partner Name:	Elizabeth Glaser Pediatric AIDS Foundation		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	2,340,285	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	567,312	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	1,115,905	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	1,400,700	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	1,970,867	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,130,032	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	570,590	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	883,256	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	4,956,786	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	357,613	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	104,512
PMTCT_ART_DSD	New on ART	2,408
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	3,350
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	60,675
PMTCT_ART_TA	New on ART	1,428
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	1,991
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	104,512
PMTCT_STAT_DSD	Number of new ANC and L&D clients	107,193
PMTCT_STAT_DSD	By: Known positives at entry	3,339
PMTCT_STAT_DSD	By: Number of new positives identified	2,737
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	6,076
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	60,675



PMTCT_STAT_TA	Number of new ANC and L&D clients	62,220
PMTCT_STAT_TA	By: Known positives at entry	1,942
PMTCT_STAT_TA	By: Number of new positives identified	1,641
PMTCT_STAT_TA	Sum of Positives Status disaggregates	3,583
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	138,496
VMMC_CIRC_DSD	By Age: 10-14	54,013
VMMC_CIRC_DSD	By Age: 15-19	40,167
VMMC_CIRC_DSD	By Age: 20-24	19,390
VMMC_CIRC_DSD	By Age: 25-29	11,077
VMMC_CIRC_DSD	By Age: 30-49	11,077
VMMC_CIRC_DSD	By Age: 50+	2,772
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	116,342
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	138,496
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	138,346
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	150
PrEP_NEW_DSD	Number of individuals who have received antiretroviral preexposure	989
PrEP_NEW_DSD	Male 15-19	246
PrEP_NEW_DSD	Male 20-24	66
PrEP_NEW_DSD	Male 25-49	89
PrEP_NEW_DSD	Male 50+	8
PrEP_NEW_DSD	Female 15-19	331
PrEP_NEW_DSD	Female 20-24	151
PrEP_NEW_DSD	Female 25-49	89
PrEP_NEW_DSD	Female 50+	9
PrEP_NEW_TA	Number of adult women and adolescent girls newly enrolled on oral or topical PrEP	100
PrEP_NEW_TA	Male 15-19	25
PrEP_NEW_TA	Male 20-24	7
PrEP_NEW_TA	Male 25-49	9



PrEP_NEW_TA	Male 50+	1
PrEP_NEW_TA	Female 15-19	33
PrEP_NEW_TA	Female 20-24	15
PrEP_NEW_TA	Female 25-49	9
PrEP_NEW_TA	Female 50+	1
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	7,146
PP_PREV_DSD	Total number of people in the target population	20,650
PP_PREV_DSD	Aggregated Age/sex: <15 Male	1,539
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	1,973
PP_PREV_DSD	Aggregated Age/sex: <15 Female	1,673
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	1,961
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	2,638
KP_PREV_DSD	Total estimated number of key population in the catchment area	5,148
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,590
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	48
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	359
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total	157



	estimated number of key population in the catchment area)	
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	4,632
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	540,550
HTC_TST_DSD	Age/sex: 10-14 Male	10,084
HTC_TST_DSD	Age/sex: 15-19 Male	54,199
HTC_TST_DSD	Age/sex: 20-24 Male	81,304
HTC_TST_DSD	Age/sex: 25-49 Male	124,659
HTC_TST_DSD	Age/sex: 50+ Male	10,843
HTC_TST_DSD	Age/sex: 10-14 Female	10,088
HTC_TST_DSD	Age/sex: 15-19 Female	46,827
HTC_TST_DSD	Age/sex: 20-24 Female	70,246
HTC_TST_DSD	Age/sex: 25-49 Female	107,700
HTC_TST_DSD	Age/sex: 50+ Female	9,349
HTC_TST_DSD	Sum of Age/Sex disaggregates	525,299
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	371
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	956
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	1,432
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	2,188
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	185
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	363
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	1,374
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	2,052
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	3,144
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	265
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	17,705
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	271,005



HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	17,718
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	234,122
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	35,423
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	505,127
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	540,550
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	639
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	4,761
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	636
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	6,835
HTC_TST_DSD	Test Result by Age: Positive: <1	114
HTC_TST_DSD	Test Result by Age: Positive: 1-9	427
HTC_TST_DSD	Age/sex: <1	3,557
HTC_TST_DSD	Age/sex: 1-9	11,694
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	79,262
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	156,336
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	30,596
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	31,013
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	107,909
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	104,687
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	4,128
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	26,619
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	255,905
HTC_TST_TA	Age/sex: 10-14 Male	5,244
HTC_TST_TA	Age/sex: 15-19 Male	22,453
HTC_TST_TA	Age/sex: 20-24 Male	33,686



HTC_TST_TA	Age/sex: 25-49 Male	51,649
HTC_TST_TA	Age/sex: 50+ Male	4,487
HTC_TST_TA	Age/sex: 10-14 Female	5,233
HTC_TST_TA	Age/sex: 15-19 Female	25,038
HTC_TST_TA	Age/sex: 20-24 Female	37,570
HTC_TST_TA	Age/sex: 25-49 Female	57,599
HTC_TST_TA	Age/sex: 50+ Female	5,003
HTC_TST_TA	Sum of Age/Sex disaggregates	247,962
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Male	208
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Male	437
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Male	659
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Male	998
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Male	82
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Female	210
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Female	865
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Female	1,301
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Female	1,982
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Female	175
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	9,221
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	112,275
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	9,199
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	125,210
HTC_TST_TA	Sum of Aggregated Age/Sex <15	18,420
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	237,485
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	255,905
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	348
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	2,176



HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	346
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	4,323
HTC_TST_TA	Test Result by Age: Positive: <1	57
HTC_TST_TA	Test Result by Age: Positive: 1-9	219
HTC_TST_TA	Age/sex: <1	1,860
HTC_TST_TA	Age/sex: 1-9	6,083
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	43,816
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	74,506
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	15,590
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	16,872
HTC_TST_TA	Service Delivery Point (Facility): VMMC	30,587
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	60,317
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	2,413
HTC_TST_TA	Service Delivery Point (Facility): Index testing	11,804
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	3,474
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	3,474
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	108
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,126
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	74
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,166
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,032



TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	1,032
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	28
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	640
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	16
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	348
GEND_GBV_DSD	Number of people receiving post-GBV care	5,866
GEND_GBV_DSD	Age/Sex: <10 Male	171
GEND_GBV_DSD	Age/Sex: 10-14 Male	171
GEND_GBV_DSD	Age/Sex: 20-24 Male	294
GEND_GBV_DSD	Age/Sex: 25-49 Male	294
GEND_GBV_DSD	Age/Sex: <10 Female	294
GEND_GBV_DSD	Age/Sex: 10-14 Female	822
GEND_GBV_DSD	Age/Sex: 20-24 Female	1,466
GEND_GBV_DSD	Age/Sex: 25-49 Female	593
GEND_GBV_DSD	Sum of Age/Sex Disaggregates	1,458
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	1,297
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	4,569
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	523
GEND_GBV_DSD	Age/Sex: 15-19 Female	1,471
GEND_GBV_DSD	Age/Sex: 15-19 male	290
GEND_GBV_TA	Number of people receiving post-GBV care	3,406
GEND_GBV_TA	Age/Sex: <10 Male	102



GEND_GBV_TA	Age/Sex: 10-14 Male	102
GEND_GBV_TA	Age/Sex: 20-24 Male	173
GEND_GBV_TA	Age/Sex: 25-49 Male	173
GEND_GBV_TA	Age/Sex: <10 Female	173
GEND_GBV_TA	Age/Sex: 10-14 Female	483
GEND_GBV_TA	Age/Sex: 20-24 Female	845
GEND_GBV_TA	Age/Sex: 25-49 Female	343
GEND_GBV_TA	Sum of Age/Sex Disaggregates	860
GEND_GBV_TA	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	748
GEND_GBV_TA	By type of service: Sexual Violence (Post-Rape Care)	2,658
GEND_GBV_TA	By PEP service provision (related to sexual violence services provided)	307
GEND_GBV_TA	Age/Sex: 15-19 Female	846
GEND_GBV_TA	Age/Sex: 15-19 Male	166
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,107
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,107
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	14
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	711
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	8
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The	372



	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	281
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	281
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	199
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	82
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	97,117
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	3,881
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	30,195
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	4,389
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	58,652
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	1,940
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	7,769
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	2,331
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	4,667
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	771
TB_SCREENDX_TA	The number of PLHIV who were screened for TB	16,514



	symptoms at the last clinical visit at a HIV facility during the reporting period.	
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	662
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	5,118
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	769
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	9,965
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	326
TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	1,318
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	403
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	793
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	122
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	3,810
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	1,051
PMTCT_EID_DSD	Sum of Infant Age disaggregates	4,861
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	191
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	37
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	2,254
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	612
PMTCT_EID_TA	Sum of Infant Age disaggregates	2,866
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	111
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	14
TX_CURR_DSD	Number of adults and children receiving antiretroviral	97,117



	therapy (ART)	
TX_CURR_DSD	Age/Sex: 15-19 Male	900
TX_CURR_DSD	Age/Sex: 15-19 Female	2,936
TX_CURR_DSD	Sum of age/sex disaggregates	3,836
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	3,881
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	30,195
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	4,389
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	58,652
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	8,270
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	88,847
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	97,117
TX_CURR_DSD	Age/Sex: <1	310
TX_CURR_DSD	Age/Sex: <1-9	1,997
TX_CURR_DSD	Age/Sex: 10-14 Male	2,758
TX_CURR_DSD	Age/Sex: 10-14 Female	3,205
TX_CURR_DSD	Age/Sex: 20-24 Male	6,039
TX_CURR_DSD	Age/Sex: 25-49 Male	21,747
TX_CURR_DSD	Age/Sex: 50+ Male	1,509
TX_CURR_DSD	Age/Sex: 20-24 Female	13,489
TX_CURR_DSD	Age/Sex: 25-49 Female	39,291
TX_CURR_DSD	Age/Sex: 50+ Female	2,936
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	16,514
TX_CURR_TA	Age/Sex: 15-19 Male	152
TX_CURR_TA	Age/Sex: 15-19 Female	501
TX_CURR_TA	Sum of Age/Sex disaggregations	653
TX_CURR_TA	Aggregated Age/Sex: <15 Male	662
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	5,118
TX_CURR_TA	Aggregated Age/Sex: <15 Female	769
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	9,965
TX_CURR_TA	Sum of Aggregated Age/Sex <15	1,431
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	15,083



TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	16,514
TX_CURR_TA	Age/Sex: <1	46
TX_CURR_TA	Age/Sex: 1-9	354
TX_CURR_TA	Age/Sex: 10-14 Male	473
TX_CURR_TA	Age/Sex: 10-14 Female	558
TX_CURR_TA	Age/Sex: 20-24 Male	1,023
TX_CURR_TA	Age/Sex: 25-49 Male	3,690
TX_CURR_TA	Age/Sex: 50+ Male	253
TX_CURR_TA	Age/Sex: 20-24 Female	2,290
TX_CURR_TA	Age/Sex: 25-49 Female	6,673
TX_CURR_TA	Age/Sex: 50+ Female	501
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	17,526
TX_NEW_DSD	By Age/Sex: <1	36
TX_NEW_DSD	By Age/Sex: 1-9	277
TX_NEW_DSD	By Age/Sex: 10-14 Male	377
TX_NEW_DSD	By Age/Sex: 15-19 Male	162
TX_NEW_DSD	By Age/Sex: 20-24 Male	1,108
TX_NEW_DSD	By Age/Sex: 25-49 Male	4,001
TX_NEW_DSD	By Age/Sex: 50+ Male	289
TX_NEW_DSD	By Age/Sex: 10-14 Female	471
TX_NEW_DSD	By Age/Sex: 15-19 Female	536
TX_NEW_DSD	By Age/Sex: 20-24 Female	2,486
TX_NEW_DSD	By Age/Sex: 25-49 Female	7,244
TX_NEW_DSD	By Age/Sex: 50+ Female	539
TX_NEW_DSD	Sum of Age/Sex disaggregates	17,213
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	536
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	5,560
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	625
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	10,805
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	17,526
TX_NEW_TA	Number of adults and children newly enrolled on	5,793



	antiretroviral therapy (ART)	
TX_NEW_TA	By Age/Sex: 1-9	76
TX_NEW_TA	By Age/Sex: 10-14 Male	107
TX_NEW_TA	By Age/Sex: 15-19 Male	48
TX_NEW_TA	By Age/Sex: 20-24 Male	373
TX_NEW_TA	By Age/Sex: 25-49 Male	1,336
TX_NEW_TA	By Age/Sex: 50+ Male	87
TX_NEW_TA	By Age/Sex: 10-14 Female	163
TX_NEW_TA	By Age/Sex: 15-19 Female	176
TX_NEW_TA	By Age/Sex: 20-24 Female	831
TX_NEW_TA	By Age/Sex: 25-49 Female	2,411
TX_NEW_TA	By Age/Sex: 50+ Female	181
TX_NEW_TA	Sum of Age/Sex disaggregates	5,713
TX_NEW_TA	Aggregated Grouping by Age: <1	4
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	151
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	1,844
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	199
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	3,599
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	5,793
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	69,932
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	77,697
TX_PVLS_DSD	Numerator: Indication: Routine	69,932
TX_PVLS_DSD	Denominator: Indication: Routine	77,697
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	2,791
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	21,769
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	3,158
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	42,214



TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	3,107
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	24,163
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	3,518
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	46,909
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	11,897
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	13,210
TX_PVLS_TA	Numerator: Indication: Routine	11,897
TX_PVLS_TA	Denominator: Indication: Routine	13,210
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	478
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	3,690
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	552
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	7,177
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	536
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	4,085
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	622
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	7,967
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	11,085
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	12,452
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	127
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults	213



	and children who are still alive and on treatment at 12 months after initiating ART	
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	200
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	34
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,919
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,676
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	216
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	186
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	850
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,472
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	182
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	12
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and	139



	children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	233
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	225
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,520
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,519
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	402
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	233
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months	206



	prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	960
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,793
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	210
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	293
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,829
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	273
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,690
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	321



TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7,666
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	296
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,169
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,700
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	4,154
TX_RET_TA	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	32
TX_RET_TA	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	68
TX_RET_TA	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	67
TX_RET_TA	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5
TX_RET_TA	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12	1,732



	months after initiating ART)	
TX_RET_TA	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	599
TX_RET_TA	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	68
TX_RET_TA	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	51
TX_RET_TA	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	260
TX_RET_TA	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	757
TX_RET_TA	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	61
TX_RET_TA	Age/Sex: <1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1
TX_RET_TA	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	34
TX_RET_TA	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	69
TX_RET_TA	Age/Sex: 15-19 Male (Denominator: Total number of	73



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	533
TX_RET_TA	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,944
TX_RET_TA	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	150
TX_RET_TA	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	71
TX_RET_TA	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	55
TX_RET_TA	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	293
TX_RET_TA	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months	857



	prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	74
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	92
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,403
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	76
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,129
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	96
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,700
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	79



TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,279
-----------	---	-------

Implementing Mechanism Details

Mechanism ID: 17688	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17690	Mechanism Name: Strengthening HRH
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: IntraHealth International, Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 2,848,876	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,848,876	
Funding Source	Funding Amount
GHP-State	2,848,876

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17690
----------------------	--------------



Mechanism Name: Strengthening HRH			
Prime Partner Name: IntraHealth International, Inc			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	2,648,876	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	203
HRH_PRE	By Graduates: Nurses	25
HRH_PRE	By Graduates: Midwives	60
HRH_PRE	By Graduates: Other	118
HRH_PRE	Sum of Graduates disaggreagtes	203

Implementing Mechanism Details

Mechanism ID: 17696	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17698	Mechanism Name: Provision of comprehensive HIV/AIDS and TB services including prevention, care, support and treatment to prisoners and staff of the prisons service in the Republic of
----------------------------	---



Uganda under PEPFAR	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Uganda Prisons Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 150,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 150,000	
Funding Source	Funding Amount
GHP-State	150,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17698		
Mechanism Name:	Provision of comprehensive HIV/AIDS and TB services including prevention, care, support and treatment to prisoners and staff of the		
Prime Partner Name:	prisons service in the Republic of Uganda under PEPFAR		
	Uganda Prisons Services		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	2,393
PMTCT_ART_TA	New on ART	102
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	139



PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	2,393
PMTCT_STAT_TA	Number of new ANC and L&D clients	2,453
PMTCT_STAT_TA	By: Known positives at entry	170
PMTCT_STAT_TA	By: Number of new positives identified	86
PMTCT_STAT_TA	Sum of Positives Status disaggregates	256
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	1,137
VMMC_CIRC_DSD	By Age: 10-14	443
VMMC_CIRC_DSD	By Age: 15-19	330
VMMC_CIRC_DSD	By Age: 20-24	159
VMMC_CIRC_DSD	By Age: 25-29	91
VMMC_CIRC_DSD	By Age: 30-49	91
VMMC_CIRC_DSD	By Age: 50+	23
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	955
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	1,137
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	1,137
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	51,249
HTC_TST_TA	Age/sex: 10-14 Male	2,039
HTC_TST_TA	Age/sex: 15-19 Male	4,683
HTC_TST_TA	Age/sex: 20-24 Male	7,022
HTC_TST_TA	Age/sex: 25-49 Male	10,767
HTC_TST_TA	Age/sex: 50+ Male	937
HTC_TST_TA	Age/sex: 10-14 Female	2,042
HTC_TST_TA	Age/sex: 15-19 Female	4,134
HTC_TST_TA	Age/sex: 20-24 Female	6,204
HTC_TST_TA	Age/sex: 25-49 Female	9,510
HTC_TST_TA	Age/sex: 50+ Female	827
HTC_TST_TA	Sum of Age/Sex disaggregates	48,165



HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Male	91
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Male	145
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Male	215
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Male	332
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Male	31
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Female	91
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Female	189
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Female	285
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Female	434
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Female	35
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3,579
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	23,409
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	3,586
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	20,675
HTC_TST_TA	Sum of Aggregated Age/Sex <15	7,165
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	44,084
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	51,249
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	158
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	723
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	161
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	943
HTC_TST_TA	Test Result by Age: Positive: <1	35
HTC_TST_TA	Test Result by Age: Positive: 1-9	102
HTC_TST_TA	Age/sex: <1	718
HTC_TST_TA	Age/sex: 1-9	2,366



HTC_TST_TA	Service Delivery Point (Facility): Inpatient	12,952
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	17,954
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	6,966
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	3,464
HTC_TST_TA	Service Delivery Point (Facility): VMMC	1,137
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	2,367
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	530
HTC_TST_TA	Service Delivery Point (Facility): Index testing	5,879
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	322
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	322
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	12
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	195
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	9
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	106
GEND_GBV_TA	Number of people receiving post-GBV care	135
GEND_GBV_TA	Age/Sex: <10 Male	4
GEND_GBV_TA	Age/Sex: 10-14 Male	4
GEND_GBV_TA	Age/Sex: 20-24 Male	7
GEND_GBV_TA	Age/Sex: 25-49 Male	7
GEND_GBV_TA	Age/Sex: <10 Female	7
GEND_GBV_TA	Age/Sex: 10-14 Female	19
GEND_GBV_TA	Age/Sex: 20-24 Female	35
GEND_GBV_TA	Age/Sex: 25-49 Female	13



GEND_GBV_TA	Sum of Age/Sex Disaggregates	34
GEND_GBV_TA	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	29
GEND_GBV_TA	By type of service: Sexual Violence (Post-Rape Care)	106
GEND_GBV_TA	By PEP service provision (related to sexual violence services provided)	12
GEND_GBV_TA	Age/Sex: 15-19 Female	33
GEND_GBV_TA	Age/Sex: 15-19 Male	6
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	180
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	180
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	115
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	60
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	4,191
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	120



TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	1,339
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	133
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	2,599
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	85
TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	335
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	101
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	200
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	34
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	159
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	47
PMTCT_EID_TA	Sum of Infant Age disaggregates	206
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	8
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	2
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	4,191
TX_CURR_TA	Age/Sex: 15-19 Male	40
TX_CURR_TA	Age/Sex: 15-19 Female	130
TX_CURR_TA	Sum of Age/Sex disaggregations	170
TX_CURR_TA	Aggregated Age/Sex: <15 Male	120
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	1,339
TX_CURR_TA	Aggregated Age/Sex: <15 Female	133
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	2,599
TX_CURR_TA	Sum of Aggregated Age/Sex <15	253
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	3,938
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	4,191



TX_CURR_TA	Age/Sex: <1	7
TX_CURR_TA	Age/Sex: 1-9	62
TX_CURR_TA	Age/Sex: 10-14 Male	86
TX_CURR_TA	Age/Sex: 10-14 Female	98
TX_CURR_TA	Age/Sex: 20-24 Male	268
TX_CURR_TA	Age/Sex: 25-49 Male	963
TX_CURR_TA	Age/Sex: 50+ Male	68
TX_CURR_TA	Age/Sex: 20-24 Female	598
TX_CURR_TA	Age/Sex: 25-49 Female	1,741
TX_CURR_TA	Age/Sex: 50+ Female	130
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,631
TX_NEW_TA	By Age/Sex: 1-9	24
TX_NEW_TA	By Age/Sex: 10-14 Male	38
TX_NEW_TA	By Age/Sex: 15-19 Male	15
TX_NEW_TA	By Age/Sex: 20-24 Male	105
TX_NEW_TA	By Age/Sex: 25-49 Male	373
TX_NEW_TA	By Age/Sex: 50+ Male	25
TX_NEW_TA	By Age/Sex: 10-14 Female	46
TX_NEW_TA	By Age/Sex: 15-19 Female	49
TX_NEW_TA	By Age/Sex: 20-24 Female	231
TX_NEW_TA	By Age/Sex: 25-49 Female	673
TX_NEW_TA	By Age/Sex: 50+ Female	50
TX_NEW_TA	Sum of Age/Sex disaggregates	1,605
TX_NEW_TA	Aggregated Grouping by Age: <1	2
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	51
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	518
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	59
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	1,003
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	1,631
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml)	3,019



	documented in the medical records and /or supporting laboratory results within the past 12 months.	
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	3,353
TX_PVLS_TA	Numerator: Indication: Routine	3,019
TX_PVLS_TA	Denominator: Indication: Routine	3,353
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	88
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	963
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	98
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	1,870
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	96
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	1,073
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	106
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	2,078
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,334
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,500
TX_RET_TA	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2
TX_RET_TA	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	14
TX_RET_TA	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	22
TX_RET_TA	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	26
TX_RET_TA	Age/Sex: 20-24 Male (Numerator: Number of adults	4



	and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_TA	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	625
TX_RET_TA	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	212
TX_RET_TA	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	21
TX_RET_TA	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	22
TX_RET_TA	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	94
TX_RET_TA	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	272
TX_RET_TA	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	20
TX_RET_TA	Age/Sex: <1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2
TX_RET_TA	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	14
TX_RET_TA	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months	24



	prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	28
TX_RET_TA	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	195
TX_RET_TA	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	702
TX_RET_TA	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	50
TX_RET_TA	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	23
TX_RET_TA	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	24
TX_RET_TA	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including	107



	those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	309
TX_RET_TA	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	22
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	32
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	867
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	27
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	408
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	34
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	975
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total	29



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	462

Implementing Mechanism Details

Mechanism ID: 17703	Mechanism Name: Monitoring and Evaluation Technical Support (METS)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Makerere University School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 7,012,253	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 7,012,253	
Funding Source	Funding Amount
GHP-State	7,012,253

Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	300,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building



Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Key Populations: FSW	50,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Key Populations: MSM and TG	50,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG



Budget Code Information

Mechanism ID: 17703			
Mechanism Name: Monitoring and Evaluation Technical Support (METS)			
Prime Partner Name: Makerere University School of Public Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	101,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	76,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	4,027,789	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	1,508,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	220,847	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	50,717	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	263,450	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	HTXS	288,450	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	126,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	224
HRH_PRE	By Graduates: Other	224
HRH_PRE	Sum of Graduates disaggreagtes	224

Implementing Mechanism Details

Mechanism ID: 17704	Mechanism Name: African Society for Laboratory Medicine - LIMS Support for hubs
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Society for Laboratory Medicine	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

Approved



(No data provided.)

Budget Code Information

Mechanism ID: 17704			
Mechanism Name: African Society for Laboratory Medicine - LIMS Support for hubs			
Prime Partner Name: African Society for Laboratory Medicine			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17705	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17706	Mechanism Name: Scaling up HIV services in Western and West Nile Regions of Uganda
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Infectious Disease Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 12,735,606	
Applied Pipeline Amount: 0	



Total All Funding Sources and Applied Pipeline Amount: 12,735,606	
Funding Source	Funding Amount
GHP-State	12,735,606

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17706			
Mechanism Name: Scaling up HIV services in Western and West Nile Regions of Uganda			
Prime Partner Name: Infectious Disease Institute			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	2,413,267	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	224,605	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	431,497	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	744,388	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	111,400	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	1,698,515	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	2,166,099	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	304,921	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	633,548	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	3,760,671	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	246,696	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	116,235
PMTCT_ART_DSD	New on ART	1,771
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	2,471
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	97,525
PMTCT_ART_TA	New on ART	1,524
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	2,119
PMTCT_STAT_DSD	Number of pregnant women with known HIV status	116,235



	(includes women who were tested for HIV and received their results)	
PMTCT_STAT_DSD	Number of new ANC and L&D clients	119,206
PMTCT_STAT_DSD	By: Known positives at entry	2,407
PMTCT_STAT_DSD	By: Number of new positives identified	2,029
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	4,436
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	97,525
PMTCT_STAT_TA	Number of new ANC and L&D clients	100,017
PMTCT_STAT_TA	By: Known positives at entry	2,058
PMTCT_STAT_TA	By: Number of new positives identified	1,736
PMTCT_STAT_TA	Sum of Positives Status disaggregates	3,794
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	121,493
VMMC_CIRC_DSD	By Age: 10-14	47,382
VMMC_CIRC_DSD	By Age: 15-19	35,234
VMMC_CIRC_DSD	By Age: 20-24	17,009
VMMC_CIRC_DSD	By Age: 25-29	9,720
VMMC_CIRC_DSD	By Age: 30-49	9,720
VMMC_CIRC_DSD	By Age: 50+	2,428
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	102,053
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	121,493
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	116,801
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	4,692
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	13,322
PP_PREV_DSD	Total number of people in the target population	33,011
PP_PREV_DSD	Aggregated Age/sex: <15 Male	2,876
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	3,671
PP_PREV_DSD	Aggregated Age/sex: <15 Female	3,117



PP_PREV_DSD	Aggregated Age/sex: 15+ Female	3,660
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	3,545
KP_PREV_DSD	Total estimated number of key population in the catchment area	6,382
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	3,545
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	6,382
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	558,817
HTC_TST_DSD	Age/sex: 10-14 Male	10,101
HTC_TST_DSD	Age/sex: 15-19 Male	56,102
HTC_TST_DSD	Age/sex: 20-24 Male	84,155
HTC_TST_DSD	Age/sex: 25-49 Male	129,042
HTC_TST_DSD	Age/sex: 50+ Male	11,224
HTC_TST_DSD	Age/sex: 10-14 Female	10,134
HTC_TST_DSD	Age/sex: 15-19 Female	48,553
HTC_TST_DSD	Age/sex: 20-24 Female	72,834
HTC_TST_DSD	Age/sex: 25-49 Female	111,669
HTC_TST_DSD	Age/sex: 50+ Female	9,704
HTC_TST_DSD	Sum of Age/Sex disaggregates	543,518
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	307
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	1,193
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	1,789
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	2,744



HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	235
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	312
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	1,448
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	2,176
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	3,338
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	289
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	17,741
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	280,523
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	17,793
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	242,760
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	35,534
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	523,283
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	558,817
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	522
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	5,961
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	550
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	7,251
HTC_TST_DSD	Test Result by Age: Positive: <1	92
HTC_TST_DSD	Test Result by Age: Positive: 1-9	361
HTC_TST_DSD	Age/sex: <1	3,567
HTC_TST_DSD	Age/sex: 1-9	11,732
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	94,575
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	152,369
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	32,043
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	25,139



HTC_TST_DSD	Service Delivery Point (Facility): VMMC	121,493
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	114,401
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	3,205
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	15,592
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	331,006
HTC_TST_TA	Age/sex: 10-14 Male	7,546
HTC_TST_TA	Age/sex: 15-19 Male	23,122
HTC_TST_TA	Age/sex: 20-24 Male	34,692
HTC_TST_TA	Age/sex: 25-49 Male	53,196
HTC_TST_TA	Age/sex: 50+ Male	4,618
HTC_TST_TA	Age/sex: 10-14 Female	7,546
HTC_TST_TA	Age/sex: 15-19 Female	37,782
HTC_TST_TA	Age/sex: 20-24 Female	56,687
HTC_TST_TA	Age/sex: 25-49 Female	86,916
HTC_TST_TA	Age/sex: 50+ Female	7,551
HTC_TST_TA	Sum of Age/Sex disaggregates	319,656
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Male	236
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Male	643
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Male	970
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Male	1,483
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Male	122
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Female	250
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Female	1,136
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Female	1,713
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Female	2,620
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Female	219
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	13,236
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	115,628



HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	13,233
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	188,936
HTC_TST_TA	Sum of Aggregated Age/Sex <15	26,469
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	304,564
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	331,033
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	401
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	3,218
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	425
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	5,688
HTC_TST_TA	Test Result by Age: Positive: <1	66
HTC_TST_TA	Test Result by Age: Positive: 1-9	274
HTC_TST_TA	Age/sex: <1	2,648
HTC_TST_TA	Age/sex: 1-9	8,729
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	66,612
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	108,894
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	23,485
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	19,215
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	96,013
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	2,294
HTC_TST_TA	Service Delivery Point (Facility): Index testing	14,493
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	3,066
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	3,066
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	95

TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,871
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	70
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,030
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	883
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	883
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	21
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	552
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	14
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	296
GEND_GBV_DSD	Number of people receiving post-GBV care	6,521
GEND_GBV_DSD	Age/Sex: <10 Male	197
GEND_GBV_DSD	Age/Sex: 10-14 Male	197
GEND_GBV_DSD	Age/Sex: 20-24 Male	331
GEND_GBV_DSD	Age/Sex: 25-49 Male	331
GEND_GBV_DSD	Age/Sex: <10 Female	331
GEND_GBV_DSD	Age/Sex: 10-14 Female	913
GEND_GBV_DSD	Age/Sex: 20-24 Female	1,593
GEND_GBV_DSD	Age/Sex: 25-49 Female	659



GEND_GBV_DSD	Sum of Age/Sex Disaggregates	1,638
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	1,437
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	5,084
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	587
GEND_GBV_DSD	Age/Sex: 15-19 Female	1,635
GEND_GBV_DSD	Age/Sex: 15-19 male	334
GEND_GBV_TA	Number of people receiving post-GBV care	5,474
GEND_GBV_TA	Age/Sex: <10 Male	166
GEND_GBV_TA	Age/Sex: 10-14 Male	166
GEND_GBV_TA	Age/Sex: 20-24 Male	280
GEND_GBV_TA	Age/Sex: 25-49 Male	280
GEND_GBV_TA	Age/Sex: <10 Female	280
GEND_GBV_TA	Age/Sex: 10-14 Female	765
GEND_GBV_TA	Age/Sex: 20-24 Female	1,343
GEND_GBV_TA	Age/Sex: 25-49 Female	555
GEND_GBV_TA	Sum of Age/Sex Disaggregates	1,377
GEND_GBV_TA	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	1,208
GEND_GBV_TA	By type of service: Sexual Violence (Post-Rape Care)	4,266
GEND_GBV_TA	By PEP service provision (related to sexual violence services provided)	493
GEND_GBV_TA	Age/Sex: 15-19 Female	1,371
GEND_GBV_TA	Age/Sex: 15-19 Male	268
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	4,256
OVC_SERV_DSD	Age/Sex: 18+ Male	480
OVC_SERV_DSD	Age/Sex: 18+ Female	578
OVC_SERV_DSD	Sum of Age/Sex disaggregates	1,058
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	1,545
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	1,653



TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	703
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	703
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	6
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	464
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	229
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	143
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	143
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	103
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	40



	TB treatment during the reporting period)	
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	65,240
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	2,054
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	20,690
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	2,315
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	40,181
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	1,307
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	5,224
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	1,573
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	3,133
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	518
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	25,119
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	817
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	7,931
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	933
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	15,438
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	505
TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	2,008
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	610
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	1,207
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	191



PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	2,792
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	750
PMTCT_EID_DSD	Sum of Infant Age disaggregates	3,542
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	142
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	27
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	2,400
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	630
PMTCT_EID_TA	Sum of Infant Age disaggregates	3,030
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	129
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	19
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	65,240
TX_CURR_DSD	Age/Sex: 15-19 Male	618
TX_CURR_DSD	Age/Sex: 15-19 Female	2,013
TX_CURR_DSD	Sum of age/sex disaggregates	2,631
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	2,054
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	20,690
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	2,315
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	40,181
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	4,369
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	60,871
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	65,240
TX_CURR_DSD	Age/Sex: <1	165
TX_CURR_DSD	Age/Sex: <1-9	1,056
TX_CURR_DSD	Age/Sex: 10-14 Male	1,458



TX_CURR_DSD	Age/Sex: 10-14 Female	1,690
TX_CURR_DSD	Age/Sex: 20-24 Male	4,137
TX_CURR_DSD	Age/Sex: 25-49 Male	14,899
TX_CURR_DSD	Age/Sex: 50+ Male	1,036
TX_CURR_DSD	Age/Sex: 20-24 Female	9,241
TX_CURR_DSD	Age/Sex: 25-49 Female	26,914
TX_CURR_DSD	Age/Sex: 50+ Female	2,013
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	25,119
TX_CURR_TA	Age/Sex: 15-19 Male	239
TX_CURR_TA	Age/Sex: 15-19 Female	774
TX_CURR_TA	Sum of Age/Sex disaggregations	1,013
TX_CURR_TA	Aggregated Age/Sex: <15 Male	817
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	7,931
TX_CURR_TA	Aggregated Age/Sex: <15 Female	933
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	15,438
TX_CURR_TA	Sum of Aggregated Age/Sex <15	1,750
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	23,369
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	25,119
TX_CURR_TA	Age/Sex: <1	48
TX_CURR_TA	Age/Sex: 1-9	452
TX_CURR_TA	Age/Sex: 10-14 Male	576
TX_CURR_TA	Age/Sex: 10-14 Female	674
TX_CURR_TA	Age/Sex: 20-24 Male	1,590
TX_CURR_TA	Age/Sex: 25-49 Male	5,704
TX_CURR_TA	Age/Sex: 50+ Male	398
TX_CURR_TA	Age/Sex: 20-24 Female	3,551
TX_CURR_TA	Age/Sex: 25-49 Female	10,339
TX_CURR_TA	Age/Sex: 50+ Female	774
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	19,157
TX_NEW_DSD	By Age/Sex: <1	26



TX_NEW_DSD	By Age/Sex: 1-9	238
TX_NEW_DSD	By Age/Sex: 10-14 Male	348
TX_NEW_DSD	By Age/Sex: 15-19 Male	186
TX_NEW_DSD	By Age/Sex: 20-24 Male	1,229
TX_NEW_DSD	By Age/Sex: 25-49 Male	4,433
TX_NEW_DSD	By Age/Sex: 50+ Male	310
TX_NEW_DSD	By Age/Sex: 10-14 Female	431
TX_NEW_DSD	By Age/Sex: 15-19 Female	594
TX_NEW_DSD	By Age/Sex: 20-24 Female	2,748
TX_NEW_DSD	By Age/Sex: 25-49 Female	8,011
TX_NEW_DSD	By Age/Sex: 50+ Female	603
TX_NEW_DSD	Sum of Age/Sex disaggregates	18,893
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	482
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	6,158
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	561
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	11,956
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	19,157
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	9,736
TX_NEW_TA	By Age/Sex: 1-9	102
TX_NEW_TA	By Age/Sex: 10-14 Male	151
TX_NEW_TA	By Age/Sex: 15-19 Male	81
TX_NEW_TA	By Age/Sex: 20-24 Male	621
TX_NEW_TA	By Age/Sex: 25-49 Male	2,264
TX_NEW_TA	By Age/Sex: 50+ Male	179
TX_NEW_TA	By Age/Sex: 10-14 Female	215
TX_NEW_TA	By Age/Sex: 15-19 Female	306
TX_NEW_TA	By Age/Sex: 20-24 Female	1,404
TX_NEW_TA	By Age/Sex: 25-49 Female	4,102
TX_NEW_TA	By Age/Sex: 50+ Female	299
TX_NEW_TA	Sum of Age/Sex disaggregates	9,622
TX_NEW_TA	Aggregated Grouping by Age: <1	12



TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	212
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	3,145
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	268
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	6,111
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	9,736
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	40,869
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	45,406
TX_PVLS_DSD	Numerator: Indication: Routine	40,869
TX_PVLS_DSD	Denominator: Indication: Routine	45,406
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	1,350
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	12,921
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	1,522
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	25,076
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	1,501
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	14,350
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	1,690
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	27,865
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	17,159
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	19,061
TX_PVLS_TA	Numerator: Indication: Routine	17,159
TX_PVLS_TA	Denominator: Indication: Routine	19,061
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	553
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	5,434



TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	635
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	10,537
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	627
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	6,010
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	715
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	11,709
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	13,940
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	15,660
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	15
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	149
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	250
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	264
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	46
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,344
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,155
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults	221



	and children who are still alive and on treatment at 12 months after initiating ART	
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	222
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,032
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,008
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	234
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	19
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	165
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	278
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	296
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of	1,978



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7,130
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	496
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	247
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	252
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,158
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,384
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months	257



	prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	345
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8,809
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	290
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,496
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	383
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9,900
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	326
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,051



TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	7,419
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	8,335
TX_RET_TA	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3
TX_RET_TA	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	56
TX_RET_TA	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	108
TX_RET_TA	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	141
TX_RET_TA	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	21
TX_RET_TA	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,617
TX_RET_TA	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,245
TX_RET_TA	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	99
TX_RET_TA	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	103
TX_RET_TA	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12	490



	months after initiating ART)	
TX_RET_TA	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,429
TX_RET_TA	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	107
TX_RET_TA	Age/Sex: <1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5
TX_RET_TA	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	60
TX_RET_TA	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	119
TX_RET_TA	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	160
TX_RET_TA	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,134
TX_RET_TA	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including	4,064



	those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	290
TX_RET_TA	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	107
TX_RET_TA	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	114
TX_RET_TA	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	551
TX_RET_TA	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,601
TX_RET_TA	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	130
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	144



TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,024
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	122
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,129
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	158
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,648
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	133
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,396

Implementing Mechanism Details

Mechanism ID: 17855	Mechanism Name: Comprehensive HIV/AIDS Prevention, Care, Treatment and Support Project with the Uganda People Defense Forces
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Research Triangle International	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 2,359,499	
Applied Pipeline Amount: 421,236	
Total All Funding Sources and Applied Pipeline Amount: 2,780,735	
Funding Source	Funding Amount
GHP-State	2,359,499

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17855		
Mechanism Name:	Comprehensive HIV/AIDS Prevention, Care, Treatment and Support		
Prime Partner Name:	Project with the Uganda People Defense Forces		
	Research Triangle International		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	445,563	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	42,304	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	113,736	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	254,319	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	280,727	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	206,157	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	75,329	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	873,237	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	68,127	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	7,610
PMTCT_ART_DSD	New on ART	702
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	355
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	7,610



PMTCT_STAT_DSD	Number of new ANC and L&D clients	8,010
PMTCT_STAT_DSD	By: Known positives at entry	395
PMTCT_STAT_DSD	By: Number of new positives identified	660
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	1,055
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	16,847
VMMC_CIRC_DSD	By Age: 10-14	6,570
VMMC_CIRC_DSD	By Age: 15-19	4,886
VMMC_CIRC_DSD	By Age: 20-24	2,359
VMMC_CIRC_DSD	By Age: 25-29	1,348
VMMC_CIRC_DSD	By Age: 30-49	1,348
VMMC_CIRC_DSD	By Age: 50+	336
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	14,151
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	16,847
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	16,847
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	92,244
HTC_TST_DSD	Age/sex: 10-14 Male	2,837
HTC_TST_DSD	Age/sex: 15-19 Male	10,678
HTC_TST_DSD	Age/sex: 20-24 Male	16,018
HTC_TST_DSD	Age/sex: 25-49 Male	24,560
HTC_TST_DSD	Age/sex: 50+ Male	2,136
HTC_TST_DSD	Age/sex: 10-14 Female	2,839
HTC_TST_DSD	Age/sex: 15-19 Female	5,779
HTC_TST_DSD	Age/sex: 20-24 Female	8,668
HTC_TST_DSD	Age/sex: 25-49 Female	13,291
HTC_TST_DSD	Age/sex: 50+ Female	1,156
HTC_TST_DSD	Sum of Age/Sex disaggregates	87,962
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	178
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	411



HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	617
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	946
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	83
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	179
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	453
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	680
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	1,043
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	91
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	4,978
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	53,392
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	4,980
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	28,894
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	9,958
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	82,286
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	92,244
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	313
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	2,057
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	313
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	2,267
HTC_TST_DSD	Test Result by Age: Positive: <1	63
HTC_TST_DSD	Test Result by Age: Positive: 1-9	206
HTC_TST_DSD	Age/sex: <1	996
HTC_TST_DSD	Age/sex: 1-9	3,286
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	27,183
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	27,862



HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	9,958
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	6,907
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	16,847
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	681
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	680
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	2,126
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	951
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	951
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	31
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	579
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	23
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	318
GEND_GBV_DSD	Number of people receiving post-GBV care	541
GEND_GBV_DSD	Age/Sex: <10 Male	16
GEND_GBV_DSD	Age/Sex: 10-14 Male	16
GEND_GBV_DSD	Age/Sex: 20-24 Male	27
GEND_GBV_DSD	Age/Sex: 25-49 Male	27
GEND_GBV_DSD	Age/Sex: <10 Female	27
GEND_GBV_DSD	Age/Sex: 10-14 Female	76
GEND_GBV_DSD	Age/Sex: 20-24 Female	135
GEND_GBV_DSD	Age/Sex: 25-49 Female	54
GEND_GBV_DSD	Sum of Age/Sex Disaggregates	135
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence	119



	(Other Post-GBV Care)	
GEND_GBVDSD	By type of service: Sexual Violence (Post-Rape Care)	422
GEND_GBVDSD	By PEP service provision (related to sexual violence services provided)	49
GEND_GBVDSD	Age/Sex: 15-19 Female	135
GEND_GBVDSD	Age/Sex: 15-19 male	28
OVC_SERVDSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	3,960
OVC_SERVDSD	Age/Sex: 18+ Male	445
OVC_SERVDSD	Age/Sex: 18+ Female	539
OVC_SERVDSD	Sum of Age/Sex disaggregates	984
OVC_SERVDSD	By Aggregated Age/Sex: <18 Male	1,438
OVC_SERVDSD	By Aggregated Age/Sex: <18 Female	1,538
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,063
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,063
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	20
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	662
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	15
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with	366

	documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	23,663
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	968
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	7,231
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	1,422
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	14,042
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	473
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	1,893
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	568
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	1,136
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	189
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	247
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	69
PMTCT_EID_DSD	Sum of Infant Age disaggregates	316
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	12
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	3
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	23,663
TX_CURR_DSD	Age/Sex: 15-19 Male	217
TX_CURR_DSD	Age/Sex: 15-19 Female	702
TX_CURR_DSD	Sum of age/sex disaggregates	919
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	968



TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	7,231
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,422
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	14,042
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	2,390
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	21,273
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	23,663
TX_CURR_DSD	Age/Sex: <1	96
TX_CURR_DSD	Age/Sex: <1-9	569
TX_CURR_DSD	Age/Sex: 10-14 Male	687
TX_CURR_DSD	Age/Sex: 10-14 Female	1,038
TX_CURR_DSD	Age/Sex: 20-24 Male	1,446
TX_CURR_DSD	Age/Sex: 25-49 Male	5,206
TX_CURR_DSD	Age/Sex: 50+ Male	362
TX_CURR_DSD	Age/Sex: 20-24 Female	3,230
TX_CURR_DSD	Age/Sex: 25-49 Female	9,408
TX_CURR_DSD	Age/Sex: 50+ Female	702
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	9,782
TX_NEW_DSD	By Age/Sex: <1	47
TX_NEW_DSD	By Age/Sex: 1-9	287
TX_NEW_DSD	By Age/Sex: 10-14 Male	399
TX_NEW_DSD	By Age/Sex: 15-19 Male	88
TX_NEW_DSD	By Age/Sex: 20-24 Male	584
TX_NEW_DSD	By Age/Sex: 25-49 Male	2,102
TX_NEW_DSD	By Age/Sex: 50+ Male	146
TX_NEW_DSD	By Age/Sex: 10-14 Female	462
TX_NEW_DSD	By Age/Sex: 15-19 Female	283
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,303
TX_NEW_DSD	By Age/Sex: 25-49 Female	3,797
TX_NEW_DSD	By Age/Sex: 50+ Female	284
TX_NEW_DSD	Sum of Age/Sex disaggregates	9,448
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	562



TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	2,920
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	633
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	5,667
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	9,782
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	17,037
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	18,930
TX_PVLS_DSD	Numerator: Indication: Routine	17,037
TX_PVLS_DSD	Denominator: Indication: Routine	18,930
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	697
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	5,211
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	1,023
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	10,106
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	774
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	5,788
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	1,137
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	11,231
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,715
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	3,050
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	27
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults	44



	and children who are still alive and on treatment at 12 months after initiating ART	
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	53
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	11
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,274
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	431
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	36
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	42
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	192
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	559
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	42
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and	31



	children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	49
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	60
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	398
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,431
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	99
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	40
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months	47



	prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	216
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	628
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	46
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	62
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,769
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	49
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	835
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	70



TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,988
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	55
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	937
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	435

Implementing Mechanism Details

Mechanism ID: 17874	Mechanism Name: NAMERU
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: National Medical Research Unit	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 150,000	
Applied Pipeline Amount: 110,000	
Total All Funding Sources and Applied Pipeline Amount: 260,000	
Funding Source	Funding Amount
GHP-State	150,000

Cross-Cutting Budget Attribution(s)



Economic Strengthening	2,000
Gender: GBV	5,000
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Gender: Gender Equality	8,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Condom programming	4,000

Budget Code Information

Mechanism ID: 17874			
Mechanism Name: NAMERU			
Prime Partner Name: National Medical Research Unit			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Approved



Treatment	HTXS	0	0
-----------	------	---	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17976	Mechanism Name: Supporting Laboratory Strengthening Activities in Resource-Limited Countries Under the President's Emergency Plan for AIDS Relief
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Association of Public Health Laboratories	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 200,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 200,000	
Funding Source	Funding Amount
GHP-State	200,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17976
Mechanism Name:	Supporting Laboratory Strengthening Activities in Resource-Limited Countries Under the President's Emergency Plan for AIDS Relief
Prime Partner Name:	Countries Under the President's Emergency Plan for AIDS Relief



Association of Public Health Laboratories			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	200,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17977	Mechanism Name: Biomedical Engineering Support for Equipment Maintenance and Training in Clinical Laboratory Sites Providing HIV/AIDS Care and Treatment
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: American International Health Alliance Twinning Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 450,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 450,000	
Funding Source	Funding Amount
GHP-State	450,000

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID:	17977		
Mechanism Name:	Biomedical Engineering Support for Equipment Maintenance and Training in Clinical Laboratory Sites Providing HIV/AIDS Care and Treatment		
Prime Partner Name:	American International Health Alliance Twinning Center		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	450,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17978	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17979	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18003	Mechanism Name: Technical assistance for strengthening national laboratory systems in Uganda under the President's Emergency Plan for AIDS Relief
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Global Healthcare Public Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No

Approved



G2G: No	Managing Agency:
Total All Funding Sources: 500,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 500,000	
Funding Source	Funding Amount
GHP-State	500,000

Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	160,000
---------------------------	---------

Budget Code Information

Mechanism ID:	18003		
Mechanism Name:	Technical assistance for strengthening national laboratory systems in		
Prime Partner Name:	Uganda under the President's Emergency Plan for AIDS Relief		
	Global Healthcare Public Foundation		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	500,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18017	Mechanism Name: EGPAF: HQ Technical Assistance CoAg
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	

Approved



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 400,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 400,000	
Funding Source	Funding Amount
GHP-State	400,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18017			
Mechanism Name: EGPAF: HQ Technical Assistance CoAg			
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	150,000	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 18029	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18030	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18031	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18032	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18033	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18034	TBD: Yes
REDACTED	

Implementing Mechanism Details



Mechanism ID: 18041	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18042	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18273	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18274	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18276	Mechanism Name: PPL-LER Monitoring and Evaluation IDIQ
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: DevTech Systems Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 400,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 400,000	
Funding Source	Funding Amount

Approved



GHP-State	400,000
-----------	---------

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18276			
Mechanism Name: PPL-LER Monitoring and Evaluation IDIQ			
Prime Partner Name: DevTech Systems Inc			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	400,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18361	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18369	Mechanism Name: Global Health Supply Chain – Procurement and Supply Management (GHSC-PSM) - HIV/AIDS Task Order
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 49,757,913	
Applied Pipeline Amount: 1,277,217	
Total All Funding Sources and Applied Pipeline Amount: 51,035,130	
Funding Source	Funding Amount
GHP-State	49,757,913

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18369		
Mechanism Name:	Global Health Supply Chain – Procurement and Supply Management		
Prime Partner Name:	(GHSC-PSM) - HIV/AIDS Task Order		
	Global Health Supply Chain Program		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	4,082,730	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	30,600	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	763,293	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	3,068,628	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVCT	2,848,906	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	500,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	1,229,468	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	27,845,935	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	9,159,893	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	228,460	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18502	Mechanism Name: DREAMS Initiative and HIV/AIDS Prevention Support to the Ugandan Peoples Defense
Funding Agency: DOD	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	



Funding Source	Funding Amount
-----------------------	-----------------------

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18502		
Mechanism Name:	DREAMS Initiative and HIV/AIDS Prevention Support to the Ugandan		
Prime Partner Name:	Peoples Defense		
	Population Services International		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	81,740
PP_PREV_DSD	Total number of people in the target population	241,933
PP_PREV_DSD	Aggregated Age/sex: <15 Male	17,277
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	22,033
PP_PREV_DSD	Aggregated Age/sex: <15 Female	18,714
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	23,716
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	3,138
HTC_TST_DSD	Age/sex: 15-19 Female	628



HTC_TST_DSD	Age/sex: 20-24 Female	941
HTC_TST_DSD	Age/sex: 25-49 Female	1,443
HTC_TST_DSD	Age/sex: 50+ Female	126
HTC_TST_DSD	Sum of Age/Sex disaggregates	3,138
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	12
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	19
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	29
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	2
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	3,138
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	3,138
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	3,138
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	62
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	3,138
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	1,958
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	587
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	392
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	979

Agency Information - Costs of Doing Business

U.S. Agency for International Development

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline



						Amount
Computers/IT Services		371,250		0	371,250	371,250
ICASS		2,619,000		0	2,619,000	2,619,000
Institutional Contractors		1,648,500		0	1,648,500	1,648,500
Management Meetings/Professional Development		123,750		0	123,750	123,750
Non-ICASS Administrative Costs		457,510		0	457,510	457,510
Staff Program Travel		2,358,750	0	0	2,358,750	2,358,750
USG Staff Salaries and Benefits - Internationally Recruited		2,837,772	0	0	2,837,772	2,837,772
USG Staff Salaries and Benefits - Locally Recruited		1,777,534	0	0	1,777,534	1,777,534
Total	0	12,194,066	0	0	12,194,066	12,194,066

U.S. Department of Defense

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories



						and Applied Pipeline Amount
ICASS		110,258		0	110,258	110,258
Management Meetings/Professional Development		48,509		2,008	48,509	50,517
Non-ICASS Administrative Costs		170,584		0	170,584	170,584
Staff Program Travel		70,749		5,056	70,749	75,805
USG Staff Salaries and Benefits - Internationally Recruited		140,800		0	140,800	140,800
USG Staff Salaries and Benefits - Locally Recruited		73,061		22,797	73,061	95,858
Total	0	613,961	0	29,861	613,961	643,822

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied
-------------------------------	-----	-----------	-----------	------------------	-------	---



						Pipeline Amount
Capital Security Cost Sharing		2,383,584		0	2,383,584	2,383,584
Computers/IT Services		762,953		0	762,953	762,953
ICASS		2,718,519		0	2,718,519	2,718,519
Management Meetings/Professional Development	123,370	672,485		0	795,855	795,855
Non-ICASS Administrative Costs		863,071		0	863,071	863,071
Non-ICASS Motor Vehicles		298,231		0	298,231	298,231
Staff Program Travel		760,890		0	760,890	760,890
USG Staff Salaries and Benefits - Internationally Recruited	2,144,065	949,860		980,000	3,093,925	4,073,925
USG Staff Salaries and Benefits - Locally Recruited	945,065	2,100,091		0	3,045,156	3,045,156
Total	3,212,500	11,509,684	0	980,000	14,722,184	15,702,184

U.S. Department of State

Agency Cost	GAP	GHP-State	GHP-USAID	Applied	Total	Total All
-------------	-----	-----------	-----------	---------	-------	-----------



of Doing Business				Pipeline		Cost of Doing Business Categories and Applied Pipeline Amount
ICASS		54,624		0	54,624	54,624
Management Meetings/Professional Development		20,405		0	20,405	20,405
Non-ICASS Administrative Costs		17,203		0	17,203	17,203
Staff Program Travel		33,200		0	33,200	33,200
USG Staff Salaries and Benefits - Internationally Recruited		0		140,000	0	140,000
USG Staff Salaries and Benefits - Locally Recruited		184,629		0	184,629	184,629
Total	0	310,061	0	140,000	310,061	450,061

U.S. Peace Corps

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing
-------------------------------	-----	-----------	-----------	------------------	-------	-------------------------

Approved



						Business Categories and Applied Pipeline Amount
Non-ICASS Administrative Costs		25,459		43,844	25,459	69,303
Peace Corps Volunteer Costs		465,703		801,995	465,703	1,267,698
Staff Program Travel		17,715		30,507	17,715	48,222
USG Renovation		120,000		120,000	120,000	240,000
USG Staff Salaries and Benefits - Locally Recruited		134,063		230,871	134,063	364,934
Total	0	762,940	0	1,227,217	762,940	1,990,157